Introduction

On July 6, 2026, Novartis announced that it has entered into an agreement to acquire Myricx Bio for $1.1 billion upfront with up to $400 million in potential milestone payments, for a total deal value of up to $1.5 billion (Novartis press release, Myricx press release). This acquisition centers on a novel platform and three preclinical programs:

• Antibody-drug conjugates (DCs) with N-myristoyltransferase inhibitor (NMTi) payloads

• A preclinical NMTi-ADC targeting B7-H3

• A preclinical NMTi-ADC targeting HER2

• A preclinical NMTi-ADC targeting TROP2, which appears in an older Myricx press release

Right off the bat, it appears that Myricx was bought for a rather healthy premium, with the upfront payment being about 80% higher than the average preclinical-stage acquisition (see graph below).

In this article, we dive into the founding story of Myricx Bio, explore the strengths of their novel NMTi-ADC platform, and opine on why strategics have gotten excited about novel ADC payload companies.

From Malaria to MYC

The founding story of Myricx Bio is a prime example of how a decades-long academic research project has positioned itself to become a multi-billion dollar biotech success story.

The journey began more than 20 years ago in the laboratories of Imperial College London. Professor Ed Tate (now the GSK Chair in Chemical Biology) and his research group were trying to defeat malaria. Their target was N-myristoyltransferase (NMT), a vital protein-modifying enzyme that the malaria parasite relies on to survive. As the team engineered small molecules to block the parasite’s version of NMT, they hit upon a fascinating side effect. Some of the molecules they designed were incredibly potent against the human version of the enzyme. Professor Tate and his team realized that NMT is also a critical lifeline for human cells, and malignant cancer cells are uniquely addicted to it. Inhibiting NMT could cut off a tumor’s cellular machinery, forcing specific cancer cells to self-destruct. Remarkably, this mechanism showed immense promise in targeting MYC-driven cancers, an oncogene that had long been deemed difficult-to-drug.

Recognizing the massive therapeutic potential, Tate knew the science needed to leave the academic bench. Backed by critical, early-stage funding from Cancer Research UK, the team refined their molecules to identify drug-like candidates fit for human clinical trials. To transform this academic breakthrough into a commercial reality, Professor Tate partnered with two crucial co-founders:

• Dr. Andrew Bell, a brilliant chemist with deep drug discovery expertise.

• Dr. Roberto Solari, a seasoned biotech executive and Venture Partner at Brandon Capital.

In 2019, the trio officially spun the company out from Imperial College London and the Francis Crick Institute under the initial name Myricx Pharma. Dr. Solari stepped in as the founding CEO, and the fledgling startup secured a £4.5 million Seed round co-led by Brandon Capital and Sofinnova Partners to kickstart their operations. While Myricx initially set out to develop traditional small-molecule oral drugs, the team faced a common biotech hurdle: ensuring the drug selectively killed cancer cells while minimizing harm to healthy tissue. In 2021, the company executed a brilliant strategic pivot. Instead of delivering the NMT inhibitors broadly across the body, they transitioned to evaluating them as payloads for Antibody-Drug Conjugates (ADCs). For those new to ADCs, they are a drug modality that acts like a biology guided missile. An antibody seeks out and binds to a specific protein on a cancer cell, and then drops a highly toxic payload (often a topoisomerase-1 or tubulin inhibitor) directly inside the tumor. Instead of traditional payloads, Myricx loaded their ADCs with their NMT inhibitor with the goal of making targeted therapeutics that sought out two targets:

• B7-H3, wh of solid tumors and has been correlated in meta-analyses with a 71% lower overall survival (OS) and a 110% lower progression-free survival (PFS).

• HER2, which is a well known breast cancer antigen going back to the 1998 approval of Herceptin (trastuzumab), the first monoclonal antibody approved for a solid tumor.

• TROP2, which is upregulated in a vast array of aggressive epithelial malignancies

The pivot transformed Myricx from a niche spinout into a biotech heavyweight. Under the subsequent leadership of Dr. Robin Carr (first serving as Chief Development Officer starting in November 2019 and becoming CEO in August 2022 before settling on CTO in late 2025), the company raised a staggering £90 million ($114 million) Series A round in 2024, one of the largest ever achieved by a European academic spinout. The round attracted major global investors, including Novo Holdings, Eli Lilly, and Abingworth. By late 2025, biopharma veteran Mohit Rawat was brought on as CEO to steer the company toward global commercialization. Prior to joining Myricx, he served as President and Chief Business Officer at Fusion Pharmaceuticals, where he played a critical role in transforming the clinical-stage radiopharmaceutical company and secured a $2.4 billion acquisition by AstraZeneca in 2024.

Professor Tate’s 20-year scientific odyssey came to fruition in July 2026 when pharma giant Novartis announced a definitive agreement to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront). What started as an accidental discovery in a British malaria lab, pivoted to cancer, and zeroed in on ADCs culminated in a significant early-stage exit.

Loading Up on Novel ADC Payloads

I realize that two points do not make a trend, but the rapid succession of +$1 billion novel ADC payload purchases has me seeing stars. Novartis’ buyout of Myricx Bio comes just one month after J&J’s $1 billion purchase of the preclinical ADC payload company Firefly Bio, which likewise commanded a healthy premium and was bought for its novel degrader antibody conjugate (DAC) platform. Furthermore, both are preclinical, suggesting that they have long-term strategic value (contrasts with Phase 3/Commerical stage companies that plug near-term revenue holes).

So, what is it about these novel ADC payloads that has piqued the interest of strategics? For years, the ADC boom relied heavily on two cytotoxic warheads: tubulin inhibitors (like MMAE) and topoisomerase I inhibitors (like DXd). While highly effective, these payloads suffer from narrow therapeutic windows, drug-resistance mutations, and systemic toxicities due to premature payload release in circulation. By acquiring Myricx and Firefly, pharma giants bypass traditional chemotherapies entirely, turning instead to differentiated mechanisms.

Firefly sits at the convergence of two powerhouse modalities: ADCs and Targeted Protein Degradation (TPD). Instead of slowly accumulating small-molecule toxins to kill a cell, a single degrader payload molecule works catalytically. It repeatedly hijacks the cell’s own ubiquitin-proteasome system to flag and destroy specific disease-driving proteins. Crucially, Firefly developed proprietary linker chemistry optimized to keep these complex degrader payloads stable in circulation, preventing the premature free payload release that plagues earlier-generation conjugates.

Myricx’s core innovation is shifting away from standard DNA/tubulin-damaging agents toward NMT inhibition. NMT is an enzyme responsible for protein myristoylation, a critical lipid modification that allows key signaling proteins to anchor to cellular membranes. Similar to Firefly, Myricx’s platform could offer an answer to tumors that have developed resistance to standard TOPO-1 or tubulin-targeting ADCs because NMT inhibition works via a completely distinct mechanism of action. However, there’s a different angle that makes NMT inhibitiors intriguing as a therapeutic class. Cancer cells, particularly those driven by the difficult-to-drug MYC oncogene, are uniquely addicted to NMT activity. Inhibiting it could cause a catastrophic collapse of intracellular signaling, triggering apoptosis. This is a big deal because the MYC proto-oncogene family is widely recognized as one of the most pervasive drivers of human tumorigenesis (see figure below). MYC is estimated to be deregulated or abnormally activated in approximately 50% to 70% of all human cancers. Even when the MYC gene itself is structurally normal, its protein product is overabundant, hyper-stable, and actively driving tumor hallmarks like metabolic reprogramming and immune evasion.

For over three decades, MYC has been difficult to drug because the protein lacks a deep ligand-binding pocket for small molecules to latch onto. Direct inhibitors have historically failed in clinical development because of the difficulty of finding a chemical binder, and because broad systemic inhibition could lead to catastrophic toxicities in normal proliferating tissues. An ADC bypassing the protein structure entirely and instead dropping a payload that exploits a MYC-addicted cellular pathway (like protein myristoylation via NMT) is hypothesized to provide a workaround. Preclinical models suggest that attaching it to an antibody may make the payload delivery more localized, which researchers hope will translate to mitigated systemic toxicity in clinical evaluation.

To evaluate their NMT inhibitor (NMTi) platform, Myricx engineered several proof-of-concept and lead assets by tethering their novel payloads to clinically validated monoclonal antibodies. These candidates achieved extensive tumor regression in various cancer cell lines (first & second figure below) and in an in vivo solid cancer xenograft model (third figure below) at doses that were generally well-tolerated in male cynomolgus monkeys.

Conclusion

The acquisition of Myricx Bio could be a sign of where the oncology market is heading. For the past few years, the ADC boom has been defined by a race to find the best surface targets, largely relying on a handful of standard, off-the-shelf chemotherapy payloads. Novartis’ ten-figure bet on Myricx (and J&J’s similar play for Firefly Bio) signals that the industry is moving past the low-hanging fruit. By shifting the focus to novel payloads, these next-generation platforms could unlock doors that have been closed to drug developers for decades. If Myricx’s platform can successfully show a workable therapeutic window in human clinical trials and pass regulatory muster, what began as a hunt for a malaria cure in a London university lab could very well redefine the standard of care in a wide variety of solid tumors.

Premium Charts & Analysis

Please feel free to email me at biotechreadout@gmail.com with “CHARTS” in the subject line to share suggestions or request chart updates. All charts reflect data current as of the specified date and may not include every drug development program, although we aimed to capture the vast majority.

• Notable Acquisitions of ADC Companies ⬇️

• Top Selling ADCs ⬇️

• Top 30 ADC Targets ⬇️

• ADC Pipeline of Strategic Acquirers ⬇️

Read more

Table of Contents

This week, we discuss:

• China Biotech

  • Big Pharma Partnerships Draw Scrutiny ⬇️

  • FDA’s Push to Re-shore Drug Manufacturing Achieves a Major Milestone ⬇️

• Acquisitions ⬇️

  • United Therapeutics to Acquire Thymmune, regenerative medicine titans join forces to grow a thymus

  • Ipsen to Acquire Memo, neutralizing the viral ghosts that haunt kidney transplant patients

  • Ipsen to Acquire Kartos, unleashing apoptotic p53 on myelofibrosis

  • Zymeworks to Acquire Theravance, M&A alchemy with a COPD sweetener

• Approvals

  • Orca Bio - Tregzi (allo HSCT) / Approved (cGVHD) ⬇️

  • Viridian - Lumvoa (IGF-1R inhibitor) / Approval (TED) ⬇️

  • Vertex - Casgevy (BCL11A-KO HSCT) / Label Expansion (SCD/β-thal age 2+) ⬇️

  • Arcutis - Zoryve (topical PDE4 inhibitor) / Label Expansion (plaque psoriasis age 2+) ⬇️

• Clinical Trial Data

  • Abivax - Obefazimod (miR-124 upregulator) / Phase 3 (UC) ⬇️

  • RevMed - Zoldonrasib (KRAS-G12D inhibitor) / Phase 1 (G12D mutated mPDAC) ⬇️

  • AbbVie - Epkinly (CD3 x CD20 mAb) / Phase 3 (DLBCL) ⬇️

  • AstraZeneca - Efzimfotase alfa (TNSALP ERT) / Phase 3 (hypophosphatasia ages 2-11) ⬇️

  • BeOne - Brukinsa (BTK inhibitor) / Phase 3 (1L MCL) ⬇️

  • Roche - Divarasib (reversible KRAS G12C inhibitor) / Phase 3 (2L NSCLC) ⬇️

  • Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN) ⬇️

  • Sanofi - Nexviazyme (M6P-GAA ERT) / Phase 3 (infant Pompe) ⬇️

China Biotech

Big Pharma Partnerships Draw Scrutiny

On June 30, 2026, Endpoints reported that the U.S. House Select Committee on China has opened a national security investigation into several major American pharmaceutical companies regarding their clinical trial operations in China. This specifically includes Bristol Myers Squibb, along with Merck, AbbVie, Pfizer, and Eli Lilly. Led by Chairman John Moolenaar (R-Mich.), the committee is investigating U.S. drugmakers for sponsoring clinical trials at Chinese military hospitals and medical centers, as well as in the Xinjiang region. According to the committee’s letters, lawmakers expressed concern that these trials could potentially present ethical risks and data security vulnerabilities that could inadvertently fuel China’s military biotechnology research. Public data from ClinicalTrials.gov revealed that Bristol Myers Squibb has sponsored at least 17 trials involving PRC military medical centers and at least eight trials in Xinjiang, where they allege is “where the Chinese Communist Party (CCP) is conducting a [redacted] of Uyghur Muslims and other minorities.” The trials involved drugs for conditions like multiple sclerosis and lupus. While companies like Bristol Myers, Merck, and AbbVie are facing heavy scrutiny, the committee commended Pfizer’s CEO, Albert Bourla, following indications that Pfizer plans to stop sponsoring trials in Xinjiang and at PRC military hospitals. The committee explicitly stated they are not accusing the drugmakers of illegal activity, but rather pointing out severe ethical and security blind spots. The panel has demanded that the companies hand over details on their due diligence processes, intellectual property protections, and trial data guidelines by July 17. This probe comes amid an escalating legislative push by the U.S. Federal Government to reduce U.S. biotech reliance on China. Lawmakers have previously introduced measures to block the FDA from accepting clinical data generated at trial sites in China to incentivize companies to bring drug development back to the U.S.

Sources: Endpoints article

Link to top ⬆️

FDA’s Push to Re-shore Drug Manufacturing Achieves a Major Milestone

This news doesn’t refer to China specifically, but more broadly relates to re-shoring of drug manufacturing in an effort to reduce supply chain reliance on foreign countries for essential healthcare needs. The PreCheck Pilot Program was launched on February 1, 2026, directly responding to Executive Order 14293 signed by President Trump on May 5, 2025 which aimed to provide regulatory relief and promote the domestic production of critical medicines. On June 29, 2026, the U.S. Food and Drug Administration (FDA) announced the selection of seven pharmaceutical and biotechnology companies to participate in the inaugural cohort of its FDA PreCheck Pilot Program. The seven chosen companies represent a mix of massive multinationals and emerging biotechs spanning various medical fields:

1. Amneal Pharmaceutical (Long Island, NY): Will manufacture small molecule sterile liquid products for pain management, respiratory, and ophthalmic diseases.

2. Cellares Corp. (Bridgewater, NJ): Will specialize in cell-based gene therapy products for oncology and hematology.

3. Eli Lilly and Company (Lebanon, IN): Will manufacture active pharmaceutical ingredients (APIs) to support its existing and future medicines, including metabolic/GLP-1 drugs.

4. FUJIFILM Biotechnologies (Holly Springs, NC): Will support commercial-scale cell culture biomanufacturing.

5. Kriya Therapeutics, Inc. (Durham, NC): Will manufacture AAV-based gene therapy products to address chronic conditions.

6. Kyowa Kirin, Inc. (Sanford, NC): Will manufacture biotechnology drug substance targeting rare diseases.

7. Regeneron Pharmaceuticals, Inc. (Saratoga Springs, NY): Will manufacture biotechnology drug substances, sterile injectables, and novel protein therapeutics.

As congressional panels simultaneously probe U.S. Pharma reliance on Chinese clinical and manufacturing sites, this pilot serves as the “carrot” to Congress’s “stick.” The FDA’s selection of these partners is a concrete step toward building a self-sustaining, highly advanced domestic drug manufacturing ecosystem designed to foster national resilience.

Sources: FDA press release, Executive Order 14293

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Orca Bio - Tregzi (allo HSCT) / Approved (cGVHD)

On June 30, 2026, the U.S. Food and Drug Administration (FDA) made a landmark decision by approving Tregzi, a precision-engineered cellular immunotherapy developed by Orca Bio. This milestone marks the first and only approved regulatory T-cell (Treg) therapy designed to improve survival free from chronic graft-versus-host disease (cGVHD) in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Unlike a traditional stem cell transplant where a mixed bag of donor cells is infused directly into the patient, Tregzi is a personalized treatment formulated from a matched donor’s blood. It isolates and sequentially delivers three distinct components:

• Hematopoietic stem and progenitor cells (HSPCs) to rebuild and reconstitute the patient’s blood-forming system.

• Highly purified Regulatory T cells (Tregs) tasked with maintaining immune tolerance and actively suppressing GVHD.

• Conventional T cells (Tcons), which are infused slightly later to eliminate any remaining cancer cells (the graft-versus-leukemia effect) and protect against infections.

The approval was driven by statistically significant data from the Phase 3 PRECISION-T clinical trial, which randomized 187 adult patients to receive either Tregzi or a standard hematopoietic stem cell transplantation. Approximately 78% of patients treated with Tregzi were alive and free from moderate-to-severe cGVHD after 1 year, compared to just 38.4% in the standard transplant control group (see graph below). The cumulative incidence of moderate-to-severe cGVHD was slashed to 12.6% in the Tregzi arm from 44% in the control group. Furthermore, the safety profile of Tregzi was strong and consistent with the toxicities typically expected during a stem cell reset (such as mouth sores and standard infections), but with lower non-relapse mortality and fewer serious infections than the traditional protocol. Fully capitalized for its upcoming launch, Orca Bio has already established reimbursement pathways across commercial and government programs to help eligible patients access this practice-changing therapy.

Sources: Orca Bio press release, Tregzi label

Link to top ⬆️

Viridian - Lumvoa (IGF-1R inhibitor) / Approval (TED)

On June 26, 2026, the U.S. Food and Drug Administration (FDA) approved Viridian Therapeutics’ Lumvoa (veligrotug-vvze) for the treatment of Thyroid Eye Disease (TED). This landmark regulatory milestone represents a paradigm shift for patients and clinicians alike. Lumvoa is the first direct competitor to Amgen’s blockbuster drug Tepezza, which was previously the only FDA-approved therapy for the condition since 2020. TED is a rare, debilitating autoimmune disorder that causes tissues behind the eyes to inflame and expand. This results in painful, disfiguring eye bulging (proptosis) and double vision (diplopia), profoundly impacting a patient’s quality of life. While both Lumvoa and Tepezza target the insulin-like growth factor-1 receptor (IGF-1R) pathway, Lumvoa enters the market with several distinct, patient-centric advantages:

• The First Broad-Spectrum Label: Lumvoa is the first approved TED treatment to explicitly include data for both active and chronic stages of the disease directly on its label, giving physicians clear guidance to treat patients regardless of how long they have suffered from the condition.

• A Faster, Shorter Dosing Schedule: Lumvoa provides a more efficient treatment course than historical options, requiring only five intravenous (IV) infusions administered over a 12-week period (one infusion every three weeks), compared to Tepezza’s standard eight-infusion regimen.

• Superior Double Vision Resolution: Clinical results from its pivotal Phase 3 THRIVE and THRIVE-2 trials demonstrated rapid, significant reductions in eye bulging as early as three weeks, alongside unprecedented rates of complete double vision resolution.

Lumvoa’s approval was supported by two pivotal, global Phase 3 clinical trials: THRIVE and THRIVE-2. Both trials met their primary and all secondary endpoints at the 15-week primary analysis mark following a shorter, 12-week course of 5 intravenous (IV) infusions (10 mg/kg administered every 3 weeks). In the THRIVE Trial, Lumvoa achieved a 70% proptosis responder rate (defined as a ≥ 2 mm reduction in eye bulging without worsening in the fellow eye) compared to just 5% in the placebo group (see graph below). Lumvoa demonstrated a highly significant 56% proptosis responder rate by Hertel measurements, compared to 8% for placebo (a 48% placebo-adjusted difference, p < 0.0001; see graph below). In the chronic population (THRIVE-2), 56% of Lumvoa patients achieved a significant improvement (at least a 1-grade reduction on the Gorman scale) compared to 25% for placebo. Onset was rapid, showing divergence by week 6. Crucially, 32% of Lumvoa patients achieved complete resolution of their double vision (a Gorman score of 0) compared to 14% in the placebo arm (p = 0.0152). Lumvoa is immediately available for physicians to prescribe. To streamline adoption, the launch is fully supported by ViridianCares, a comprehensive hub providing insurance verification, coverage support, and patient co-pay assistance.

Sources: Viridian press release, Viridian slide deck, Lumvoa label

Link to top ⬆️

Vertex - Casgevy (BCL11A-KO HSCT) / Label Expansion (SCD/TDT age 2+)

On July 1, 2026, the U.S. Food and Drug Administration (FDA) granted a major label expansion for Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel), extending its indication to include children as young as 2 years old. Previously restricted to patients aged 12 and older, Casgevy is now the first and only CRISPR-based gene-editing therapy approved for young pediatric patients suffering from either severe sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT). Both SCD and TDT stem from genetic defects in adult hemoglobin. Casgevy bypasses the mutated adult gene entirely by utilizing ex vivo CRISPR/Cas9 technology to edit a patient’s own hematopoietic stem and progenitor cells. The therapy precisely targets and knocks out the erythroid-specific enhancer region of the BCL11A gene. BCL11A acts as a genetic switch that normally shuts down the production of fetal hemoglobin (HbF) shortly after birth. By knocking out this switch, Casgevy permanently reactivates high-level HbF production. In SCD patients, the robust presence of HbF prevents red blood cells from sickling. In TDT patients, it corrects the severe hemoglobin deficiency, eliminating the root causes of both diseases.

The landmark expansion was supported by data from the ongoing Phase 3 open-label CLIMB-141 and CLIMB-151 pediatric trials. While Vertex initially sought approval for ages 5 to 11, the striking consistency of the data prompted the FDA to expand the label down to age 2:

• Sickle Cell Disease Cohort (Ages 5 to <12): The FDA evaluated 11 young patients with severe SCD. Out of the 8 patients who reached the timeframe to be evaluable for efficacy, 100% (8/8) achieved complete freedom from severe vaso-occlusive crises (VOC-free status) for at least 12 consecutive months within the first two years post-infusion.

• β-Thalassemia Cohort (Ages 5 to <12): In a trial of 15 pediatric patients with TDT, 88.9% (8/9) of the efficacy-evaluable children achieved complete transfusion independence for at least 12 consecutive months, boasting a median duration of 20.1 months without needing a single blood transfusion.

• Extrapolation to Ages 2-4: Since trials for children aged 2 to 4 were still ongoing but showing nearly identical biological and product characteristics, the FDA utilized clinical extrapolation. Recognizing the highly predictable consistency of the gene-editing mechanism across age groups, regulators simultaneously granted the wider age clearance.

The approval was processed with remarkable speed through the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, which shaved traditional 10-to-12-month review timelines down to just 53 days from the official filing date.

Sources: Vertex press release, updated Casgevy label

Link to top ⬆️

Arcutis - Zoryve (topical PDE4 inhibitor) / Label Expansion (plaque psoriasis age 2+)

In a significant advancement for pediatric dermatology, the U.S. Food and Drug Administration (FDA) has granted a major label expansion for Arcutis Biotherapeutics’ Zoryve (roflumilast) cream 0.3%. Previously indicated only for individuals aged 6 and older, Zoryve is now approved for the treatment of mild, moderate, and severe plaque psoriasis in pediatric patients as young as 2 years old. Plaque psoriasis in toddlers and young children can be exceptionally difficult to manage. The disease frequently presents in highly sensitive, thin-skin regions, such as the face, neck, and skin folds (intertriginous areas), where traditional mid-to-high-potency topical steroids are strictly restricted due to the risk of skin thinning, systemic absorption, and stretch marks. This expansion provides families and pediatricians with a much-needed, steroid-free alternative.

The regulatory clearance was supported by a comprehensive package demonstrating consistent safety and efficacy across age groups. Initial approvals in adults and older children were established by the twin, pivotal DERMIS-1 and DERMIS-2 Phase 3 trials, which demonstrated rapid plaque clearance, marked reduction in itch, and a highly favorable safety profile. To expand the label down to age 2, Arcutis conducted a specific open-label Phase 3 maximal usage pharmacokinetics (PK) study in toddlers. The data confirmed that the 0.3% dose was excellently tolerated, showed a predictable and safe systemic exposure profile identical to older demographics, and generated no new safety signals. Arcutis has ensured immediate commercial availability for this expanded age group, backed by its existing commercial access programs to minimize out-of-pocket friction for families seeking a steroid-free option for their young children.

Sources: Arcutis press release, updated Zoryve label

Link to top ⬆️

Clinical Trial Data

Abivax - Obefazimod (miR-124 upregulator) / Phase 3 (UC)

On June 29, 2026, Abivax reported highly anticipated topline data from Part 2 of its Phase 3 ABTECT maintenance trial for obefazimod in moderate-to-severe ulcerative colitis (UC). This readout addressed lingering market anxieties regarding a potential malignancy signal from the earlier Part 1 readout, positioning the asset for a planned regulatory submission.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation of the colon, driven by a dysregulated immune response against intestinal microbiota that triggers epithelial barrier breakdown and an overproduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-12/23). While standard treatment escalates from anti-inflammatory 5-ASAs and corticosteroids for mild disease to biologics and oral small molecules (JAK or S1P inhibitors) for moderate-to-severe cases, obefazimod introduces a potential first-in-class, oral mechanism of action to this therapeutic landscape. By selectively binding to the cellular cap-binding complex (CBC) 80/20, obefazimod enhances RNA splicing to upregulate microRNA-124 (miR-124), which functions as a physiological brake that systematically suppresses key pro-inflammatory cytokines (IL-6, TNF-α, IL-17) and limits pathogenic Th17 cell proliferation, effectively downregulating colonic inflammation without inducing broad, systemic immunosuppression.

The Phase 3 ABTECT maintenance program evaluated daily oral obefazimod (25 mg and 50 mg) against a placebo in moderate-to-severe ulcerative colitis (UC) across two parts: a 44-week randomized responder re-randomization trial (Part 1, n=580) and an expansion study in refractory or relapsed cohorts (Part 2). Part 2 demonstrated that dose optimization with continuous 50 mg obefazimod rescued 37.2% of initial induction non-responders into clinical remission and recaptured clinical remission in approximately 45% of patients who had relapsed during Part 1. Crucially, Abivax reported a pooled analysis of 1,704 patient-years of exposure demonstrating a malignancy rate (0.56 IR/100 PY) that the company noted falls within the expected UC background range (0.30–0.70 IR/100 PY), with non-melanoma skin cancers isolated to older patients with pre-existing risk factors.

Abivax is fully capitalized and remains on track to submit its formal New Drug Application (NDA) to the U.S. FDA for obefazimod in ulcerative colitis. The company anticipates the topline data readout from its Phase 2b ENHANCE-CD induction trial in mid-2027, which is currently evaluating obefazimod’s clinical utility in Crohn’s disease with the goal of expanding its IBD franchise footprint.

Sources: Abivax press release, Abivax slide deck

Link to top ⬆️

RevMed - Zoldonrasib (KRAS-G12D inhibitor) / Phase 1 (G12D mutated mPDAC)

At the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, Revolution Medicines presented encouraging Phase 1/2 data for its candidate zoldonrasib (RMC-9805) in combination with its multi-RAS inhibitor daraxonrasib (RMC-6236). This readout established early signs of clinical efficacy in heavily pretreated, advanced KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (mPDAC), a disease historically resistant to standard therapies.

KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy where a specific missense mutation permanently locks the KRAS protein into an active, GTP-bound “ON” conformation, continuously fueling downstream proliferative pathways (MAPK/ERK, PI3K/AKT) and leaving patients with limited standard options beyond intense systemic chemotherapies like FOLFIRINOX or gemcitabine/nab-paclitaxel. Addressing this historically untargetable driver, zoldonrasib introduces a first-in-class, oral, mutant-selective mechanism that directly targets the active “ON” state of the mutated KRAS G12D protein. By utilizing a molecular glue approach, zoldonrasib binds the active KRAS G12D mutant and an abundant intracellular chaperone protein, cyclophilin A, to form a stable tri-complex. This steric block selectively modifies the mutant aspartic acid residue to turn off hyperactive MAPK signaling and prevent downstream effector interaction while minimizing disruption of wild-type RAS variants or harm to healthy tissue.

The multicenter, open-label Phase 1 RMC-9805-001 trial evaluated a daily oral combination of the mutant-selective covalent RAS(ON) G12D inhibitor zoldonrasib (1200 mg) and the pan-RAS(ON) inhibitor daraxonrasib (300 mg) in 60 patients with advanced, chemotherapy-refractory KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma (mPDAC). In the second-line setting (n=30), the combination achieved a 50% objective response rate (ORR), a 97% disease control rate (DCR), and an unprecedented median progression-free survival (mPFS) of 9.6 months, while maintaining a 47% ORR and 7.6 months mPFS in third-line or later patients (n=30). Furthermore, the combination exhibited a predictable and manageable safety profile. Treatment-emergent adverse events were primarily mild-to-moderate (Grade 1/2) on-target toxicities such as rash (90%), diarrhea (63%), nausea (57%), and stomatitis (53%). The combination also had low discontinuation rates and minimal severe toxicities. Building on this foundational late-line success, Revolution Medicine has pushed zoldonrasib into earlier settings. At the same congress, the company detailed its front-line (1L) combination strategies with chemotherapy (mFOLFIRINOX and GnP), which achieved staggering front-line ORRs up to 82%.

Revolution Medicine has initiated the global, randomized Phase 3 RASolute 305 trial. This study will evaluate zoldonrasib directly alongside investigator’s choice of standard chemotherapy backbones in treatment-naïve, first-line metastatic KRAS G12D PDAC patients, laying the groundwork for a future definitive regulatory approval.

Sources: RevMed press release

Link to top ⬆️

AbbVie - Epkinly (CD3 x CD20 mAb) / Phase 3 (R/R DLBCL)

On July 3, 2026, AbbVie and Genmab announced positive topline results from their Phase 3 EPCORE DLBCL-1 clinical trial evaluating Epkinly (epcoritamab-bysp) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This successful readout provides a major clinical victory and redemption for the asset’s late-line franchise after it missed an overall survival milestone earlier in the year.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy characterized by the uncontrolled clonal proliferation of malignant B-lymphocytes, driven by chromosomal translocations (MYC, BCL2, BCL6) and dysregulated signaling pathways (NF-κB) that block cellular differentiation. While frontline treatment relies on intense chemoimmunotherapy like R-CHOP or Polivy-R-CHP, and later-line options shift based on transplant eligibility to salvage chemotherapy, CAR-T, or targeted agents, Epkinly (epcoritamab-bysp) introduces a highly targeted therapeutic approach. As a first-in-class, subcutaneous CD3×CD20 T-cell engaging bispecific antibody, Epkinly simultaneously binds to CD20 on malignant B-cells and CD3 on mature T-cells. By physically bridging these cells, it bypasses traditional major histocompatibility complex (MHC) class I restrictions to trigger the direct activation of endogenous T-cells, which release cytotoxic perforins and granzymes to induce immunologically driven lysis of the lymphoma cells. Check out CAR-T, Part 2 if you are interested in learnings more about the history and cutting edge of TCEs.

The global, randomized, open-label Phase 3 EPCORE DLBCL-1 trial evaluated subcutaneous Epkinly monotherapy against standard salvage chemotherapy (primarily the R-GemOx regimen) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were transplant-ineligible and had failed at least two prior systemic lines. Topline data demonstrated that Epkinly met its primary endpoint by remarkably reducing the risk of disease progression or death by 60% (HR=0.40) compared to standard chemotherapy, while maintaining a predictable safety profile with low-grade, manageable cytokine release syndrome (CRS) confined to the initial step-up dosing weeks. This decisive victory rehabilitates the Epkinly franchise after an earlier 2026 second-line clinical trial setback.

AbbVie and Genmab have announced they will immediately engage with global regulatory authorities (including the U.S. FDA and European Medicines Agency) to submit these data to expand Epkinly‘s label from its current accelerated status into a full, definitive regulatory approval for late-line DLBCL. The next major inflection point for the franchise will occur later in 2026, when AbbVie expects to read out pivotal Phase 3 data evaluating Epkinly moved up into first-line (1L) newly diagnosed DLBCL in combination with standard R-CHOP chemotherapy.

Sources: AbbVie press release, Genmab press release

Link to top ⬆️

AstraZeneca - Efzimfotase alfa (TNSALP ERT) / Phase 3 (hypophosphatasia ages 2-11)

On July 2, 2026, AstraZeneca announced positive topline results from its global, randomized Phase 3 clinical trial evaluating efzimfotase alfa (ALXN1850) in pediatric patients aged 2 to 11 with hypophosphatasia (HPP). This pediatric readout establishes a distinct clinical data package for the asset, which previously did not meet its primary endpoints in a separate Phase 3 trial evaluating adolescents and adults.

Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that result in a deficiency of tissue-nonspecific alkaline phosphatase (TNSALP), leading to an extracellular accumulation of inorganic pyrophosphate (iPP), a potent biochemical inhibitor of hydroxyapatite crystal formation that causes rickets, progressive skeletal deformities, and muscle weakness. While standard care focuses on supportive management or the established enzyme replacement therapy (ERT) Strensiq (asfotase alfa) to restore bone mineralization, efzimfotase alfa (ALXN1850) introduces a next-generation, bone-targeted TNSALP enzyme replacement therapy to addressing this enzyme deficiency. Engineered as a recombinant soluble TNSALP fusion protein modified with a negatively charged, deca-aspartate peptide tail, efzimfotase alfa selectively binds with high affinity to hydroxyapatite crystals within the mineralizing bone matrix. Once localized, it directly cleaves accumulated iPP into inorganic phosphate, systematically removing the biochemical barrier to healthy bone architecture and mineralization.

The global, randomized, double-blind Phase 3 trial evaluated the efficacy and safety of subcutaneous efzimfotase alfa against a placebo over a 25-week primary evaluation period in 64 pediatric patients (aged 2 to 11) with pediatric-onset hypophosphatasia (HPP). Topline results demonstrated that the trial successfully met its primary endpoint, with the efzimfotase alfa cohort achieving a statistically significant mean Radiographic Global Impression of Change (RGI-C) score improvement of +1.67 points compared to 0.00 points in the placebo arm (P=0.0003), driving substantial radiographic healing of active rickets and skeletal lesions alongside robust improvements in growth velocity and motor function. The next-generation enzyme replacement therapy was well-tolerated, with mild-to-moderate injection-site reactions representing the most frequent adverse events and no severe systemic toxicities reported. This successful pediatric readout provides critical continuity for AstraZeneca’s Alexion rare disease franchise as a pipeline successor to Strensiq, demonstrating a highly effective targeted therapeutic window during early childhood development when bone turnover is highest, despite the asset’s previous clinical failures in less dynamic adolescent and adult populations.

Armed with a highly significant pediatric dataset, AstraZeneca intends to discuss these results with global regulatory bodies, including the U.S. FDA and the European Medicines Agency (EMA), to seek marketing authorization specifically for pediatric HPP patients. The trial is transitioning into its open-label extension phase to monitor the long-term durability of bone mineralization, growth parameters, and antibody safety profiles out to two years post-infusion.

Sources: AstraZeneca press release

Link to top ⬆️

BeOne - Brukinsa (BTK inhibitor) / Phase 3 (1L MCL)

On July 3, 2026, BeOne announced positive topline results from its global Phase 3 clinical trial evaluating Brukinsa (zanubrutinib) in treatment-naïve patients with mantle cell lymphoma (MCL). This successful frontline readout marks a major therapeutic milestone, positioned to disrupt the traditional chemoimmunotherapy paradigm for newly diagnosed patients.

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy driven by the hallmark t(11;14) translocation that causes constitutive overexpression of cyclin D1, forcing unchecked cell cycle progression, which is further sustained by hyperactive B-cell receptor (BCR) signaling mediated by Bruton’s tyrosine kinase (BTK). The frontline standard of care is strictly stratified by patient fitness, relying on intensive cytarabine-based chemoimmunotherapy and autologous stem cell transplantation (ASCT) for younger patients, and regimens like bendamustine plus rituximab (BR) for transplant-ineligible individuals. As a next-generation, oral small-molecule BTK inhibitor, Brukinsa forms an irreversible, covalent bond within the ATP-binding pocket of the BTK enzyme to profoundly disrupt downstream proliferative networks (MAPK, NF-κB). It was specifically engineered to maximize target occupancy while minimizing off-target inhibition of structurally similar kinases (such as EGFR, TEC, and ITK), thereby turning off oncogenic survival signals while successfully reducing common class-related toxicities.

The global, randomized, open-label Phase 3 trial evaluated oral Brukinsa (zanubrutinib) monotherapy as a chemotherapy-free alternative against standard investigator-chosen chemoimmunotherapy (such as bendamustine plus rituximab) in previously untreated, transplant-ineligible adult patients with newly diagnosed mantle cell lymphoma (MCL). Topline data demonstrated that frontline Brukinsa significantly met its primary endpoint, cutting the risk of disease progression or death by 43% (HR=0.57) while showcasing a favorable selectivity profile with low rates of cardiac adverse events and significantly lower rates of severe myelosuppression and febrile neutropenia compared to the chemotherapy arm. Secondary endpoints, including objective response rate and a positive trend in overall survival, also favored Brukinsa.

BeOne plans to present the detailed, granular survival and response data at an upcoming major medical congress and will initiate discussions with global regulatory authorities (including the U.S. FDA and EMA) to file supplemental regulatory submissions for expanded frontline approval. Moving forward, next steps will focus on exploring Brukinsa-led combinations in earlier lines of therapy, including ongoing trials evaluating its synergy with BCL-2 inhibitors (such as venetoclax) to achieve deeper, fixed-duration molecular remissions.

Sources: BeOne press release

Link to top ⬆️

Descriptive data releases without numerical data

• Roche - Divarasib (reversible KRAS G12C inhibitor) / Phase 3 (2L NSCLC): The Phase 3 Krascendo-1 trial evaluating Roche’s divarasib, a reversible KRAS G12C inhibitor, achieved a statistically significant and clinically meaningful success in the second-line relapsed or refractory non-small cell lung cancer (2L NSCLC) setting. The trial demonstrated that divarasib delivered robust improvements in both overall survival (OS) and progression-free survival (PFS) when compared directly against the investigator’s choice of standard covalent KRAS G12C inhibitors, specifically Amgen’s Lumakras (sotorasib) or Bristol Myers Squibb’s Krazati (adagrasib). While detailed data from this readout are slated for presentation at an upcoming medical conference, Roche is already advancing the asset’s clinical pipeline, with the Krascendo-2 trial actively ongoing to evaluate divarasib’s therapeutic potential in the frontline (1L NSCLC) setting.

• Otsuka - Voyxact (anti-APRIL mAb) / Phase 3 (IgAN): Otsuka announced positive topline results from its Phase 3 trial evaluating Voyxact (sibeprenlimab-szsi), a first-in-class anti-APRIL monoclonal antibody, in patients with primary IgA nephropathy (IgAN). The trial successfully met its key long-term objectives, demonstrating that Voyxact treatment led to a statistically significant and clinically meaningful stabilization of kidney function after two years of follow-up compared to placebo. These critical 24-month data, slated for full presentation at an upcoming medical conference, establish the durable clinical efficacy of the therapy and serve as the foundational evidence required to secure full regulatory approval.

• Sanofi - Nexviazyme (M6P-GAA ERT) / Phase 3 (infant Pompe): The Phase 3 trial evaluating Sanofi’s Nexviazyme (avalglucosidase alfa), a next-generation, mannose-6-phosphate-enriched receptor-targeted acid alpha-glucosidase (M6P-GAA) enzyme replacement therapy, achieved a clinical success in treatment-naïve, infant-onset Pompe disease. The study successfully met its primary efficacy endpoint, which measured the percentage of treatment-naïve infants aged 6 months and younger who were alive and free from the need for invasive ventilation at 52 weeks. Although specific data metrics and numbers were not disclosed in the initial announcement, Sanofi is scheduled to present the comprehensive data from this readout on July 8 at the International Congress on Neuromuscular Diseases.

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On July 2, 2026, United Therapeutics Corporation announced that it has acquired Thymmune Therapeutics, Inc. for $140 million in cash plus up to $160 million based on the achievement of certain clinical and regulatory milestones by the end of 2031, for a total deal value of up to $300 million. This acquisition centers on THY-100, an investigational, preclinical neo-thymus cell therapy being evaluated to treat congenital athymia (infants born without a functional thymus).

In this article, we dive into the role of stem cell reprogramming in regenerative medicine, explore how foundational work in the George Church lab led to the spinout of Thymmune, and learn how Thymmune fits into United Therapeutics’ regenerative medicine ambitions.

The Church of Cell Reprogramming

Thymmune Therapeutics traces its roots back to foundational research in George Church’s laboratory at Harvard Medical School and the Wyss Institute. A major focus of his lab is regenerative medicine, which aims to do something pharmacological medicine struggles to achieve: repair, replace, or regenerate damaged tissues and organs rather than managing disease symptoms. Stem cells are a foundational engine of this field because they possess two unique properties that make them the cellular raw material for regeneration:

• Self-Renewal: The ability to divide and replicate themselves indefinitely in a lab environment, creating an inexhaustible supply of starting material.

• Potency: The ability to differentiate (mature) into specialized functional cells, such as heart muscle cells, neurons, or insulin-producing pancreatic cells.

An enabling technology for the Church lab’s research is the induced pluripotent stem cell (iPSC). The process of making iPSCs was discovered in 2006 by Shinya Yamanaka (which earned him a Nobel Prize). It involves taking adult cells and introducing a specific cocktail of four master genes, known as the Yamanaka Factors (Oct3/4, Sox2, Klf4, and c-Myc). These factors wipe the cell’s memory, rewinding its developmental clock back to zero. To be clear, iPSCs are different from embryonic stem cells (ESCs). Both types of stem cells are theoretically able to differentiate into virtually any cell type in the human body, but they diverge in their origin and the ethical considerations surrounding them. Embryonic stem cells are derived directly from the inner cell mass of a pre-implantation human embryo that is typically four to five days old. This derivation process inherently results in the destruction of the embryo, which has historically sparked intense ethical, religious, and political debates worldwide, leading to strict regulatory bottlenecks. In contrast, iPSCs come from fully mature adult cells (typically skin fibroblasts or peripheral blood cells) and are genetically reprogramed back into an embryonic-like state using Yamanaka Factors.

Yet, making stem cells is half the battle. In order to craft a regenerative medicine for a particular treatment context, you need to know how to program the stem cells into the specific type of mature cell that you need. For example, you would need to make collagen-producing fibroblasts in the context of knee regeneration, but you would need to make nerve cells in the context of spine regeneration. That last mile of cell programming is where the Church lab shines. The lab uses synthetic biology and machine learning techniques to figure out how to make specific cell types from iPSCs. By utilizing pooled screens of transcription factors, researchers in the lab systematically identified the master switches required to convert induced pluripotent stem cells (iPSCs) directly into highly specialized cell types.

Their 2020 Nature Biotechnology paper entitled “A comprehensive library of human transcription factors for cell fate engineering” was a major advance in the field of regenerative medicine. Traditional stem cell differentiation relied on recreating natural, slow, and expensive embryonic signaling pathways using chemical morphogens in specialized lab environments. The Church lab bypassed this developmental path by focusing entirely on transcription factors, the master genetic switches that control cell identity. By executing massive pooled genetic screens on human induced pluripotent stem cells (hiPSCs), the team identified 290 distinct transcription factors capable of driving stem cells to differentiate into mature target cells within just 4 days. Remarkably, 241 of these TFs were previously entirely unreported to possess cell-fate capabilities. The researchers validated their screening hits by programming stem cells into high-quality, fully functional adult tissue lineages that matched primary human tissue control profiles. The paper specifically demonstrated four distinct lineages:

• Neurons & Fibroblasts: The team derived functional neurons that displayed proper electrophysiological patch-clamp readings and fibroblasts that successfully healed an in vitro wound-scratch monolayer.

• Vascular Endothelial Cells: Utilizing a specific splice variant (ETV2 isoform 2), they achieved nearly 100% differentiation efficiency into endothelial-like cells that successfully formed functional, perfusable blood vessels integrated with host circulatory systems in vivo.

• Oligodendrocytes: They co-cultured engineered, oligodendrocyte-inducible hiPSCs alongside unmodified hiPSCs to generate complex cerebral organoids. This allowed different cell types to mature synchronously, radically accelerating in situ myelination of axons.

Ultimately, the Church lab’s Human TFome project wrote the rules of cell reprogramming. The ability to program induced pluripotent stem cells (iPSCs) rapidly and autonomously provided the means to mass-produce complex, therapeutic tissues, setting the stage for spinouts like Thymmune to engineer a functional neo-thymus in vivo.

Growing a Thymus

The thymus is a small organ located behind your breastbone, and it acts as the training ground for the immune system. It takes immature immune cells from the bone marrow and teaches them to become T-cells, the specialized soldiers that fight off viruses, bacteria, and cancer. Unfortunately, this crucial organ is not as resilient as it ought to be.

Unlike almost every other organ, the thymus begins to shrink and turn to fat starting at puberty. By the time you reach old age, your thymus is operating at a fraction of its capacity. This is a primary reason why older adults are far more vulnerable to new infections (like COVID-19 or influenza) and why their bodies are less effective at clearing emerging cancer cells. Patients with congenital athymia, a rare genetic condition where children are born entirely without a thymus, cannot produce T cells, leaving them with a severely weakened immune system. Historically, the condition is fatal within the first two years of life without an intervention.

If you want to fix an organ using a regenerative medicine approach with embryonic stem cells (ESCs), you could take a stem cell and expose it to a sequence of chemical growth factors (morphogens) that mimic human embryonic development. However, growing Thymic Epithelial Cells (TECs) was particularly challenging for three reasons:

• The Complexity of the Epithelial Scaffold: The thymus isn’t just a collection of loose cells. It is a highly intricate, three-dimensional physical meshwork. As immature T-cells crawl through this biological maze, TECs must physically touch them to present self-antigens. This teaches the T-cells two things: how to recognize foreign invaders (positive selection) and how not to attack your own body (negative selection). Replicating this complex, interactive 3D behavior in a flat plastic dish using standard chemical signaling had proven nearly impossible.

• High Instability and Loss of Identity: When researchers did manage to isolate primary thymic epithelial cells from tissue donors, they encountered a major hurdle: the moment these cells were cultured outside the body, they rapidly lost their functional identity in a process called dedifferentiation. Within a few cell divisions, they ceased expressing the critical genes, like FOXN1 (the master regulator of thymic development), needed to train T-cells.

• The Yield Problem: Since the differentiation pathways are so convoluted, traditional methods resulted in horribly low yields. You might end up with a tiny fraction of functional cells hidden among a mess of chaotic, half-differentiated tissues. To treat a patient, doctors need hundreds of millions of highly pure, synchronized cells.

The George Church lab’s Human TFome project gave scientists much higher agency in making Thymic Epithelial Cells (TECs) from iPSCs. The actual translation of this platform specifically into the thymic lineage was driven by Stan Wang, during and immediately following a postdoctoral fellowship in the Church lab. Rather than publishing the specific iPSC-to-TEC cocktail in an open-access academic paper, the specialized genetic recipes, machine learning optimization algorithms, and methods for forming a functional neo-thymus in vivo were largely protected as proprietary intellectual property and patent filings. This proprietary execution of the Church lab’s screening methodology became the foundation upon which Wang spun out Thymmune Therapeutics in 2019.

The company established its operations in Kendall Square in 2021 and immediately captured the interest of major pharmaceutical players. That year, Thymmune won five “Golden Tickets” from major sponsors including Pfizer, Novo Nordisk, LG Chem Life Sciences, Boehringer Ingelheim, and Astellas. These awards equipped the fledgling company with critical early industry validation and lab space. Thymmune formally launched out of stealth in March 2023, securing a $7 million seed financing round led by Pillar VC, with participation from New York Blood Center’s NYBC Ventures, George Church, and former Alnylam CEO John Maraganore. The corporate trajectory accelerated significantly in September 2023, when Thymmune became one of the very first industry projects funded by the Biden administration’s newly formed Advanced Research Projects Agency for Health (ARPA-H). The agency awarded Thymmune up to $37 million under its Open Broad Agency Announcement to fund its “Thymus Rejuvenation” project. This non-dilutive capital gave Thymmune an immense runway to build out its infrastructure across two parallel validation phases:

• Phase 1: Utilizing human induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) to restore T-cell development in thymus-incompetent animals and slow immunologic aging.

• Phase 2: Scaling up the manufacturing process for transplantation models to establish a viable clinical pathway.

With strong financial backing, leadership expanded the executive layer, bringing on veteran biopharma talent including Chief Scientific Officer Bing Lim, and Chief Technology Officer Manish Jain. The team directed their machine learning platform toward industrializing the production of off-the-shelf, scalable iPSC-derived thymic cells. The buildout centered heavily on THY-100, the company’s lead preclinical candidate for congenital athymia (infants born without a functional thymus). In animal models, Thymmune demonstrated that a less-invasive injection of their engineered cells could induce in vivo self-assembly, forming a functional, vascularized neo-thymus capable of facilitating independent T-cell development in these models. Beyond athymia, the company scaled its research into broader horizons, targeting age-related immune decline and post-transplant organ tolerance.

The rapid buildout of Thymmune’s platform culminated in a major consolidation of the regenerative medicine space. On July 2, 2026, Thymmune was acquired by United Therapeutics, a company that is not a stranger to regenerative medicine. Driven by CEO Martine Rothblatt’s mission to solve the global organ shortage, the company’s alternative organ pipeline is organized across three scientific pillars:

• Xenotransplantation: Xenotransplantation relies on genetic engineering to strip porcine (pig) organs of the carbohydrate molecules that trigger hyperacute human immune rejection, turning them into immediate, viable alternatives for human transplant. They are developing UHeart for end-stage heart disease, UKidney for end-stage renal disease, and UThymoKidney to solve the problem of post-transplant rejection (the goal is to the train the patient’s recipient T-cells to recognize the foreign organ as self).

• Allogeneic Bioengineered Organs: Acquired by United Therapeutics for over $100 million, the Miromatrix subsidiary bypasses gene-editing by leveraging a unique perfusion decellularization and recellularization technology. Scientists take an off-the-shelf porcine organ and use a specialized chemical wash to strip away all animal cells, leaving behind an intact, pristine, non-immunogenic three-dimensional collagen scaffold. This scaffold is seeded (recellularized) with human vascular and organ-specific cells. They are starting with an external liver assist product, which is similar to dialysis for liver failure.

• Autologous iPSC Regenerative Medicine: The long-term holy grail of United Therapeutics’ pipeline is to completely eliminate human immune rejection by utilizing a patient’s own cells or universal, stealth cellular lines to manufacture personalized tissue. Here, they are starting with ULung and ULobe for end-stage lung disease. Developed through partnerships with 3D-bioprinting leaders like 3D Systems, this program prints complex, high-resolution synthetic lung scaffolds embedded with patient-derived or highly compatible human stem cells. The long-term developmental goal is to construct a fully functioning, cellularized human lung capable of independent gas exchange. The Thymmune acquisition falls squarely into this bucket.

Conclusion

The acquisition of Thymmune by United Therapeutics represents a textbook synergy between academic innovation and industry acceleration. The foundational work emerging from the George Church lab provided its enabling technology: a method for using transcription factors to orchestrate cellular reprogramming. Nevertheless, turning a brilliant academic insight into a scalable cell therapy requires a completely different set of capabilities. It demands the refinement of experiments into repeatable & scalable processes, the navigation of complex regulatory frameworks, and a long financial runway. By absorbing Thymmune, United Therapeutics is integrating a sophisticated cellular programming platform into their broader organ-manufacturing apparatus. Together, they hope to manifest their shared dream of engineering functional, patient-specific organs in vivo.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On July 1, 2026, Ipsen announced a definitive agreement to acquire Memo Therapeutics AG for €200 million (about $228 million USD) upfront at closing and up to a total of €700 million (about $797 million USD) contingent upon the achievement of specified development, regulatory approval and sales-based milestones (Ipsen press release, Memo press release). This acquisition centers on potravitug, an investigational first-in-class BK polyomavirus (BKV) monoclonal antibody that is currently being evaluated for the treatment of active BK polyomavirus associated nephropathy (BKVAN) and the prevention of graft loss or transplant failure in kidney transplant patients.

In this article, we dive into the history of BK polyomavirus (BKV), uncover the foundational discoveries that enabled Memo Therapeutics’ potravitug, and relive the company’s fascinating backstory.

Hidden Plague

BK polyomavirus (BKV) is a small, double-stranded DNA virus belonging to the Polyomaviridae family that is highly ubiquitous in the human population, with up to 90% of adults worldwide maintaining a lifelong, asymptomatic latent infection within the epithelial cells of the kidney and urinary tract. While the virus is benign in individuals with intact immune systems, it presents a severe clinical threat to kidney transplant recipients. For context, kidney transplant patients must take a cocktail of immune suppressing medicines after a transplant so that the donor organ can engraft and start working. However, that cocktail makes the patient functionally immunocompromised, with a diminished capacity to defend against infectious diseases. When host immunity is suppressed, BKV can reactivate and undergo unchecked lytic replication, leading to severe complications such as BK virus-associated nephropathy (BKVAN). BKVAN can cause premature kidney allograft failure, or hemorrhagic cystitis, characterized by painful bladder inflammation and bleeding.

But, how did we discover BKV if it’s invisible to most people? This story of its discovery is a journey from an accidental virological discovery to an emerging clinical challenge. The virus was first isolated in 1970 at the Virus Research Laboratory in London, England. A virologist named Dr. Sylvia Gardner was investigating the epidemiology of a different virus, cytomegalovirus (CMV). While examining the urine of a 39-year-old Sudanese kidney transplant recipient who had developed a severe ureteric stricture (narrowing of the ureter), Dr. Gardner noted numerous cells containing prominent viral inclusions. Using electron microscopy, Dr. Anne Field identified viral particles that structurally resembled papillomaviruses. Once successfully cultured and confirmed as a distinct, novel agent, the virus was named “BK” after the initials of that first patient. The original viral isolate is still referred to as the Gardner strain. The discovery was formally published in a landmark 1971 issue of The Lancet, in a back-to-back sequence with the discovery of the closely related JC polyomavirus (JCV).

Following the isolation of BKV, extensive serological and epidemiological studies revealed a striking paradox: while the virus was discovered in a severely ill transplant patient, it was actually ubiquitous in the general population. Researchers discovered that primary BKV infection typically occurs in early childhood (often by age 4 or 5), spreading asymptomatically via respiratory or fecal-oral routes. By adulthood, 80% to 90% of the global population is seropositive. Investigators realized that after the primary childhood exposure, the virus establishes a lifelong, silent residency (latency) within the renal tubular epithelial cells and the urothelium of the urinary tract. Since it remains completely benign and asymptomatic in healthy individuals, BKV was largely categorized as an opportunistic pathogen of low clinical priority throughout the 1970s and 1980s.

The clinical significance of BKV changed dramatically in the late 20th century, driven by a major evolution in transplant medicine: the introduction of highly potent, next-generation immunosuppressive drugs (such as tacrolimus and mycophenolate mofetil) in the mid-1990s. In 1993, at the University of Pittsburgh, clinicians documented the first definitive, biopsy-proven case of BK virus-associated nephropathy (BKVAN), then termed polyomavirus interstitial nephritis, in a kidney transplant recipient presenting with unexplained graft dysfunction. As these potent triple-drug immunosuppressive regimens became the global standard of care to prevent organ rejection, rates of BKV reactivation skyrocketed. Unchecked viral replication leads to a vicious cascade: viruria (shedding in urine), progressing to viremia (virus entering the bloodstream), and ultimately resulting in BKVAN, a leading cause of premature kidney allograft loss. Concurrently, BKV emerged as a primary culprit behind hemorrhagic cystitis (characterized by severe, painful bladder inflammation and bleeding) in bone marrow and stem cell transplant recipients.

Today, BKV remains a factor in transplant success. Since there are still no universally approved, highly effective antiviral medications specifically targeting BKV, clinical management historically relies on a delicate balancing act: reducing a patient’s immunosuppression to allow their own immune system to clear the virus, which simultaneously spikes the risk of acute organ rejection.

Secrets in the Serum

For decades after the discovery of the virus in 1971, the role of antibodies in controlling BKV was highly debated. Researchers knew that 80% to 90% of adults were seropositive for BK virus, yet immunosuppressed patients still suffered from severe viral reactivation leading to BK virus-associated nephropathy (BKVAN). Early serology relied on hemagglutination inhibition (HI) assays, which lacked the sensitivity to distinguish true virus neutralization from broad cross-reactive binding. Since patients with high antibody titers still developed active viremia, the initial medical consensus was that humoral immunity was largely ineffective, and that viral control depended almost entirely on cell-mediated (T-cell) immunity.

The modern understanding of BKV neutralizing antibodies was unlocked by a critical technological breakthrough: the development of BK polyomavirus pseudoviruses (BK-PsVs), pioneered heavily by researchers like Diana Pastrana and Christopher Buck at the National Institutes of Health (NIH). By engineering pseudoviruses that packaged a reporter gene (such as green fluorescent protein or luciferase) inside recombinant viral capsid proteins (VP1, VP2, VP3), scientists could finally measure actual in vitro neutralization in cell culture. Utilizing these pseudovirus systems, researchers demonstrated that the four major genomic variants of BKV (Genotypes I-IV) behaved as completely distinct serotypes. An antibody that neutralized Genotype I would often fail to neutralize Genotype IV, explaining why a patient could have high total antibody titers but still be susceptible to a different, donor-derived strain of the virus.

Equipped with functional neutralization assays, clinical cohorts were closely monitored. The landmark 2018 study published in the Journal of the American Society of Nephrology (JASN) was conducted by a highly collaborative, multidisciplinary team of clinical and research experts based out of Strasbourg University Hospital (Hôpitaux Universitaires de Strasbourg) and the University of Strasbourg. It demonstrated that kidney transplant recipients who possessed high pre-transplant neutralizing antibody titers specifically matched to their donor’s BKV serotype were profoundly protected against post-transplant viruria (virus in the urine) and viremia (virus in the blood). A neutralizing antibody (NAb) titer <4 log10 IC50 on the day of transplantation was associated with an 88% higher risk of BKV replication after transplantation (HR, 1.88; 95% CI, 1.06 to 3.45; P=0.03).

Why did patients with neutralizing antibodies above the threshold still develop BKV infection? About 17% of patients with viruria lacked neutralizing antibodies against the specific strains of BKV that they contracted, a mismatch that allowed infection to slip through the cracks. While patients with neutralizing antibody titers during the observation period came with a 56% lower risk of transitioning from viruria (local infestation) to viremia (more global infestation), antibody mismatch with the replicating strain nevertheless resulted in a 2.3-fold increased risk of viremia. It’s not enough to simply have neutralizing antibodies. They have to hit the relevant strain in order to effectively reduce the risk of infection.

Making Medicines

With clinical pathophysiology established, the race began to isolate potent, pan-serotype human monoclonal antibodies capable of blocking all four genotypes without allowing for easy mutational escape.

Researchers at Amplyx Pharmaceuticals successfully isolated P8D11, a human-derived antibody with picomolar affinity that targeted a highly conserved structural epitope on the major capsid protein VP1. P8D11 blocked the viral attachment mechanism to host sialic acid receptors. This antibody was subsequently humanized and advanced into clinical development as MAU868. When Pfizer acquired Amplyx for an undisclosed amount in 2021 to secure its anti-fungal portfolio, the BKV program sat outside Pfizer’s core therapeutic focus. In late 2021, Vera Therapeutics acquired MAU868 from Amplyx/Pfizer for a rather paltry $5 million upfront plus up to $7 million upon reaching certain regulatory milestones. For Vera, a biotechnology company heavily anchored in serious kidney-related diseases, MAU868 was a good fit in its pipeline.

Vera took over and presented data from a randomized, double-blind, placebo-controlled Phase 2 study evaluating MAU868 in adult kidney transplant recipients who had developed active BK viremia within one year post-transplant. Participants were randomized (2:1) to receive four intravenous doses every 28 days across two distinct treatment cohorts or a matching placebo. Vera first presented the interim 12-week topline data for MAU868 at the American Transplant Congress (ATC) on June 4, 2022, in a late-breaking oral presentation. Following that initial look, Vera shared the final, full 36-week results later that year at the American Society of Nephrology (ASN) Kidney Week annual meeting in November 2022. By Week 36, more MAU868-treated patients achieved a ≥1 log₁₀ reduction in plasma viral load (75% versus 50% for placebo), and reduced viral loads below the lower limit of quantification (30% versus 0% for placebo), showing that a passive antibody therapy can effectively manage post-transplant BK virus replication without requiring hazardous adjustments to a patient’s core immunosuppressive regimen.

Despite this early success, Vera has shifted nearly all of its near-term corporate energy, funding, and public focus toward their lead asset, atacicept, whose PDUFA target action date for IgA Nephropathy (IgAN) is less than a week away from this article’s time of publication (July 7, 2026). The molecule appears to be in limbo, neither discontinued nor advanced into the larger Phase 2b/3 that Vera telegraphed back in 2022.

However, progress in the field didn’t stop with MAU868. Memo Therapeutics was founded in 2012 as a spin-off from the Swiss Federal Institute of Technology (ETH Zurich). Headquartered in the biotech hub of Schlieren/Zurich, Switzerland, the company was co-founded by Dr. Christoph Esslinger (who long served as Chief Scientific Officer) and a team of molecular biologists. In 2018, Memo raised their Series A, bringing in Swiss-based Verve Ventures, which anchored the company’s early expansion. The company was built entirely around a singular technological breakthrough: the DROPZYLLA platform. Rather than engineering synthetic antibodies in a lab or using humanized mice, DROPZYLLA was designed as an “antibody repertoire copying engine.” It used single-cell microfluidics to isolate individual memory B cells from rare human donors, specifically elite neutralizers, or rare patients who had naturally beaten severe viral infections or cancers. This could effectively capture the best blueprints of the human immune system.

In 2021, they pointed their DROPZYLLA platform not at BKV, but at COVID-19. Amid the global pandemic, Memo closed a CHF 13.8 million Series B round led by Swisscanto and rapidly validated its platform by isolating a highly potent, fully human neutralizing antibody (MTX-COVAB) from convalescent COVID-19 donors in just three weeks. Preventative vaccines beat them to the punch, and COVID-19 dropped off of the priority list. However, they had been working on a second program. Scientists at Memo had begun screening the B-cell repertoires of elite neutralizers of BKV, rare transplant patients who rapidly cleared massive BK viral loads on their own. They once again leveraged their DROPZYLLA platform to clone the paired antibody genes from elite neutralizers of BKV into mammalian expression vectors, creating a recombinant library of their immune responses. They then ran high-throughput functional screens using BKV pseudoviruses to identify candidates that blocked cell entry. Out of millions of candidates, mAb 319C07 (potravitug) emerged as the winner. It exhibited exceptional picomolar binding affinity to a highly conserved, conformationally complex structural epitope on the VP1 capsid pentamer. Since this specific epitope is indispensable for the virus to attach to host sialic acid receptors, potravitug exerts a structural blockade that prevents cell-to-cell viral spread across all four major BKV serotypes (see graph below).

Armed with this ultra-potent molecule, Memo raised a $25 million Series C round in late 2023 led by Pureos Bioventures. In May 2024, they secured a CHF 20 million Series C extension (bringing the total round to CHF 45 million), adding investors like Ysios Capital and Kurma Partners. This capital was deployed to evaluate potravitug in the Phase 2 SAFE KIDNEY II trial (NCT05769582), the largest randomized, double-blind, placebo-controlled trial ever conducted for the treatment of BKV-associated nephropathy (BKVAN). The study enrolled 95 kidney transplant recipients across 22 sites in the U.S. who had active, high-load BKV DNAemia (≥ 10,000 IU/mL). Patients received four intravenous infusions of either potravitug (500 mg or 1000 mg) or a placebo, spaced 4 weeks apart, on top of standard-of-care immunosuppression adjustments. Initial analyses from the study were first shared at the 63rd European Renal Association (ERA) Congress in early June 2026, followed immediately by the presentation of the complete, long-term 38-week dataset at the American Transplant Congress (ATC) on June 23, 2026. By week 38, 24.4% of potravitug-treated patients achieved plasma BKV-DNAemia below the lower limit of quantification compared to 13.0% in the placebo cohort, with a ≥2 log₁₀ reduction in viral load observed in 40.3% versus 24.7% of patients, respectively. Crucially, protocolized kidney biopsies at week 20 revealed that active, biopsy-proven BKVAN declined from 51.2% to 31.6% in the treatment arm while remaining completely unchanged in the placebo group, all while demonstrating a generally well-tolerated safety profile with no treatment-related serious adverse events.

A few weeks lated on July 1, 2026, the global biopharmaceutical giant Ipsen announced a definitive agreement to acquire Memo Therapeutics, securing potravitug for its expanding rare disease portfolio. To separate the drug from the platform in the transaction, a condition of the acquisition required a corporate split. While Ipsen absorbed the potravitug program to push it into global Phase 2/3 trials, Memo’s original discovery foundations are set to be spun off into a newly incorporated entity named Memorises Bio that encompasses:

• The proprietary DROPZYLLA platform

• An ongoing recombinant polyclonal IgG collaboration with CSL

• Its early-stage oncology pipeline

Memorises Bio is to remain held by Memo’s original shareholders and will continue finding the next generation of human antibodies.

Conclusion

Memo Therapeutics’ development effort is a text-book validation of reverse-translational medicine. By hunting for answers within the immune systems of rare elite neutralizers, scientists bypassed traditional lab-bench guesswork to uncover a neutralizing antibody optimized by nature. In acquiring potravitug, Ipsen secures a pan-serotype weapon against a historically hard to treat post-transplant threat. As potravitug marches toward global Phase 2/3 trials under Ipsen’s rare disease banner, the legacy of the DROPZYLLA engine lives on. The birth of Memorises Bio ensures that the hunt for the next generation of natural human antibodies continues. If pivotal trials succeed and the medicine passes through regulatory review, it could someday allow clinicians to treat active BKVAN without forcing a hazardous compromise on a patient’s core immunosuppressive safety net.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 29, 2026, Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for approximately $929 million in cash consideration subject to customary adjustments (Zymeworks press release, Zymeworks slide deck, Theravance press release). This acquisition centers on Yupelri, a nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

In this article, we dive into the story of Yupelri’s development, identify its place in the COPD landscape, and discuss the deal’s unique business development angle.

Breathing Room

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, inflammatory lung condition that causes long-term breathing difficulties by restricting airflow into and out of the lungs. Primarily caused by smoking or long-term exposure to airborne irritants, it encompasses chronic bronchitis (inflammation and mucus buildup in the bronchial tubes) and emphysema (the destruction of the lung’s fragile air sacs). Over time, this damage leads to persistent symptoms like shortness of breath, a chronic cough, and wheezing, which gradually worsen but can be managed with bronchodilators, lifestyle changes, and targeted anti-inflammatory therapies.

Yupelri represents an effort to deliver a long-acting bronchiodilator directly to the lungs, with the goal of relax airway smooth muscle and improve airflow in patients with COPD. Muscarinic antagonists are a relatively old drug class in the COPD space. Boehringer Ingelheim’s Atrovent (ipratropium bromide) achieved first-in-class status with its FDA approval on December 29, 1986. However, it was a short-acting muscarinic antagonist (SAMA), requiring patients to use it 3 to 4 times a day due to its short half-life. The early 2000s oversaw a race for long-acting muscarinic antagonists (LAMAs), which could provide similar relief as SAMAs but with the convenience of once daily dosing. Boehringer Ingelheim once again stood at the vanguard, securing the first LAMA approval for COPD with Spiriva HandiHaler (tiotropium bromide) on January 30, 2004. Today, LAMAs are the drug class with the most FDA approvals in COPD (see graph below).

So, where did Yupelri come in? The active pharmaceutical ingredient in Yupelri is called revefenacin (initially designated as TD-4208) and was discovered by Theravance in the early 2000s. With their new medicine, Theravance set out to raise the bar for the COPD treatment landscape in two ways:

• Enhance inhaled delivery using a nebulizer: While several long-acting LAMAs existed for handheld dry-powder or metered-dose inhalers, patients with severe or advanced COPD often lacked the inspiratory flow rate necessary to use those devices effectively. Theravance specifically developed TD-4208 as an inhalation solution designed to be compatible with standard jet nebulizers.

• Make it safer by reducing systemic exposure: They applied their lung-selective chemistry platform to create a LAMA that was designed to provide sustained bronchodilation locally in the lungs while rapidly breaking down if it entered systemic circulation. This could minimize classic anticholinergic side effects, such as dry mouth and urinary retention, that frequently occur with systemic exposure.

In 2015, Theravance entered into a strategic collaboration with Mylan to advance the asset through late-stage global clinical trials and commercialization. Under the agreement, Theravance led the U.S. clinical development program, while Mylan heavily financed the registrational path and managed ex-U.S. expansion. Theravance retained a U.S. profit-sharing model and global rights to alternative delivery formats (like MDI/DPI inhalers).

The clinical path to approval culminated in an extensive Phase 3 program evaluating more than 2,300 patients with moderate-to-very-severe COPD. Two identical 12-week pivotal Phase 3 efficacy trials demonstrated that a once-daily dose of revefenacin led to statistically significant and clinically meaningful improvements in trough forced expiratory volume in one second (FEV₁) compared to placebo (+102-127 mL for Yupelri versus -19-45 for placebo; see table below). In July 2017, Theravance and Mylan announced positive results from a large, 1,055-patient, 12-month Phase 3 safety study. The data showed that revefenacin was well-tolerated over long periods, whether used as a standalone maintenance bronchodilator or as an add-on to other COPD regimens, such as LABAs or ICS/LABA combinations.

Backed by successful Phase 3 efficacy and safety data, Yupelri’s New Drug Application (NDA) was filed in late 2017. On November 9, 2018, the U.S. Food and Drug Administration officially granted market authorization for Yupelri (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. In June 2019, Theravance and Mylan expanded their collaboration agreement to grant Mylan exclusive development and commercialization rights for nebulized revefenacin in China and adjacent territories, tapping into an underserved market of nearly 100 million COPD patients. In late 2020, Mylan merged with Pfizer’s off-patent medicine division (Upjohn) to form Viatris. Consequently, commercial marketing and co-promotion responsibilities for Yupelri transitioned under the Viatris banner.

While the success of Yupelri created breathing room for Theravance, the rest of their pipeline was defined by a sequence of high-profile clinical trial stumbles. Ampreloxetine, a once-daily selective norepinephrine reuptake inhibitor (NRI), was Theravance’s flagship late-stage asset behind Yupelri. It was designed to treat neurogenic orthostatic hypotension (nOH), a severe drop in blood pressure upon standing, in patients with rare neurodegenerative conditions. However, it failed three separate Phase 3 trials (Study 0169 in 2021, REDWOOD in 2022, CYPRESS in 2026) and ultimately landed on the out-licensing list. Nezulcitinib (TD-0903) was an inhaled, lung-selective Janus kinase (JAK) inhibitor being developed to treat acute lung injury, chronic lung inflammation, and fibrotic lung diseases (including severe COVID-19-associated lung injury). It was discontinued after a Phase 2 trial reported in 2023 failed to show clinical efficacy. Before focusing exclusively on ampreloxetine and respiratory medicine, Theravance attempted to develop an oral, gut-selective JAK inhibitor for inflammatory bowel disease (IBD) in collaboration with Janssen (Johnson & Johnson). That too met an untimely end when, in late 2021, it missed its primary endpoint of clinical remission in a Phase 2b/3 trial for ulcerative colitis.

In June 2026, oncology and immunology biopharma company Zymeworks announced a definitive agreement to acquire Theravance Biopharma for roughly $929 million. The acquisition explicitly absorbed Theravance’s remaining financial stakes in Yupelri. While Yupelri generated an impressive $266.6 million in U.S. net sales in 2025, it has been overtaken by dual or triple single-inhaler therapies that combine muscarinic agonists, beta agonists, and corticosteroids (Trelegy Ellipta, Breztri, and others) and novel mechanisms (such as the anti-IL5 mAb Nucala for eosinophilic phenotypes of COPD).

Acquisition Alchemy

To be clear, the Biotech Readout is not a financial newsletter. However, Zymeworks’ deal structure is creative enough to merit a brief discussion.

While the total cash consideration of acquiring Theravance is approximately $929 million, Zymeworks only expects to pay out $119 million in net cash at close (see graph below). How is it that they only need to pay out about 1/8 of the total deal value? Theravance’s net cash on the balance sheet, a non-recourse note backed by U.S. YUPELRI profit share, and a milestone from Royalty Pharma for Trelegy Ellipta expected in 1Q 2027 reduce Zymeworks’ net cash requirements by a combined $810 million. That’s not even the half of it.

When accounting for other milestones and tax offsets mentioned in their press release, Zymeworks could actually gain $319 million in net cash from the acquisition (see graph below) leaving them with Yupelri, an asset pro-forma modeled to generate an estimated $15 million per year (derived from the ~$60 million annualized cash flow mentioned in the press release minus the 75% profit share owed to OMERS Life Sciences). Yes, there is a scenario where Zymeworks could actually get paid to acquire another company. Out-licensing the investigational asset ampreloxetine could add additional cash to Zymeworks’ haul.

Clever investment bankers indeed.

Conclusion

The saga of Theravance and Yupelri highlights the unpredictable nature of drug development. Pipeline stumbles can dismantle even the most veteran R&D organizations, but a single well-designed, organ-selective molecule can establish a permanent footprint within the standard of care. As for Zymeworks, their acquisition of Theravance is a masterclass in creative deal structures. While Yupelri never quite transformed into the commercial blockbuster its early developers envisioned, its durable cash flows in a highly resilient niche provided Theravance with an exit. By structuring a transaction that mitigates capital risk, Zymeworks has secured a steady commercial baseline while preserving its firepower for downstream oncology innovation.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 29, 2026, Ipsen announced a definitive agreement to acquire Kartos Therapeutics for $450 million upfront at closing and up to $1.3 billion of regulatory and sales-based milestones, for a total deal value of up to $1.75 billion. This acquisition centers on navtemadlin, an oral MDM2 inhibitor that is currently being evaluated in a Phase 3 myelofibrosis trial. This is the second acquisition in the myelofibrosis space in about two months, with the first being Eli Lilly’s $2.3 billion purchase of Ajax Therapeutics.

In this article, we explore the recent interest in myelofibrosis acquisitions and unravel the novel mechanism behind Kartos’ lead molecule.

The Duality of Myelofibrosis

In Roman mythology, Janus is the god of duality. He is uniquely depicted with two faces looking in opposite directions, a representation known as Janus Bifrons (Janus Two-Faced). The two heads symbolize fundamental dualities of the human experience and the natural universe.

Myelofibrosis has a duality of its own: it is both big (by sales) and small (by the number of R&D candidates). As of the 1Q 2026, FDA-approved myelofibrosis medicines account for an almost $6.3 billion annualized revenue run rate, placing the indication comfortably in the blockbuster zone. Nevertheless, clinical-stage R&D pipeline is rather sparse. Ironically, the duality of myelofibrosis’ big market and small competition has emerged due to biotech/pharma crowding around inhibitors of Janus kinase (JAK), a protein named after Roman god Janus.

As of June 2026, all FDA-approved myelofibrosis drugs target JAK. To be clear, they each have their nuances. They span two generations, each with unique safety and efficacy profiles, but all target JAK nonetheless (we covered that history here). Of course the relentless the pursuit of JAK inhibitors that isn’t surprising, given that JAK mutations are the most common genetic drivers of primary myelofibrosis (50-60% of cases), followed by CALR mutations (25-35% of cases; 2 mutant CALR inhibitors in development) and MPL mutations (remaining 5-10% of cases; no drugs directly targeting this). Kartos’ navtemadlin stands alone as the first and only myelofibrosis drug that targets MDM2.

Programming Cancer Cell Death

The central thesis of Kartos’ navtemadlin centers on harnessing the therapeutic potential of the p53 pathway. In many cancers, the crucial tumor-suppressor protein p53 remains un-mutated (wild type), but is functionally inactivated by the overexpression of its negative regulator, MDM2. By blocking the MDM2-p53 interaction, Kartos’ candidate is designed to force the reactivation of p53 to drive apoptosis in cancer cells. In other words, navtemadlin a de-represses of programmed cell death. If it’s confusing to you, don’t be alarmed. The legendary scientists who discovered p53 were just as baffled.

The path to uncovering the role of p53 in oncology is one of the most famous plot twists in biomedical history. When p53 was first discovered in 1979 by several independent groups (including David Lane, Arnold Levine, and Lloyd Old), it was completely mischaracterized. Researchers isolated p53 because it physically bound to the SV40 Large T-antigen, a viral protein known to transform normal cells into cancerous ones. Since high levels of p53 were found in tumor cells but were nearly undetectable in healthy cells, scientists reasoned that p53 was an oncogene, a gene that accelerated tumor growth. This theory was accidentally formulated when early labs cloned p53 DNA and showed it could transform healthy cells in vitro. What they didn’t realize was that they had unknowingly cloned a mutated isoform of p53 DNA rather than the normal, wild-type version.

In 1989, Arnold Levine’s lab and Bert Vogelstein’s team discovered that wild-type p53 actually inhibited cell transformation. Vogelstein found that the TP53 gene was frequently deleted or mutated in human colorectal cancers. The scientific community realized they had it backward: p53 was a tumor suppressor gene (slows tumor growth), not an oncogene (accelerates tumor growth). When functioning correctly, wild-type p53 acts as a transcription factor activated by cellular stress (like DNA damage or low oxygen). It forces the cell into cell-cycle arrest to repair the damage or triggers apoptosis if the damage is catastrophic. If p53 is mutated or inactivated, cells can accumulate genetic mutations unchecked, paving the way to malignancy.

How does this relate to myelofibrosis? For years, the molecular focus remained largely fixed on its three genetic driver mutations (JAK, CALR, MPL). However, next-generation sequencing and longitudinal tracking revealed that p53 plays a crucial, distinct role in disease architecture and progression. While p53 mutations are relatively rare in the early, chronic phases of primary or secondary myelofibrosis (occurring in only 3-5% of patients), their emergence is heavily tied to blast-phase progression (transformation into secondary Acute Myeloid Leukemia, or sAML). Once a myelofibrosis clone acquires a TP53 mutation, the cells rapidly accrue massive chromosomal structural variations and deletions.

The status of p53 mutations in myelofibrosis significantly impacts overall survival and relapse incidence, according to retrospective cohort data from a 349-patient study of patients with myelofibrosis undergoing an allogeneic hematopoietic stem cell transplantation (HSCT) published in Blood. Patients with a mutation in only one allele, while the other remains wild-type, often experience a clinical course similar to non-mutated patients. When a patient suffers a multi-hit mutation event, such as losing the second allele through a deletion (like 17p deletion) or a second mutation, their prognosis drops dramatically. Multi-hit TP53 status is associated with about half the overall survival after 6 years (only 25% of multi-hit survived versus 56% single-hit, P< 0.001) and is associated with a 42% higher risk of disease recurrence compared to patients with single-hit TP53 status (P=0.03), following a haematopoietic stem cell transplant (HSCT).

Crucially, even when the TP53 gene is not mutated in myelofibrosis, the pathway is frequently hijacked. In many high-risk MF patients, the wild-type p53 protein is functionally suppressed because the cell overexpresses MDM2, a principal negative regulator that tags p53 for degradation. MDM2 has “high expression” in 71% of CD34⁺ hematopoietic progenitor cells from patients with myelofibrosis compared to 34% in healthy people (see graph below). In fact, Nakatake et al. Oncogene (2012) suggests that JAK2^V617F driver mutations may cause MDM2 overexpression via the abnormal accumulation of the La autoantigen (a protein that significantly boosts MDM2 protein levels by binding & stabilizing MDM2 mRNA). This overabundance of MDM2 forces the continuous degradation of p53, preventing apoptosis even when the cell undergoes DNA damage. By either downregulating the La protein or treating the cells with an MDM2 antagonist (using Nutlin-3 as a tool compound), the team successfully rescued the p53 response to DNA damage and restored normal cytokine dependence to JAK2^V617F mutant cells, curbing their unchecked growth.

This biological interplay is precisely where Kartos’ lead program steps into the spotlight. Navtemadlin is designed to restore apoptotic p53 signaling by blocking MDM2-mediated degradation. In a therapeutic landscape heavily saturated with successive generations of JAK inhibitors, Kartos’ investigational candidate stands out as a mechanically distinct approach under evaluation for patients who have exhausted standard options.

Spinning Out

The founding of Kartos Therapeutics is a classic story of biotech spin-outs, where a highly promising molecule developed by a pharma giant was given a dedicated, laser-focused home to reach its clinical potential. Its scientific foundation started inside the research engines of Amgen, where navtemadlin was originally developed. While the molecule (then known as AMG 232) showed immense structural promise, pharmaceutical giants often have to ruthlessly prioritize their vast pipelines. Recognizing the asset’s potential but needing a dedicated team to push it through complex clinical development, Amgen looked for a strategic way to externalize the program.

In 2018, Kartos Therapeutics was officially launched to breathe new life into the asset, establishing its operations with dual headquarters in Redwood City, California, and Bellevue, Washington. The company was co-founded by industry veterans, most notably Jesse McGreivy, who stepped in as Chief Medical Officer (CMO) and Chief Executive Officer (CEO). McGreivy brought immense credibility to the venture, having previously served as a CMO at Acerta Pharma, where he played a pivotal role in the clinical development of the blockbuster blood cancer drug Calquence (acalabrutinib) before its $7 billion acquisition by AstraZeneca in 2016. Upon launch, Kartos secured an exclusive worldwide licensing agreement with Amgen for the MDM2 inhibitor, renaming the drug candidate KRT-232 (later given the generic name navtemadlin). This molecule became the sole cornerstone of the company’s pipeline. The company secured robust financial backing from premier life science institutional investors, including SR One and OrbiMed Advisors, and got straight to work.

Shortly after licensing the molecule, Kartos launched a broad clinical screening strategy. Since MDM2 inhibition restores wild-type p53 to trigger apoptosis, the company initiated parallel Phase 1 and Phase 2 trials across several oncology indications. Navtemadlin was clinically tested in multiple p53 wild-type malignancies, including acute myeloid leukemia (AML), polycythemia vera (PV), and Merkel cell carcinoma (MCC). While solid tumor cohorts encountered the traditional dose-limiting toxicities historic to the MDM2 class (primarily thrombocytopenia and gastrointestinal distress), a more favorable therapeutic window emerged in myelofibrosis.

These efforts culminated in the open label Phase 3 BOREAS trial, which represents a landmark attempt to introduce a non-JAK-inhibitor mechanism to a patient population who have relapsed or become refractory to frontline JAK inhibitor therapies. The study enrolled 183 patients with confirmed wild-type p53 primary or secondary myelofibrosis. They wanted to address the true unmet need, so approximately 65% of their recruited patients were refractory to previous JAK inhibitors, 30% presented with severe baseline thrombocytopenia (platelets < 100,000 / μL), and over 60% carried high molecular risk mutations. Topline clinical data and correlative biomarker data were first presented at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.

Navtemadlin tripled the percent of patients who achieved a ≥35% reduction in spleen volume compared to best available therapy at week 24 (SVR₃₅: 15% versus 5%), although it narrowly missed statistical significance (P=0.0815) due to adjustments in the trial’s accrual targets. It also doubled the percent of patients who experienced a ≥50% reduction in disease-related constitutional symptoms compared to best available therapy (TSS₅₀ 24% versus 12%, P=0.05). While the primary endpoint did not achieve traditional statistical significance in this specific cohort, investigators noted that the observed data trends provided a rationale for further clinical evaluation of navtemadlin’s potential impact on tumor bulk and constitutional symptoms.

Where BOREAS truly generated excitement in the hematology community was in its exploratory, correlative biomarker readouts. Unlike JAK inhibitors, which primarily mask symptoms, navtemadlin demonstrated anti-clonal activity based on three orthogonal readouts:

• CD34+ Cell Clearance: Circulating CD34+ cells, the hallmark malignant driving cells of myelofibrosis, dropped -70% at Week 24 in the navtemadlin arm compared to just -38% in the BAT arm.

• Variant Allele Frequency (VAF): Navtemadlin doubled the molecular response rate, achieving a ≥50% reduction in the underlying driver gene VAF (such as JAK2 or CALR) in 21% of patients versus 12% for BAT.

• Bone Marrow Fibrosis Reversal: At 24 weeks, nearly half of the evaluable navtemadlin patients (48%) achieved a documented reduction of at least 1 grade in bone marrow fibrosis, compared to just 24% in the control wing.

The adverse event profile yielded the expected on-target effects of the MDM2 inhibitor class, characterized by hematologic suppression and gastrointestinal distress. The enrollment of the BOREAS trial was eventually halted prior to its original total accrual target. This was a deliberate corporate pivot. The Kartos team believed that they had enough evidence from BOREAS to convince them that navtemadlin possessed robust monotherapy activity and genuine disease-modifying capability. With proof-of-concept secured, Kartos chose to push navtemadlin into a pivotal Phase 3 POIESIS trial, testing it as an add-on combination therapy to rescue suboptimal frontline Jakafi responders before their disease progresses to a completely relapsed/refractory state. It’s a much needed addition given that 60-70% of myelofibrosis patients treated with the frontline JAK inhibitor Jakafi fail to hit optimal clinical responses (defined as ≥35% spleen volume reduction and ≥50% symptom improvement). Ipsen plans to report topline data from POIESIS are expected in 2027.

Conclusion

For years, the myelofibrosis field remained tethered to JAK inhibition, a class that masterfully treats symptoms but is prone to resistance in a majority of patients. By charting a course as the MDM2 lone wolf, Kartos’ navtemadlin forged a new therapeutic approach. In doing so, it taps into a legacy of p53 biology nearly fifty years in the making. As Ipsen prepares to steer this molecule through the global expanse of the Phase 3 POIESIS trial, we will soon see whether the p53 pathway can be safely harnessed to alter the trajectory of myelofibrosis.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Table of Contents

This week, we discuss:

• China Biotech

  • World’s first CAR-T approval for solid tumors ⬇️

  • BIO board met with U.S. national security & health officials to discuss China ⬇️

• Acquisitions

  • AbbVie to Acquire Apogee, Paragon’s long-acting atopic dermatitis & asthma pipeline pays off ⬇️

• Approvals

  • Ionis - Tryngolza (APOC3 ASO) / Approval (sHTG) ⬇️

  • Gilead - Trodelvy (TROP2 ADC) / Approval (1L TNBC) ⬇️

• Clinical Trial Data

  • Absci - ABS-201 (anti-PRLR mAb) / Phase 1 (alopecia) ⬇️

  • Definium - DT120 (LSD ODT) / Phase 3 (MDD) ⬇️

  • Otsuka - Centanafadine (SNDRI) / Phase 3b (ADHD) ⬇️

  • Verastem - VS-7375 (KRAS G12D inhibitor) / Phase 1/2 (KRAS G12D+ solid tumors) ⬇️

  • Merck - Tulisokibart (TL1A inhibitor) / Phase 3 (UC) ⬇️

China Biotech

World’s first CAR-T approval for solid tumors

In a historic development for CAR-T, the National Medical Products Administration (NMPA) has approved CARsgen’s satri-cel (satricabtagene autoleucel), a CAR-T cell therapy targeting Claudin 18.2, for use in China. It is indicated for patients with Claudin 18.2-positive, HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC). For me, the NMPA approval of satri-cel marks the precise moment when China Biotech officially became innovators, rather than imitators. Sure, Summit/Akeso’s PD1 x VEGF bispecific antibody ivonescimab has generated a lot of buzz, but its OS advantage over Keytruda hasn’t yet been established in U.S. patients. The approval of satri-cel in China is a first on two fronts:

• First Solid Tumor CAR-T Approval Worldwide: This marks the first time any regulatory body in the world has approved a CAR-T cell therapy for a solid tumor indication. Historically, approved cell therapies have been restricted to hematologic malignancies (such as leukemia, lymphoma, and multiple myeloma). To break through the solid tumor microenvironment, CARsgen utilized a unique, optimized preconditioning regimen prior to satri-cel infusion. This added low-dose nab-paclitaxel to the standard cyclophosphamide and fludarabine (Cy/Flu) lymphodepletion backbone, which was designed to enhance CAR-T cell infiltration and anti-tumor durability.

• First Approved Claudin 18.2 Targeting Therapy: This approval represents the global debut of a therapeutic specifically targeting Claudin 18.2 (CLDN18.2), a highly validated and sought-after biomarker in gastrointestinal cancers.

Led by Professor Lin Shen at Peking University Cancer Hospital, the study evaluated 156 patients with heavily pretreated, Claudin 18.2+ HER2- advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who had progressed on at least two prior lines of therapy. Patients were randomized 2:1 to receive either satri-cel (up to 3 infusions of 250 × 10⁶ cells) or treatment of physician’s choice (TPC), which included standard chemotherapies or an anti-PD-1 antibody. The trial demonstrated a statistically significant and clinically meaningful benefit across both primary and secondary endpoints. Satri-cel nearly doubled the median PFS compared to standard care, achieving 3.25 months versus 1.77 months in the control arm (HR = 0.37, p < 0.0001). Median overall survival was significantly extended to 7.92 months with satri-cel, compared to 5.49 months for patients receiving standard therapies (HR = 0.693, p = 0.0416). True to the nature of CAR-T cell therapies, CRS occurred in 95% of treated patients, though it was characterized as “manageable”. Grade 3 or higher treatment-emergent adverse events (TEAEs) occurred in 99% of the satri-cel arm (vs. 63% in the TPC arm), primarily driven by predictable lymphopenia (98%), leukopenia (77%), and neutropenia (66%) resulting from the lymphodepletion regimen.

Sources: CARsgen press release, OncLive article

Link to top ⬆️

BIO board met with U.S. national security & health officials to discuss China

Endpoints broke the news that the board of the Biotechnology Innovation Organization (BIO), led by CEO John Crowley, met directly with US national security and health officials to discuss the biotech industry’s evolving relationship with China. For context, Biotechnology Innovation Organization (BIO) is the world’s largest trade association representing more than 1,000 members in the biotechnology industry. It is based in Washington, D.C. and it serves as a powerful advocacy group, political lobby, and networking hub for the life sciences sector. Under Crowley’s leadership, the major biotech trade group has taken a decidedly patriotic turn, leaning heavily into national security. Crowley has previously characterized the dependence on Chinese contract manufacturers as a “Sputnik moment” for the US to regain control over its medical supply chain and manufacturing capabilities. The meeting aligns with BIO’s dramatic organizational about-face to support the controversial Biosecure Act. This legislative push aims to restrict US biotech companies from working with specific Chinese contract research and manufacturing entities (like WuXi AppTec). While Crowley has emphasized that the goal is not a wholesale “decoupling” from China, the strategy is explicitly designed to address congressional anxieties regarding intellectual property, data security, and geopolitical reliance.

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Ionis - Tryngolza (APOC3 ASO) / Approval (sHTG)

The FDA has granted a major label expansion for Tryngolza (olezarsen), an antisense oligonucleotide (ASO) targeting APOC3. Originally approved for the ultra-rare familial chylomicronemia syndrome (FCS), Tryngolza is now approved as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with Severe Hypertriglyceridemia (sHTG; defined as triglycerides ≥500 mg/dL) and will be available for sHTG in the U.S. starting in July. The expansion is supported by robust data from two pivotal Phase 3 trials (CORE and CORE2), which enrolled over 1,000 patients. The trials demonstrated dramatic, placebo-adjusted triglyceride reductions (up to 72% at the 80 mg monthly dose) and a critical 85% reduction in the risk of acute pancreatitis episodes. This shifts Tryngolza from a niche rare-disease drug (FCS has ~3,000 U.S. patients according to Ionis) to a broad commercial therapeutic with more than a million patients in the U.S. with “high risk” (defined by Ionis as “triglycerides ≥800 mg/dL or triglycerides ≥500 mg/dL + acute pancreatitis and/or comorbidities”). Close competition is on the horizon. Arrowhead Pharmaceuticals (ARWR) is expected to file its competing APOC3-targeted RNAi therapeutic, Redemplo, for sHTG by the end of 2026.

Sources: Ionis press release, Ionis presentation, new Tryngolza label, NEJM paper

Link to top ⬆️

Gilead - Trodelvy (TROP2 ADC) / Approval (1L TNBC)

The FDA has granted a landmark dual label expansion for Trodelvy, a first-in-class TROP2-directed antibody-drug conjugate (ADC). Moving up from its established late-line indications, Trodelvy is now approved for the first-line (1L) treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) across all patient populations regardless of PD-L1 status. The broad frontline label explicitly covers two distinct metastatic patient populations, each supported by a Phase 3 clinical trial:

1. Monotherapy for patients who are not candidates for checkpoint inhibitor (PD-1/L1) therapy. This was supported by the Phase 3 ASCENT-03 trial, which enrolled 558 checkpoint-ineligible patients. Trodelvy monotherapy demonstrated a median progression-free survival (mPFS) of 9.7 months vs. 6.9 months for physician’s choice chemotherapy, reflecting a 38% reduction in the risk of disease progression or death (HR = 0.62; p < 0.0001).

2. Combination with Merck’s Keytruda (pembrolizumab, including the subcutaneous Keytruda Qlex) for patients with PD-L1-positive tumors (CPS ≥10). This was supported by the Phase 3 ASCENT-04 / KEYNOTE-D19 trial, which enrolled 443 PD-L1+ patients. Trodelvy + Keytruda extended mPFS to 11.2 months vs. 7.8 months for chemo + Keytruda, reflecting a 35% risk reduction (HR = 0.65; p = 0.0009). Overall survival (OS) data for both trials remained immature at the time of analysis.

Since over half of mTNBC patients historically never survive or progress to receive a second line of therapy, establishing an ADC-based regimen in the frontline setting represents a significant paradigm shift in the standard of care. The National Comprehensive Cancer Network (NCCN) immediately incorporated both regimens as Category 1 preferred frontline options. Trodelvy‘s approval follows closely behind AstraZeneca and Daiichi Sankyo’s TROP2 ADC Datroway (datopotamab deruxtecan), which was approved for the checkpoint-ineligible frontline setting. However, only Trodelvy’s label has the broader inclusion of the PD-L1+ combo population.

Source: Gilead press release, new Trodelvy label

Link to top ⬆️

Clinical Trial Data

Absci - ABS-201 (anti-PRLR mAb) / Phase 1 (androgenetic alopecia)

Absci has announced highly encouraging interim Phase 1 data from its HEADLINE trial evaluating ABS-201, an AI-designed, long-acting monoclonal antibody targeting the prolactin receptor (PRLR).

Androgenetic alopecia (AGA) is primarily driven by genetic hypersensitivity to dihydrotestosterone (DHT), which causes follicular miniaturization, a shortened anagen growth phase, and progressive hair thinning. While the standard of care relies on daily treatments like oral finasteride to suppress DHT and topical minoxidil to boost follicular blood flow, Absci’s ABS-201 introduces a novel mechanism as an AI-designed, long-acting monoclonal antibody targeting the prolactin receptor (PRLR). By blocking localized prolactin signaling, which otherwise triggers hair follicle stem cell apoptosis and forces follicles into dormancy, ABS-201 is designed to the progenitor cell pool and prolongs the active anagen phase to restore terminal hair growth.

The ongoing Phase 1/2a HEADLINE trial evaluated Absci’s antibody, ABS-201, in a randomized, placebo-controlled single ascending dose (SAD) study of 32 healthy volunteers across four intravenous cohorts (150 mg to 1800 mg). Data from the June 8, 2026 cutoff demonstrated that the biologic was well-tolerated with zero serious adverse events and mostly mild treatment-related effects (primarily headaches). Crucially, ABS-201 exhibited an exceptionally prolonged half-life of at least 65 days with no anti-drug antibody impact, supporting a highly convenient maintenance dosing schedule of just one injection every two to three months. This profile validates Absci’s de novo generative AI platform by proving a fully AI-designed antibody can achieve optimal, non-immunogenic drug properties in humans, while offering a potential long-acting therapeutic alternative that, if approved, could alleviate the daily compliance burden and side-effect profiles of current standard-of-care treatments like minoxidil and finasteride

Following Safety Review Committee approval, the HEADLINE trial has immediately advanced into the Subcutaneous (SC) Multiple Ascending Dose (MAD) phase in patients with active AGA. Dosing cohorts are set at 300 mg, 600 mg, and 1200 mg SC to establish real-world, patient-friendly administration parameters. Absci plans to report interim clinical proof-of-concept (PoC) data from the SC MAD cohorts in the second half of 2026 and full clinical proof-of-concept data in early 2027. Since prolactin signaling is a known driver of endometrial lesions and pelvic pain sensitivity, Absci plans to advance ABS-201 into a global Phase 2 trial for endometriosis by the end of 2026. Pending FDA interactions on the MAD dose-ranging data, Absci aims to leapfrog directly into two global Phase 3 studies in male-pattern hair loss by late 2027.

Sources: Absci press release

Link to top ⬆️

Definium - DT120 (LSD ODT) / Phase 3 (MDD)

Definium Therapeutics has announced successful topline results from its pivotal Phase 3 Emerge trial evaluating DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate, for the treatment of Major Depressive Disorder (MDD).

Major Depressive Disorder (MDD) is a complex neuropsychiatric condition characterized by persistent depressed mood and anhedonia, pathophysiologically driven by neural circuitry dysfunction, monoamine depletion, and impaired neuroplasticity. While the current standard of care relies on chronic daily pharmacotherapy, such as SSRIs or SNRIs, and psychotherapy to gradually alter neurotransmitter levels, Definium’s DT120 ODT (lysergide tartrate) introduces a novel approach as an optimized, orally disintegrating tablet (ODT) formulation of LSD. Functioning as a potent 5-HT2A (serotonin 2A) receptor agonist, a single acute administration of DT120 triggers rapid downstream intracellular signaling pathways that drive an immediate burst of cortical synaptogenesis and structural neural plasticity, with the goal of resetting disrupted frontostriatal networks to restore mood and cognitive flexibility without requiring daily dosing.

The pivotal Phase 3 Emerge trial (NCT06941844) evaluated a single 100 µg dose of DT120 ODT against placebo in 149 adults with moderate-to-severe Major Depressive Disorder (MDD), in an effort to isolate the drug’s organic pharmaceutical effect without adjunctive psychotherapy. The study met its primary endpoint at Week 6, achieving a statistically significant (p<0.0001) and clinically meaningful placebo-adjusted LS mean reduction in MADRS total score of -8.1 points (−13.3 vs. −5.2 for placebo), alongside a 35% response rate and 24% remission rate. Secondary endpoints highlighted a rapid onset at Week 1 (−14.2 point placebo-adjusted reduction) and sustained durability out to Week 12 (−7.3 point placebo-adjusted reduction). DT120 ODT was generally well tolerated with no new safety signals or increased suicidal ideation. Approximately 99% of adverse events were mild-to-moderate, transient, and limited to the dosing day, with all patients successfully clearing clinic monitoring within 8 hours (mean: 5.8 hours). By delivering rapid, quarter-long depression relief from a single acute session, DT120 ODT could shift the treatment paradigm away from burdensome daily oral therapies and differentiates itself from existing acute options like J&J’s Spravato, which requires ongoing bi-weekly maintenance visits and averages a numerically smaller cross-trial MADRS delta ( -6.8 points versus -8.1 points for DT120).

Definium is currently running Ascend (NCT07592689), a second late-stage Phase 3 trial in MDD exploring safety and varying doses in ~175 patients to complete its registration package for the FDA. Topline Phase 3 data in Generalized Anxiety Disorder (GAD) from the Panorama and Voyage studies are anticipated in Q3 2026. Definium plans to initiate its Phase 3 Haven study evaluating DT120 in Post-Traumatic Stress Disorder (PTSD) in early 2027.

Sources: Definium press release, Definium slide deck

Link to top ⬆️

Otsuka - Centanafadine (SNDRI) / Phase 3b (ADHD)

Otsuka presented highly statistically significant Phase 3b data for centanafadine, demonstrating a reduction in ADHD symptoms compared to placebo in adults with comorbid anxiety ahead of its July 24, 2026 PDUFA date.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition driven by a dysregulation of dopamine and norepinephrine signaling in the prefrontal cortex, which impairs key executive functions like impulse control and sustained attention. While the standard of care primarily relies on central nervous system stimulants (such as methylphenidate or amphetamines) to boost these neurotransmitters, or non-stimulants like atomoxetine for patients who cannot tolerate them, Otsuka’s centanafadine introduces a novel approach as a first-in-class Norepinephrine, Dopamine, and Serotonin Reuptake Inhibitor (NDSRI). By simultaneously inhibiting the reuptake of all three major monoamine neurotransmitters, this triple reuptake inhibitor aims to deliver robust clinical efficacy with a favorable tolerability profile and a lower potential for abuse than traditional stimulants.

The Phase 3b study (NCT06973577) evaluated once-daily centanafadine XR (280 mg) over 8 weeks in 315 adults with ADHD and comorbid anxiety, a historically underserved population that comprises up to 50% of adult ADHD cases. The trial met its primary endpoint, demonstrating a statistically significant early-onset reduction in ADHD symptoms by Week 8 (LS mean change in AISRS of -18.5 versus -12.6 for placebo; p < 0.0001), alongside significant improvements in anxiety symptoms (HAM-A placebo-adjusted reduction of 1.92 points). The treatment was generally well tolerated with a safety profile consistent with previous trials, characterized by a low potential for abuse and common adverse events like decreased appetite and headache. Ultimately, these data demonstrate encouraging preliminary evidence of simultaneous efficacy on both core ADHD and anxiety symptoms, yielding a -5.87 placebo-adjusted AISRS treatment difference that numerically surpasses Otsuka’s earlier 6-week Phase 3 trials and validates the extended 8-week extended-release strategy, though direct cross-trial comparisons carry inherent limitations due to differing study designs and patient populations.

The FDA is currently reviewing centanafadine’s New Drug Application (NDA) under Priority Review across pediatric, adolescent, and adult ADHD populations. The PDUFA target action date is July 24, 2026. Otsuka is actively building out its commercial infrastructure and training sales forces ahead of the looming decision. While the drug has shown low abuse liability in trials, a standard Drug Enforcement Administration (DEA) scheduling review is expected post-approval, which could delay the actual commercial launch by approximately three months, according to Otsuka.

Sources: Otsuka press release

Link to top ⬆️

Verastem - VS-7375 (KRAS G12D inhibitor) / Phase 1/2 (KRAS G12D+ solid tumors)

Verastem Oncology has announced preliminary anti-tumor activity from its Phase 1/2 mixed clinical trial evaluating VS-7375, an oral, highly selective small-molecule KRAS G12D inhibitor, in patients with advanced solid tumors.

The KRAS G12D mutation is a prevalent oncogenic driver occurring in 30-45% of pancreatic ductal adenocarcinoma (PDAC) cases, where a missense mutation locks the KRAS protein in a constitutively active state that hyperactivates downstream MAPK and PI3K-AKT pathways to drive uncontrolled cell proliferation, metabolic reprogramming, and survival. Since the structural complexity of the G12D pocket has historically limited targeted therapy options, the standard of care for advanced solid tumors like PDAC has relied on toxic systemic chemotherapy backbones (such as mFOLFIRINOX or gemcitabine plus nab-paclitaxel) that offer only modest survival extensions. Verastem’s VS-7375 directly addresses this therapeutic void as an oral, highly selective small-molecule inhibitor engineered to bind both the active and inactive states of the mutated KRAS G12D protein. By selectively turning off this aberrant signaling, VS-7375 is designed to disrupt the core oncogenic driver pathway, arresting cell-cycle progression and inducing apoptosis exclusively within mutant tumor cells while sparing wild-type tissue.

The open-label, multicenter Phase 1/2 dose-escalation and cohort-expansion study evaluated Verastem’s oral KRAS G12D inhibitor, VS-7375, in patients with advanced, refractory KRAS G12D-mutated solid tumors, focusing primary endpoints on safety, tolerability, and determining the recommended Phase 2 dose. While early data from an expansion cohort of 14 heavily pre-treated, second- or third-line (2-3L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients remained light on mature, radiological RECIST efficacy numbers, it demonstrated anti-tumor activity using a biomarker, with 93% (13 out of 14) of patients achieving a clinically significant ≥50% reduction in the prognostic tumor biomarker CA19-9. Additionally, VS-7375 proved to be generally well-tolerated with an on-target safety profile (such as manageable gastrointestinal issues and rash) what was free of treatment-limiting cumulative toxicities during the trial’s observation period. This biochemical response indicates that VS-7375 could be exerting therapeutic pressure on a notoriously lethal malignancy, potentially positioning the asset to address an unmet need left untouched by existing treatments.

Rather than lingering in heavily pre-treated, refractory populations where tumors have accumulated bypass resistance mechanisms, Verastem is moving the asset forward into early-line treatment. Verastem announced plans to initiate a pivotal Phase 3 clinical trial evaluating VS-7375 in the first-line (1L) PDAC setting. The global Phase 3 study is scheduled to begin enrollment in the first half of 2027, likely evaluating VS-7375 in combination with standard frontline chemotherapy backbones (e.g., mFOLFOXIRINOX or gemcitabine/nab-paclitaxel).

Sources: Verastem press release, Verastem slide deck

Link to top ⬆️

Descriptive data releases without numerical data

• Merck - Tulisokibart (TL1A inhibitor) / Phase 3 (UC): Merck has announced positive topline results from its Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting TL1A to address immuno-fibrosis in adults with moderately to severely active ulcerative colitis (UC). The trial successfully met its primary endpoint of clinical remission, as measured by the Modified Mayo Score (MMS) at Week 12, marking the first successful Phase 3 victory for an anti-TL1A biologic. Tulisokibart also achieved key secondary endpoints, including endoscopic improvement, clinical response, and histologic-endoscopic mucosal improvement, while demonstrating a well-tolerated safety profile consistent with previous Phase 2 observations. Since Merck’s initial announcement was limited to qualitative topline conclusions without granular numerical data, this analysis relies strictly on the sponsor’s self-reported summaries pending full presentation at a future medical congress. Sources: Merck press release.

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 22, 2026, AbbVie announced a definitive agreement on an all-cash acquisition of Apogee Therapeutics for a total value of approximately $10.9 billion (AbbVie press release, AbbVie slide deck, Apogee press release). This acquisition centers on Apogee’s “diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases”:

• Zumilokibart: Their lead program is a subcutaneous, half-life-extended mAb targeting IL-13 (a core driver of Type 2 inflammation) with maintenance dosing intervals of every 3 to 6 months (quarterly or twice-yearly). AbbVie/Apogee plans to start a Phase 3 atopic dermatitis trial in late 2026.

• APG273: This is a fixed-dose combination of zumilokibart (anti-IL-13) + APG333 (an extended half-life anti-TSLP mAb). While the combination asset itself is in early stages, its components have demonstrated clinical activity in completed trials. In addition to zumilokibart’s positive Phase 1b asthma data, APG333 completed a Phase 1 trial confirming a long half-life in healthy volunteers and the ability to suppress relevant Type 2 inflammatory biomarkers for up to six months after a single dose.

• APG279: This is a fixed-dose combination of zumilokibart (anti-IL-13) + APG990 (an extended half-life anti-OX40L mAb). A Phase 1b head-to-head study comparing APG279 directly against standard-of-care Dupixent in AD is fully enrolled and data are anticipated in late 2026.

The $10.9 billion price tag of Apogee is unusually large. In fact, it is by far the largest acquisition in the atopic dermatitis and asthma spaces (first graph below), and is almost four-fold larger than the average acquisition with a lead asset in Phase 3 (see below).

In this article, we will focus on unpacking the M&A strategy that AbbVie highlighted in their presentation, finding out why Apogee’s high price tag is justified, and exploring the corporate history of Apogee.

A Peek Into AbbVie’s M&A Strategy

AbbVie has spent over two decades building a pipeline of blockbuster medicines in immunology. Humira was their biggest inflection point, and the basis on which they spun out of their parent company, Abbott Labs, back in 2013. Humira became the #1 best selling drug of all time in early 2013, surpassing Pfizer’s Lipitor after generic competition precipitated a 60% drop in its sales (1Q 2013 sales: $8.9 billion for Humira versus $3.6 billion Lipitor, a drop from $9 billion in the prior quarter). The reign of Humira lasted almost a decade, until Pfizer retook the crown with their COVID-19 vaccine Comirnaty (2Q 2021 sales: $20.3 billion for Humira versus $31.4 billion for Comirnaty). By targeting TNF-alpha, Humira created a pipeline-in-a-product that revolutionized rheumatology, dermatology, and gastroenterology. However, broad systemic inhibition acted like a blunt instrument, highly effective at dampening systemic inflammation, but frequently constrained by systemic side effects and ceiling effects in clear skin or mucosal healing. As Humira approached its own patent cliff in January 2023 (triggered by the launch of Amgen’s biosimilar Amjevita), AbbVie leveraged their decades of clinical insight to develop more targeted immunology medicines:

• Skyrizi zeroed in on the p19 subunit of IL-23, cleanly shutting down the pathogenic Th17 pathway in psoriasis and IBD without touching the IL-12 pathway, thereby avoiding broad immune suppression.

• Rinvoq moved intracellularly to selectively inhibit JAK1, providing a potent, rapid small-molecule alternative where broad biologics failed.

The increased specificity of these molecules yielded superior efficacy, allowing AbbVie to replace their own legacy asset with a dual-engine blockbuster portfolio.

AbbVie’s current pipeline expansion, anchored by the Apogee acquisition, represents a third act. Their immunology strategy rests on three pillars:

1. Elevate Care: This strategic goal focuses on maximizing existing blockbusters through indication expansion and developing multi-targeting novel combinations to achieve deeper efficacy. Specific implementation includes expanding Rinvoq into new indications, advancing assets like lutikizumab for HS, and building combo regiments across dermatology, gastroenterology, and rheumatology.

2. Offer Convenience: AbbVie recognizes that long-term patient adherence and market dominance rely heavily on treatment convenience, ease of administration, and less frequent dosing. This is highlighted by the development of Skyrizi subcutaneous induction in IBD, which allows patients patients more manageable administration routes during the intense initial phases of treatment.

3. Develop Cures: The final, most ambitious pillar represents a shift from merely managing chronic inflammation to achieving profound, long-lasting disease modification or complete clinical remission. By targeting and deleting the specific B-cells driving autoimmune pathogenesis, AbbVie’s ultimate strategic goal under this pillar is to reset the immune system, moving closer to functional “cures” for severe rheumatological diseases.

The Apogee acquisition falls under the first two pillars (elevate care, offer convenience). By bringing in zumilokibart and its companion fixed-dose combinations (APG279 and APG273), AbbVie elevates care through multi-variant targeting, designed to simultaneously shut down downstream inflammation (IL-13) and upstream triggers (OX40L/TSLP) to bypass compensatory immune escape pathways and induce deeper clinical remissions. Crucially, these assets leverage advanced half-life extension technology, potentially offering unprecedented convenience in atopic dermatitis and allergy markets by shifting the standard of care from frequent bi-weekly injections to quarterly or twice-yearly maintenance dosing.

Atopic dermatitis and allergy markets are nothing to sneeze at. When combined, the commercial market for atopic dermatitis and allergy generates more than $43 billion every year and is growing at 28% annually, but market share is heavily concentrated at the very top. Sanofi/Regeneron’s Dupixent is the undisputed titan of this landscape, pulling in $19.5 billion on its own, accounting for nearly 45% of the entire listed market’s revenue. Rinvoq stands in second place at $8.5 billion. Combined, Dupixent and Rinvoq commands almost 65% of total sales among these leading brands, highlighting the massive commercial success of targeting Type 2 inflammation pathways (IL-4/IL-13) and JAK pathways in atopic dermatitis and severe asthma. Could Apogee be the key to claiming the top spot?

Atopic dermatitis and allergy spaces are very crowded, suggesting the highly selective nature of AbbVie’s purchase. Atopic dermatitis has the highest volume of active development (55 assets). The vast majority of its pipeline is concentrated in early-to-mid stage research (Phase 1 and Phase 2), indicating a massive wave of next-generation candidates working their way through clinical testing. There is also a notable block of Phase 3 assets preparing for market entry. While slightly smaller than the atopic dermatitis pipeline (42 assets), asthma boasts a highly robust clinical portfolio. Interestingly, a much larger proportion of the asthma pipeline is already sitting in the commercial category compared to atopic dermatitis, reflecting a mature biologic and triple-therapy marketplace that next-generation assets will have to disrupt. Standard me-too drugs could struggle in crowded markets like this. To win a share of this multi-billion dollar pie, next-generation drugs will likely need to offer clear points of differentiation. Apogee’s founding team baked in points of differentiation from the very start.

Entering the Fray

Apogee Therapeutics started as part of a hub-and-spoke biotech company, a corporate structure where a central parent organization (the hub) provides capital, operational infrastructure, and shared expertise to incubate and manage a portfolio of distinct, specialized subsidiary companies (the spokes). We’ve discussed this corporate structure before (Incyte to Acquire Vega). It enables companies to develop a medicine in a more capital efficient way and sell it without giving up the rest of the pipeline. In less than four years, Apogee went from an incubation concept to a multi-billion-dollar market leader, culminating in its acquisition.

In 2021, the investment firm Fairmount Funds launched Paragon Therapeutics (the hub) to serve as a high-efficiency antibody discovery engine. Apogee Therapeutics (a spoke) was built to solve a specific problem: navigating crowded immunology markets by utilizing superior antibody engineering rather than completely unproven biology. Founded by Fairmount and Venrock, Apogee officially launched in December 2022 as the very first spinout company from Paragon. Led by CEO Michael Henderson, Apogee secured exclusive development and commercial rights to a suite of pre-optimized, half-life-extended antibodies discovered by Paragon. The company emerged from stealth with a total of $169 million across Series A and B rounds, with the latter round adding Deep Track Capital and RTW Investments to the cap table.

Instead of spending years in early preclinical phases, Apogee moved at an extraordinary pace due to the high-throughput engineering foundation inherited from Paragon. Just seven months after emerging from stealth, Apogee went public on the Nasdaq. Despite a relatively cold market for biotech IPOs at the time, investor enthusiasm for their extended half-life value proposition allowed Apogee to raise $300 million. In March 2024, Apogee announced highly anticipated Phase 1 clinical data for its lead asset, APG777 (zumilokibart). The trial demonstrated that zumilokibart possessed an unprecedented 75-day half-life, roughly 3 to 4 times longer than existing IL-13 competitors like lebrikizumab. This readout confirmed that Apogee’s half-life extension thesis translated to humans.

Over the next two years, the company executed a tightly coordinated clinical program designed to uncover zumilokibart’s efficacy profile. In March 2026, Apogee took a direct shot at the market’s heavy hitters by reporting long-term 52-week data from Part A of its Phase 2 APEX trial in moderate-to-severe atopic dermatitis. While current biologics require bi-weekly or monthly maintenance injections, Apogee evaluated maintenance dosing intervals stretching to every 3 and 6 months. Among patients who initially responded at Week 16, 75% of those on the 3-month regimen and 85% on the 6-month regimen successfully maintained their EASI-75 response out to one full year. This data appears competitive with commercial anti-IL13 mAbs on a cross-trial basis.

A mere two months later, in May 2026, Apogee closed the loop on its Phase 2 program by presenting the 16-week Part B induction dose optimization data. Enrolling 346 adult patients across low, mid, and high doses against placebo, the trial established the mid-dose as a formidable winner. Nearly two-thirds of patients (66%) achieved EASI-75 at week 16, accompanied by robust skin clearance (47% achieving IGA 0/1) and rapid itch relief. With the asset demonstrating a safety profile that was generally well-tolerated and entirely in line with the class, Part B gave Apogee the information required to lock in its Phase 3 protocol.

While cementing its position in dermatology, Apogee simultaneously expanded zumilokibart’s footprint into respiratory medicine. In January 2026, the company announced positive proof-of-concept interim results from a Phase 1b trial in mild-to-moderate asthma, confirming that the asset’s tissue penetration and biomarker suppression mirrored its dermatological success. Zumilokibart established a competitive profile in suppressing fractional exhaled nitric oxide (FeNO), a crucial biomarker of Type 2 airway inflammation, when evaluated alongside leading and emerging asthma therapies at the 12-week mark. While the cross-trial comparison below differs in trial design and patient baselines, the data paints a compelling narrative for zumilokibart’s best-in-class potential in asthma.

Concurrently, the foundational single-agent components of Apogee’s multiplexed combinations were validated. APG333 (the anti-TSLP arm of the APG273 combination) completed its own Phase 1 trial, matching zumilokibart’s extended kinetics and demonstrating competitive Type 2 inflammatory biomarker suppression for up to six months from a single dose. This paved a clinical path for late-2026 combination trials in asthma and COPD.

By mid-2026, Apogee’s clinical momentum had caught the attention of an industry titan managing its own immunology legacy, AbbVie. Armed with clean 52-week maintenance data, optimized Phase 3-ready dosing, an expanded Phase 1b head-to-head trial of APG279 versus Dupixent, and a pristine cash position of $1.3 billion, Apogee reached its ultimate destination. On June 22, 2026, AbbVie announced a definitive agreement to acquire Apogee for $10.9 billion in cash, bringing this chapter of rapid clinical execution to a historic, mega-blockbuster conclusion.

Conclusion

AbbVie’s $10.9 billion acquisition of Apogee Therapeutics represents a masterclass in strategic execution from both sides:

• For AbbVie: It secures a powerful third act to succeed the Humira era and complement Skyrizi and Rinvoq. The potential to shift the standard of care from bi-weekly maintenance injections to a quarterly or twice-yearly schedule gives them an unmatched weapon in convenience to challenge Sanofi/Regeneron’s dominant Dupixent.

• For Apogee: It stands as a flawless validation of the hub-and-spoke biotech model. Moving from stealth incubation to a historic $10.9 billion mega-blockbuster exit in under four years proves that combining highly efficient antibody engineering with hyper-accelerated clinical execution can disrupt even the most crowded therapeutic landscapes.

As these next-generation assets head into Phase 3 trials and direct head-to-head readouts later this year, the spotlight shifts to how quickly AbbVie can scale this pipeline. The race for dominance in the $43+ billion atopic dermatitis and allergy markets is heating up, and AbbVie has a hot hand.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

In Part 1 of this two-part series on AI and the Decline of Artisanal Labor, we reviewed the 1st and 2nd Industrial Revolutions and explored how these two waves of automation disrupted the artisans of their day and sparked different ideological backlashes (Luddites, Communists).

The 1st Industrial Revolution separated the artisan from their physical tools, moving labor from the home cottage to the water-powered loom. The 2nd Industrial Revolution separated the artisan from their intellectual workflow, using Taylorism and the assembly line to strip away autonomous judgment and turn humans into cogs. The Generative AI Revolution represents the modern wave of automation: it is beginning to separate the worker from their cognitive execution.Today, we approach the Turning Point. The choices we make now will determine whether the age of AI becomes a centralized, corporate Erebus of algorithmic replacement, or a collaborative Eden that supercharges human creativity.

In Part 2, we take a closer look at modern artisanship, separate the durable from the disrupted, and explore the backlash movements that respond to the 3rd Industrial Revolution of artificial intelligence (AI).

AI Giveth, and AI Taketh Away

ChatGPT started the fire in November 2022, Big Tech companies plowed billions to building data centers, Gemini caught up, Anthropic plowed ahead, but what do we have to show for all of this “progress”? Well, >90% of the value created by AI has come from… *drum roll*…building AI in the first place. That includes the chips (memory, GPUs), the equipment used to make the chips (Semi Cap), and the infrastructure that rents out the chips (Cloud). The only AI outputs that generate enterprise value (EV) at scale as of June 2026 are coding agents, which represent a meager 8% of economic value created by AI. The AI use cases most used by the average person (better search, generative images/videos/games) seem to have created negligible economic value for the AI labs, as of June 2026. This is underscored by OpenAI’s sudden cancellation of their AI slop app social video app, Sora. By doing this, OpenAI simultaneously walked away from a $1 billion deal with Disney that came with unprecedented access to their intellectual property, which would have allowed users to make videos with Disney’s copyrighted characters.

Nevertheless, LLMs compress research time from weeks to minutes, and generate text/images/videos at the touch of a button. How exactly has AI impacted knowledge work? To explore this question, one of the AI labs (Anthropic) built directly upon a foundational framework established by Eloundou et al. Science (2024). Anthropic divided the labor market into broad job categories, and determined the approximate share of tasks within each category that could theoretically be performed by LLMs. Recall that in the 1st and 2nd Industrial Revolutions, automation disrupted specific categories of artisanal labor (ex. power looms replaced textile workers), but the job categories that they augmented laid the groundwork for “new” industries. For example, steel production led to railroad expansion and seeded employment in that field. According to Anthropic’s research, only a few categories can be highly automated by AI (computer & math, business & finance, management), but most other job categories are merely augmented by AI. In fact, there are more job categories that AI barely touches (those with <20% of automatable tasks), mainly pertaining to real-world industry and in-person care.

Of course, people don’t work in a “job category” they work a “job”. Within each category, there are specific jobs that Anthropic defines as having higher or lower exposure , which I took to mean they were had higher or lower disruption risk. We are doing to dive deeper into the six jobs highlighted in purple in the table below to determine what makes specific jobs more disruptable or durable.

The resilience of these jobs, according to an indices of business performance, is consistent with the disruptability suggested by Anthropic. Generally, the more disruptable jobs have declined since the beginning of 2026 (yellow), while the more resilient jobs have grown during the same period (purple).

Rise & Fall of Modern Artisans

Software Engineers: Disrupted

In the most ironic twist of fate imaginable, software engineers disrupted themselves first. Coding is the #1 most disruptable job by LLMs, according to Anthropic’s research. Remember that LLMs are Large Language Models, but in natural human languages (like English), text is ambiguous, contextual, and often contains filler words (and, no, I don’t mean “lode-bearing”). However, code is a closed symbolic system with deterministic rules. Since LLMs are inherently engines of syntax and structural patterns, they are more fluent in programming languages far than the nuanced, ambiguous socio-political contexts of natural human languages.

Released as research preview in February 2025 and achieving general availability in May 2025, Claude Code pioneered the rise of coding agents. Powered by models like Claude 3.7 Sonnet, Claude 4, and the latest Claude Opus 4.8, Claude Code operates in a continuous loop. It can read files, execute shell commands, run test suites, and iteratively fix its own syntax errors directly inside a terminal window. Within just two months of launch, Claude Code surpassed $500 million in annualized revenue. By late May of 2026, Anthropic announced that their annualized recurring revenue (ARR) had surpassed $47 billion, soaring past the annual sales of juggernauts like Netflix ($46.9 billion), Bank of America ($44 billion), and Visa ($43 billion).

For two decades, the bedrock of Software-as-a-Service (SaaS) industry was the predictable recurring revenue of the per-seat license model (the cost of a subscription service for a specific company increased if more employees or “seats” used the software). As automated developer tools and workflow agents show an increased capacity to execute multi-step coding tasks, a growing number of industry analysts suggest that traditional software engineering headcounts face significant re-evaluation. TechCrunch recently reported that tech layoffs in May 2026 have hit its highest monthly level in two years (according to Challenger, Gray & Christmas) and have accelerated to rate that is 44% faster than last year (363 layoffs affecting nearly 150,000 people according to TrueUp).

Writers & Authors: Durable

Fear not, my faithful Substack reader, for us writers & authors are one of the safer artisans. While LLMs are incredibly adept at pattern recognition, linguistic mimicry, and structural optimization, they are not capable of true creativity. LLMs can string together a sentence, but they can’t speak to the soul.

True creativity begins with intentionality. A human author writes because they want to bridge the gap between their inner consciousness and the outer world. They are trying to communicate a specific, subjective experience. The words are merely vehicles for a deeply felt meaning. For an LLM, the words are all there is.

By definition, LLMs are trained to find and replicate the common denominators of human language. An LLM can effortlessly generate a story “in the style of Hemingway” or “with the plot structure of a classic noir film.” However, it is only rearranging existing tropes, syntax structures, and narrative conventions found in its training data. True creative insights, by definition, are statistical outliers. A jarring metaphor, an unprecedented narrative structure, or a tonal shift that a probability distribution would flag as a low-probability anomaly. Human creativity lives in the margins of what has never been said before, while LLMs live in the center of what has been said a million times.

A writer draws upon the sensory richness of a specific childhood memory, the exact physical ache of a heartbreak, the lingering grief of a loss, or the specific texture of the morning light in a city they love. When an LLM writes about grief, it is merely synthesizing what thousands of other people have written about grief. It is a photocopy of a photocopy. It can mimic the vocabulary of sorrow, but it cannot invent a completely new way to express it because it has never felt the weight of it.

The cherry on top is that AI applications in the writing industry are major tailwinds. Within publishing houses, LLMs can serve to accelerate the time-to-market for a manuscript by partially automating mundane tasks that are far more mechanistic than creative:

• Copyediting: While macro-level developmental editing (shaping a book’s voice or plot) remains firmly human, publishers deploy customized enterprise LLMs to handle initial technical passes. The models screen manuscripts against rigorous internal style guides (e.g., The Chicago Manual of Style or custom house constraints) to fix basic syntax mechanics, saving human editors hundreds of hours.

• Continuity and Consistency Checking: For sprawling fantasy epics, non-fiction textbooks, or multi-volume series, LLMs are used to track logic over hundreds of thousands of words. A model can instantaneously scan an entire catalog to ensure a character’s physical traits, specific terminology, timelines, or citation structures remain relatively consistent from Chapter 1 through Chapter 30.

• Triage and Metadata Generation: Before a book can be sold, it requires an immense amount of administrative data. Publishers use LLMs to analyze a text and autonomously generate optimized book descriptions, marketing blurbs, search keywords, and standardized classification tags (like BISAC codes).

• Translation: The cost of translating a 90,000-word book into dozens of foreign languages has historically been a massive financial barrier, preventing many mid-list titles from ever reaching international markets. Publishers are using specialized translation LLMs to generate highly advanced initial drafts across dozens of languages simultaneously.

Altogether, LLMs are statistical average machines, whereas writers are uniquely human, as one should expect.

Consulting: Disrupted

For decades, the consulting industry’s economic model relied on a straightforward formula: recruit elite graduates, bill clients by the hour for manual analysis and deck creation, and charge high premiums for proprietary frameworks. The rise of advanced Large Language Models (LLMs) and the sudden pivot toward fully autonomous agentic workflows is disrupting this model.

Analysts and associates used to spend hundreds of hours conducting primary research, cleaning datasets, formatting slide decks, and auditing spreadsheets. Enterprise LLMs paired with tools like Claude Code and specialized agentic pipelines can execute complex technical and operational tasks in minutes. Activities like refactoring legacy corporate code, translating structured regulatory compliance data, or auditing deep financial accounting models no longer require teams of junior consultants working for months. Since consulting firms historically billed on time and materials (hourly or per-consultant), automating 60% of the baseline research hours severely shrinks the billable project footprint. Clients are increasingly demanding fixed-price or value-delivered billing structures, squeezing traditional consulting profit margins:

• McKinsey & Company: Senior leadership disclosed that 25% of McKinsey’s global fees are now explicitly linked to outcome-based or performance-based pricing structures rather than traditional hourly models.

• Boston Consulting Group (BCG): In an interview regarding the industry-wide evolution of pricing models, BCG Global CEO Christoph Schweizer revealed an even more aggressive pivot for major AI implementations, noting that three-quarters (75%) of BCG’s largest AI cases are now structured under variable, value-based fee arrangements linked directly to client outcomes like cost reduction or revenue growth.

Furthermore, corporations used to hire top-tier firms like McKinsey, BCG, or Bain to gain access to proprietary methodologies, synthesized market telemetry, and executive synthesis. LLMs are effectively democratizing this baseline knowledge. With AI, major corporations are building internal, highly secure RAG (Retrieval-Augmented Generation) clusters trained on their own historical data, transaction records, and industry literature. Corporate strategy teams can now query their own custom models for market analysis, strategic option framing, or competitor vulnerability screening. A task that previously required a $1 million, six-week strategy engagement can now be run internally as an interactive, multi-step scenario simulation.

The impacts are being felt slowly but surely. On June 19, 2026, Accenture cut its revenue growth guidance for their financial year, which some market analysts interpreted as a sign of broad-based concerns about both domestic and international IT consultancy businesses. New bookings were lower than the same period last year (by 2%) and they discontinued their disclosure of specific generative AI bookings. Industry analysts had previously used this metric as a barometer for how much new AI spending was replacing legacy IT budgets, a move thought to be a saving grace for the consulting industry. Certain market observers have speculated that Accenture’s move could introduce opacity, raising questions among some analysts regarding the pace of the generative AI pivot.

Biotech Scientists: Durable

AI has had some very unique breakthroughs in biotech, but much of the industry remains largely unchanged. In 2020, AlphaFold 2 solved the structure of isolated proteins, predicting how a single chain of amino acids would fold in a vacuum. It gave the global scientific community open-access to the predicted structures of virtually every known protein. Four years later in 2024, AlphaFold 3 leaped from mapping standalone proteins to predicting biomolecular complexes. Co-developed with Isomorphic Labs, it can model how proteins interact with DNA, RNA, chemical compounds (ligands), and ions simultaneously. A generative model can dream up a million chemically plausible tool compounds in seconds.

Nevertheless, those molecules must still pass through the gauntlet of preclinical and clinical evaluation, which is still highly unpredictable and cannot be helped by AI in any major way. Unlike Silicon Valley’s traditional “move fast and break things” ethos, biotech operates under the strict oversight of agencies like the FDA and EMA. Regulators require total traceability and explicit explainability. A developer cannot submit an Investigational New Drug (IND) application based on a black-box generative model’s output without showing exactly why and how a specific conclusion was reached. Regulatory frameworks (including the rolling enforcement of the EU AI Act) mandate rigorous validation documentation and contextual risk evaluation for AI-derived assets.

That early ideation stage is the sweet spot for AI in biotech and Big Pharma companies are leaping at the opportunity. In late 2025, Eli Lilly partnered with Nvidia to build the pharmaceutical industry’s most powerful supercomputer and announced a joint $1 billion, five-year investment to launch a co-innovation AI lab in the San Francisco Bay Area. In 2026, Chai Discovery, a generative antibody design company, announced strategic research collaborations with Eli Lilly and Pfizer.

Graphic Design (the software not the designers themselves): Disrupted

The rise of frontier AI image generation models, ranging from standalone aesthetic powerhouses like Midjourney to advanced multi-modal reasoning engines like Google’s Gemini-powered Nano Banana models (Nano Banana 2 and Nano Banana Pro), has had a big impact on the graphic design landscape. Historically, companies like Adobe, Figma, and Canva monetized the tools used to construct visuals (layers, vectors, pen tools, grids). AI image generation has disintermediated this process by shifting the core activity of graphic design from manual creation to creative curation and prompt engineering. Before the explosion of models like Midjourney and Nano Banana, a designer spent hours drawing paths, correcting lighting, and masking backgrounds. With these tools, a marketer or product manager no longer needed to commission an illustrator or spend days in Photoshop to create an editorial graphic or a hyper-realistic mood board. They could generate a high-fidelity visual asset in seconds.

Adobe faced the most disruption risk. If a user can generate a workable image via a chat prompt, the learning curve and subscription cost of Photoshop become harder to justify for casual and mid-tier enterprise users. Rather than fighting the tide, Adobe turned its platform into an ecosystem for these models. Through its Adobe Firefly umbrella, Adobe integrated premier third-party models directly into the Photoshop and Illustrator workspaces. Adobe natively integrated Gemini 2.5 (Nano Banana) and Gemini 3 (Nano Banana Pro) directly into Photoshop’s Generative Fill and Firefly Boards. This allowed Adobe to retain its professional user base. A designer might use Nano Banana Pro inside Photoshop to handle complex multi-element compositions or render crisp typography layout ideas, but they still use Adobe’s classic, high-precision selection brushes and layering tools to refine the final, production-ready output. While these integration steps are substantial, the transition comes during a period of executive realignment. After a 19-year tenure, Adobe CEO Shantanu Narayen unexpectedly announced plans to step down from the company despite not having a successor in place.

Figma’s core value proposition is collaborative interface design. The disruption here has less to do with photorealistic art (Midjourney) and more to do with structural design velocity (Nano Banana). Tools leveraging Nano Banana’s deep prompt understanding can ingest a product brief and output a fully formed, multi-screen app concept layout instantly. Designers frequently use Midjourney to generate highly stylized user interface concepts, texturing ideas, and abstract design systems during the pitching phase. It has compressed the timeline of the exploratory phase of product design from weeks to an afternoon, putting pressure on Figma to natively embed more automated canvas layouts (like Claude Design integrations and proprietary AI wireframing) to keep developers on their platform.

Canva built a multi-billion-dollar empire by making graphic design accessible to non-designers via drag-and-drop templates. Ironically, generative AI has democratized design so thoroughly that it threatened the concept of templates themselves. Why browse through thousands of pre-made templates for a social media banner when you can type your exact corporate requirements into a text prompt and get a bespoke asset? To counter this, Canva rolled out its own “Magic Studio” suite, partnering with backend AI engines to allow creators to generate custom imagery, auto-translate marketing assets into multiple global languages, and swap styles instantaneously. Crucially, users can generate the raw imagery with advanced AI, but rely on Canva to instantly format it for print, presentations, or multi-platform social media dimensions.

The disruption in graphic design software hasn’t eliminated the need for human graphic designers. The tool was never the artist. Instead, AI has stripped away some of the tedious hurdles that historically ate up 80% of a creative’s billable hours. Armed with frontier models like Midjourney and Google’s Nano Banana family, an individual designer can now operate with the speed, scale, and output volume of a multi-person agency. By automating the mechanical, time-consuming execution barrier of graphic design, AI image generation allows individual creatives to spend less time wrestling with complex software paths and significantly more time operating in their zone of genius: exercising original human taste, structural intent, and emotional storytelling.

Or, graphic designers can just do things the old-fashioned way: oil on canvas. Some people think it’s the best. I know I do!

Pediatricians (or most other medical specialties): Durable

Pediatricians and specialist physicians exhibit an incredibly low risk of AI displacement. Reports indicate that an increasing number of clinicians are exploring medical AI platforms such as OpenEvidence (which fields over 1 million clinical queries daily across U.S. health systems), UpToDate Expert AI, and general models (Gemini, Claude, ChatGPT), these platforms are utilized strictly as augmentative references under human supervision.

A pediatrician rarely gets a clean, chronological history of a present illness. Instead, they must conduct a live, multi-speaker interview, often translating a parent’s anxious observation (”He’s been pulling at his ears and acting fussy since Tuesday”) alongside a non-verbal child’s behavioral cues. The physician must parse subjective, heterogeneous caregiver reports, cross-reference them with visual, physical examinations (e.g., looking at an erythematous, bulging tympanic membrane via an otoscope), and extract the true clinical signal. In other words, much of diagnostic activity occurs in the real world, rather than the digital world.

While frontier LLMs score above 90% on static medical board examinations, real-world clinical reasoning is very different from a multiple-choice test. Board exams present a perfectly curated text blob where all relevant variables can be digested by a LLM. In practice, a physician faces incomplete heuristics and diagnostic ambiguity. Specialists deal with non-linear, complex variables where the “statistically highest-probability answer” generated by an LLM could be a fatal misdiagnosis. A pediatrician tracking developmental milestones or complex genetic markers must synthesize longitudinal trends, such as a subtle weight drop crossing two percentile lines on a growth chart, and map it against family context, socioeconomic factors, and rare disease indices. AI can rapidly surface peer-reviewed literature via OpenEvidence, but the human specialist must synthesize it to make high-stakes, custom exceptions to standard protocols.

Artificial Indignation

So, we have reviewed a few examples showing that jobs that are anchored to the real world and require creativity are more durable than digital, text-based jobs. Clearly, AI isn’t coming for everyone’s job, but that’s a nuanced discussion. Wait a second. Society as we know it isn’t particularly good at appreciating nuance, is it?

It doesn’t help that the doomsayers are front-and-center almost all day everyday. In fact, the loudest doomsayer is the head of one of the winningest AI labs: Dario Amodei, co-founder & CEO of Anthropic, the company behind Claude. Since early 2025, Amodei has spent almost every blog post, TV interview, and news article declaring that “AI could displace half of all entry-level white collar jobs in the next 1-5 years”. Why are people scared? The answer is simple. The AI CEO is scaring people. What do they fear? Quite a lot. AI-related job loss tops Anthropic’s AI fear leaderboard shown below.

Hold on a second. Does the AI fear leaderboard literally say “go rogue and end civilization”, and is it somehow the smallest fear on the list? Let’s go ahead and bump that up to #1, shall we.

It’s no surprise that the sudden and rapid integration of AI into daily American life has triggered a wave of social, economic, and political backlash. Far from being confined to tech circles, this pushback has evolved into a highly coordinated mass political effort involving grassroots activists, labor unions, and a complex patchwork of state and federal legislators.

While much of the public debate focuses on algorithms, one of the most intense, localized political backlashes is targeted at the physical footprint of AI: data centers. Communities across states like Virginia, Arizona, and Georgia have actively revolted against the construction of data centers, citing severe strain on local power grids, immense water consumption for cooling, and persistent noise pollution. Voters have begun treating data center approvals as a local election issue. In mid-2026, severe public blowback in Arizona led to a controversial tax-exemption moratorium for data center developers. This pushback has polarized politicians, with some framing data center opposition as a threat to American technological competitiveness, while local populist movements demand the protection of community resources. This mirrors the 19th Century Luddites who, as we discussed in Part 1, were not were not blindly afraid of technology but were comprised of highly skilled artisans looking to protect their communities and autonomy.

Speaking of skilled artisans, the initial anxiety regarding white-collar automation has solidified into an organized labor offensive. Consumers and creators have fiercely pushed back against the flooding of digital marketplaces with low-quality, AI-generated content (”AI slop”). Independent authors, visual artists, and major publishing houses have pushed the backlash into federal courts. A key tension sits between the Trump administration’s National Policy Framework for AI (released in March 2026), which strongly advocates that training AI models on copyrighted data constitutes fair use. Creators allege in pending litigation that this training paradigm constitutes a unauthorized infringement of intellectual property rights.

In his June 2026 New York Times op-ed, “Bernie Sanders: A.I. Is a Public Resource. Your should Own Half of It.”, Senator Sanders builds an argument on a simple premise: AI was not created out of thin air; it was trained on public information. The written works, art, journalism, code, and ideas produced by millions of ordinary citizens, usually without permission or compensation, were used to train the AI models. Therefore, Senator Sanders argues that the public is their rightful owner.

He proposes the American AI Sovereign Wealth Fund Act. The bill mandates a one-time 50% stock tax on the largest AI companies (those reaching $200 million in annual sales, such as OpenAI, Anthropic, and xAI), thereby creating a $7 trillion public sovereign wealth fund. A seven-person Independent Commission for Democratic AI would manage the fund. The government would use its voting shares to sit on corporate boards, allowing the public to block decisions that harm workers (like mass layoffs) and push for ethical guardrails. Companies running both legacy software/cloud operations and AI units would be forced to spin off their AI businesses so the public could cleanly capture its equity stake. The fund would pay an annual dividend (estimated at over $1,000 per citizen) and potentially funnel trillions of dollars into public goods like universal healthcare, education, and housing. Sanders’ modern critique of “Big Tech Oligarchs” mirrors the late 19th and early 20th-century Marxist and Communist backlash to the 2nd Industrial Revolution.

In the 2nd Industrial Revolution, early communist and socialist theorists argued that the immense wealth of the “Robber Barons” (Carnegie, Rockefeller, Vanderbilt) was stolen from the collective labor of the working class. Workers built the tracks and poured the steel, yet a handful of industrialists privatized the profits. Sanders applies a similar framework to intellectual property and data, arguing that tech moguls have effectively privatized the digital commons. The AI is only smart because it digested human history. Therefore, allowing Big Tech companies to unilaterally monetize it is a modern form of surplus-value extraction.

The core tenet of Marxist-Leninist thought during the industrial era was that the “means of production” (the factories, the textile mills, the mines) should not be owned by private capitalists, but by the state or the public collectively to prevent exploitation. Sanders’ bill is one of the most mainstream American proposals for the socialization of a core economic sector. By demanding 50% equity and board seats, he is arguing that the “digital means of production” (the algorithmic models and compute clusters) are too powerful to remain under private control and must be partially nationalized.

Lastly, the 2nd Industrial Revolution caused massive social dislocation as machines replaced artisanal labor, giving rise to intense labor movements and radical political backlash against the dehumanization of the assembly line. Sanders explicitly warns that unchecked AI threatens the “jobs, privacy rights, and mental health” of citizens. Just as early industrial socialists demanded a shorter workweek to distribute the gains of mechanization, Sanders uses this op-ed to advocate for a 32-hour workweek and a robot tax, ensuring that automation results in human liberation rather than mass poverty.

While the ideological roots are explicitly tied to the socialist and communist critiques of industrial capitalism, Sanders’ 2026 proposal adapts the concept for a modern venture-backed economy. Instead of armed revolution or total state command-and-control, his proposal leverages the mechanisms of the capital markets (equity stakes, sovereign wealth funds, and board voting shares) to achieve the historic socialist goal: ensuring that the fruits of human progress belong to the collective public that built it.

What about the Republicans? How do they feel about AI? While the Democrat backlash focuses heavily on corporate labor issues and wealth inequality, the Republican strategy treats frontier AI strictly through the lens of national security, geopolitical containment, and state enforcement. This approach culminated in the sudden, historic export-control shutdown of Anthropic’s Fable 5 and Mythos 5 models on June 12-13, 2026.

Just days after Anthropic released its highly advanced “Mythos-class” reasoning models (Mythos 5 for enterprise and Fable 5 for general users), the U.S. Department of Commerce, led by Secretary Howard Lutnick, issued an emergency export-control directive. Research teams, reportedly including teams at Amazon and SK Telecom, identified a narrow, non-universal jailbreak. The vulnerability allowed Fable 5 to bypass its anti-hacking guardrails when instructed to read a specific codebase, autonomously discovering and outlining exploitable software vulnerabilities. Citing strict national security authorities and the administration’s broader push to prevent foreign adversaries from leveraging American innovation, the directive ordered Anthropic to immediately suspend all access to Fable 5 and Mythos 5 by any foreign national. Since Anthropic could not actively audit and verify the citizenship of hundreds of millions of global API and web interface users in real time, the company had no choice but to comply uniformly. Both models were completely switched off globally, marking the first time in history that the U.S. government forced a commercially deployed, market-leading AI model offline.

It appears that Dario Amodei’s fear-mongering has stoked backlash on both sides of the aisle in D.C.

Conclusion

We stand at a historical crossroads that would look intimately familiar to both the 19th-century and the 20th-century cycles of creative destruction. Each industrial revolution forced a restructuring of what it meant to work. The 1st Industrial Revolution detached the artisan from their physical tools. The 2nd Industrial Revolution stripped away their autonomy. Today, the Generative AI Revolution threatens to replace knowledge work.

Yet, as we examine the labor market in mid-2026, a notable truth is emerging from the economic data and political battlegrounds. The professions facing the starkest disruption, such as horizontal software engineering and legacy IT consulting, are those that treated human intellect like a deterministic machine, optimized for strict syntax and predictable patterns. Conversely, the fields displaying the most stubborn durability, from the empathetic, multi-modal diagnostic loops of the pediatrician to the outlier leaps of the literary novelist, are anchored in the beautifully messy, un-automatable margins of the human experience.

The chaotic geopolitical tug-of-war we are witnessing, suggests that both major political parties in the U.S. view artificial intelligence as too powerful to remain unregulated. Whether the future mirrors Senator Bernie Sanders’ vision of a socialized digital commonwealth or a tightly controlled, national security-preempted state apparatus, the underlying mandate remains the same: AI tools must serve the collective progress of humanity, not its displacement.

Love biotech? I talk about biotech in the rest of this newsletter, I promise you. Check out Biotech Readout’s full library of content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of professional independence. To ensure full transparency regarding the technology infrastructure and semiconductor market segments discussed in this report, please note that at the time of publication, the author holds personal financial positions/long equity in Alphabet Inc. (Google), Taiwan Semiconductor Manufacturing Company (TSMC), and diversified S&P 500 index funds. Aside from these broad-market and specific technology holdings, the author holds no direct financial interest, equity, or options in any other individual companies mentioned in this report. No compensation has been received from any third party to feature, mention, or analyze specific corporate entities or therapeutic candidates.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

This week, we discuss:

• China Biotech

  • U.S. Treasury Department Weighs Screening Investments in China Biotech ⬇️

• Acquisitions ⬇️

  • Biogen to Acquire RayThera

  • Eli Lilly to Acquire 4E Therapeutics

• Approvals

  • Sanofi - Tzield (anti-CD3 mAb) / T1D ⬇️

  • Merck - Welireg (HIF-2α inhibitor) & Keytruda (anti-PD1 mAb) / ccRCC ⬇️

• Clinical Trial Data

  • Intellia - Lonvo-z (KLKB1 KO) / Phase 3 (HAE) ⬇️

  • J&J - Talvey (GPRC5D x CD3 TCE) / Phase 3 (RRMM) ⬇️

  • Eli Lilly - AJ1-11095 (Type II JAK2 inhibitor) / Phase 1 (myelofibrosis) ⬇️

  • Edgewise - EDG-7500 (allosteric cardiac myosin inhibitor) / Phase 2 (oHCM & nHCM) ⬇️

China Biotech

U.S. Treasury Department Weighs Screening Investments in China Biotech

An Endpoints article published last night outlines a strategic escalation in Washington’s scrutiny of cross-border capital flows, specifically looking at how the U.S. Department of the Treasury is evaluating outbound investment screening protocols for the Chinese biotech sector. Expanding beyond original executive restrictions focused heavily on semiconductors, quantum computing, and specific AI infrastructure, the federal framework is actively assessing biotechnology as a critical dual-use and national security vertical. Two unnamed sources at Treasury stated, “biotech is likely to be included in coming draft regulations that will say which sectors are going to be subject to outbound investment screening.” The Treasury is weighing rules that would mandate disclosures or outright restrict U.S. venture capital, private equity, and joint-venture capital from funding Chinese entities engaged in advanced biomanufacturing, genomics, and synthetic biology.

In a piece that I wrote about 3 weeks ago entitled China Biotech: Feast or Famine?, I discussed the risks & rewards associated with deeper entanglement of U.S. and China Biotech. Chinese biotech has evolved from an era of fast-follower generics into a powerhouse of validated, highly competitive clinical assets, particularly in oncology and immunology. The Treasury’s push to screen investments represents a surgical attempt to prevent U.S. capital from building up foundational infrastructure within China that could, ultimately, hollow out U.S. infrastructure.

Link to top ⬆️

Acquisitions

Link to top ⬆️

Approvals

Sanofi - Tzield (anti-CD3 mAb) / T1D

In a historic development for diabetes care, the FDA granted accelerated approval to Sanofi’s Tzield (teplizumab-mzwv), making it the first-ever disease-modifying therapy approved for children and adolescents aged 8 to 17 years who have been recently diagnosed with Stage 3 Type 1 Diabetes (T1D). For over a century, treating Stage 3 T1D (the symptomatic phase where patients require daily insulin injections) has been entirely reactive, focusing on managing blood sugar after the pancreas has already suffered severe damage. Previously approved only to delay the onset of Stage 3 disease in patients with asymptomatic Stage 2 T1D, this new approval allows clinicians to intercept the disease after a clinical diagnosis. It aims to protect the remaining insulin-producing beta cells in the pancreas before they are completely destroyed by the body’s own immune system. The FDA’s decision was heavily anchored by data from the Phase 3 PROTECT study, a randomized, double-blind, placebo-controlled clinical trial involving 328 pediatric patients diagnosed with Stage 3 T1D within the preceding six weeks. The trial successfully met its primary goal, demonstrating that Tzield significantly improved and preserved beta cell function by substantially slowing down the decrease of average C-peptide levels compared to the placebo group.

Link to top ⬆️

Merck - Welireg (HIF-2α inhibitor) & Keytruda (anti-PD1 mAb) / ccRCC

The FDA granted a significant label expansion to Merck’s oncology portfolio, officially approving the combination of Welireg (belzutifan) and Keytruda (pembrolizumab). This milestone introduces the first-ever approved regimen combining a PD-1 inhibitor with a HIF-2α inhibitor for the adjuvant treatment of clear cell renal cell carcinoma (ccRCC). The FDA’s decision was fast-tracked via a priority review based on compelling data from the Phase 3 LITESPARK-022 trial, a global study involving 1,841 patients. At a pre-specified interim analysis, the Welireg combination demonstrated a 28% reduction in the risk of disease recurrence, metastasis, or death compared to Keytruda alone (HR = 0.72, P= 0.0003).

Link to top ⬆️

Clinical Trial Data

Intellia - Lonvo-z (KLKB1 KO) / Phase 3 (HAE)

The Phase 3 data for Intellia’s lonvoguran ziclumeran (lonvo-z) was published in NEJM and marks a watershed moment in genetic medicine, delivering the first-ever complete Phase 3 dataset for an in vivo CRISPR gene-editing therapy.

Hereditary Angioedema (HAE) is a rare, autosomal dominant genetic disorder where a deficiency or dysfunction in the C1 esterase inhibitor (C1-INH) protein leads to the unchecked activation of the contact pathway, driving hyper-production of the vasoactive peptide bradykinin, which triggers life-threatening vascular leakage and severe swelling. The standard of care is bifurcated into acute and preventative management: acute attacks are intercepted with on-demand therapies like intravenous C1-INH concentrates (Berinert), plasma kallikrein inhibitors (Kalbitor), or B₂ receptor antagonists (Firazyr), while chronic long-term prophylaxis (LTP) relies on routine sub-Q infusions of C1-INH (Haegarda), oral small-molecule kallikrein inhibitors (Orladeyo), or monoclonal antibodies targeting activated kallikrein (Takhzyro). Delivered as a single intravenous lipid nanoparticle infusion, lonvo-z utilizes in vivo CRISPR/Cas9 gene editing to permanently knock out the liver’s KLKB1 gene, potentially potentially fixing the root cause of HAE. By selectively shutting down the production of prekallikrein (the upstream precursor to active kallikrein) this one-time intervention halts the continuous generation of downstream bradykinin, offering a functional cure by structurally preventing the vascular permeability that drives HAE attacks.

The global, randomized, double-blind, placebo-controlled Phase 3 HAELO trial (N=80) evaluating lonvo-z in Type I/II HAE patients established the first-ever Phase 3 validation of a systemic, in vivo CRISPR-Cas9 platform. The trial met its primary endpoint with a highly significant 87% reduction in mean monthly attacks (0.26 vs. 2.10 for placebo; P<0.0001), alongside a 91% reduction in moderate-to-severe episodes, enabling 62% of patients to achieve a completely attack-free status without long-term prophylaxis. On the safety front, the therapy was well-tolerated with no serious adverse events. The knock is that approximately 15% of patients experienced AST/ALT liver enzyme elevations. However, this transaminitis was entirely transient, asymptomatic, and self-limiting, reflecting a standard, class-wide characteristic of LNP clearance by hepatocytes. Ultimately, by delivering a uniform attack-rate reduction across 100% of treated patients, lonvo-z could minimize breakthrough anxiety and might transition HAE management away from a lifetime of chronic injections and toward a one-time, durable functional cure (counteracting the root cause of HAE).

Intellia initiated a rolling Biologics License Application (BLA) submission with the U.S. FDA in April 2026. The company plans to finalize the complete BLA submission package by H2 2026. Leveraging expedited regulatory designations, Intellia is targeting an FDA approval decision and potential commercial U.S. launch in H1 2027. Patients from the HAELO trial will continue to be monitored in long-term extension protocols to confirm the life-long durability of the KLKB1 gene knockout.

Sources: Intellia press release, NEJM paper

Link to top ⬆️

J&J - Talvey (GPRC5D x CD3 TCE) / Phase 3 (RRMM)

The Phase 3 data for Johnson & Johnson’s Talvey (talquetamab-tgvs) represents a major advance in hematologic oncology. Presented as a plenary abstract at the 2026 European Hematology Association (EHA) Congress, the results from the MonumenTAL-3 trial provide the first randomized, Phase 3 validation for moving a GPRC5D-targeted bispecific antibody combination into earlier-line treatment settings for multiple myeloma. The data was also published in NEJM.

Relapsed or refractory multiple myeloma (RRMM) occurs when malignant plasma cells evolve and escape frontline therapies (typically lenalidomide-based regimens), triggering bone marrow infiltration and clinical manifestations like anemia, hypercalcemia, and lytic bone lesions. While the current second-line standard of care relies on class-switching triplet regimens, such as pairing an anti-CD38 monoclonal antibody with a next-generation immunomodulatory drug (iMiD) or a proteasome inhibitor, Johnson & Johnson’s Talvey (talquetamab-tgvs) introduces a novel T-cell redirecting paradigm. As a first-in-class bispecific T-cell engager (TCE) targeting GPRC5D, Talvey simultaneously binds to CD3 on cytotoxic T cells and GPRC5D, an orphan receptor highly overexpressed on myeloma cells but absent on healthy B cells, thereby preserving baseline humoral immunity. When combined with Darzalex Faspro (daratumumab), the regimen drives anti-tumor synergy. Darzalex systematically de-bulks immunosuppressive cells and primes the marrow microenvironment, significantly amplifying Talvey’s targeted T-cell-mediated destruction of refractory clones.

The global, randomized Phase 3 MonumenTAL-3 trial (N=864) evaluating Talvey (talquetamab-tgvs) combinations against standard-of-care DPd in early relapsed/refractory multiple myeloma (2L+) demonstrated unprecedented efficacy, breaking Talvey out of its late-line niche and potetnially establishing it as a premier frontline option, particularly for tough-to-treat lenalidomide-refractory patients. At a median follow-up of 24.6 months, both experimental arms demonstrated overwhelming, statistically significant superiority over the standard of care, showing a 67-72% reduced risk of disease progression or death (Tal-DP: HR = 0.28, P < 0.0001; Tal-D HR = 0.33, P < 0.0001) and a 49-53% reduced risk of death (Tal-DP: HR = 0.47, P = 0.0006; Tal-D HR = 0.51, P = 0.0015). The overall response rates (ORR) hovered around 88% for both Talvey arms (vs. 77.6% for DPd). Furthermore, the Talvey regimens almost doubled complete response rates (71.1% for Tal-DP and 69.0% for Tal-D versus 34.5% for standard of care), translating to an impressive MRD-negativity rate (52.3% Tal-DP and 46.3% Tal-D versus 15.9% for standard of care). While expected, low-grade GPRC5D-related skin and taste toxicities occurred frequently, the doublet configuration (Tal-D) presented an invaluable, highly potent iMiD-free treatment alternative that dramatically slashed the rate of severe Grade 3/4 infections (29.2% vs. 42.2% for standard DPd) to optimize patient quality of life.

Backed by this definitive dataset, Johnson & Johnson has already submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA seeking approval for Talvey + Darzalex Faspro (with or without pomalidomide) in patients with RRMM who have received at least one prior line of therapy. J&J is preparing to aggressively position this combination to capture early-line market share, directly challenging established triplet and quadruplet sequencing strategies. Future clinical analysis will focus on how this GPRC5D-targeted combination can best be sequenced with or after BCMA-targeted CAR-T therapies (like Carvykti) and other T-cell engagers.

Sources: J&J press release, NEJM paper

Link to top ⬆️

Eli Lilly - AJ1-11095 (Type II JAK2 inhibitor) / Phase 1 (myelofibrosis)

The Phase 1 data presentation for Eli Lilly’s newly acquired AJ1-11095 (from Ajax Therapeutics) represents a major technological leap forward in treating myelofibrosis. Presented orally at the 2026 European Hematology Association (EHA) Congress by Dr. John Mascarenhas (Abstract S218), the initial readout establishes a compelling validation for the industry’s first clinical-stage Type II JAK2 inhibitor.

Myelofibrosis is a rare myeloproliferative neoplasm driven by somatic mutations (JAK2, CALR, or MPL) that hyperactivate the JAK/STAT signaling pathway, triggering a pro-inflammatory cytokine storm that results in progressive bone marrow fibrosis, severe cytopenias, and extramedullary hematopoiesis presenting as profound splenomegaly. While the current intermediate-to-high risk standard of care relies heavily on approved Type I JAK inhibitors (ruxolitinib, fedratinib, pacritinib, or momelotinib) these conventional agents only bind to the active conformation of the JAK2 kinase, failing to eradicate the underlying mutant clone and frequently inducing resistance or “clonal persistence” via adaptive pathway heterodimerization. Eli Lilly’s AJ1-11095 introduces a novel structural paradigm as a first-in-class oral Type II JAK2 inhibitor designed via computational chemistry to bind selectively to the inactive, DFG-out conformation of the kinase. By structurally stabilizing this inactive state, AJ1-11095 is designed to prevent both JAK2 homodimerization and cross-talk heterodimerization with JAK1 or TYK2, potentially unlocking deeper, more durable signaling suppression capable of fundamentally overcoming the molecular workarounds that drive Type I treatment failure.

The global, open-label Phase 1 AJX-101 trial (N=23) utilizing a traditional 3+3 dose-escalation design across five once-daily oral cohorts (25–125 mg) investigated AJ1-11095 as a potentially new second-line salvage paradigm for intermediate-2 or high-risk primary/secondary myelofibrosis patients who had failed or proved completely refractory to at least one prior Type I JAK inhibitor. AJ1-11095 achieved a 70% SVR35 rate (16/23 patients) and a parallel 70% TSS50 rate by Week 12, outperforming historical 2L benchmarks (0–32%). Crucially, the candidate demonstrated the first clear evidence of true molecular remission and disease modification in this setting, with 91% of patients achieving a reduction in mutant Variant Allele Frequency (VAF) across JAK2, MPL, or CALR clones, including a ≥50% VAF reduction in 35% of patients by Week 24. On the safety front, the small molecule had zero dose-limiting toxicities or treatment discontinuations. Expected hematologic class effects like anemia (52% Grade ≥3) and thrombocytopenia (30% Grade ≥3) were effectively managed via dose adjustments, while a 35% incidence of ALT/AST liver enzyme elevations proved entirely transient, asymptomatic, and self-limiting.

Following the completion of the escalation phase, Eli Lilly has selected the 75 mg once-daily dose as the candidate for initial dose expansion. The program has rapidly transitioned into recruiting a larger 2L myelofibrosis expansion phase to solidify these registrational metrics. Backed by their recent $2.3 billion acquisition of Ajax Therapeutics in April 2026, Lilly plans to expand the clinical footprint of AJ1-11095 into treatment-naïve (1L) myelofibrosis as well as high-risk polycythemia vera.

Sources: Eli Lilly press release, Eli Lilly to Acquire Ajax

Link to top ⬆️

Edgewise - EDG-7500 (allosteric cardiac myosin inhibitor) / Phase 2 (oHCM & nHCM)

The top-line data readout for Edgewise Therapeutics’ EDG-7500 represents a new development in the hypertrophic cardiomyopathy (HCM) landscape, delivering strong Phase 2 data that sets up a direct late-stage challenge to established cardiac myosin inhibitors (CMIs). Importantly, this it the first major clinical update from Edgewise after the sale of their muscular dystrophy business to Servier for up to $2.65 billion ($1.55 billion upfront + up to $1.1 billion in regulatory and commercial milestone payments) and focus on cardiovascular.

Hypertrophic Cardiomyopathy (HCM) is a genetic disorder marked by sarcomeric mutations that cause myocardial hypercontractility and fibrosis. Obstructive HCM (oHCM) occurs when septal hypertrophy drives systolic anterior motion (SAM) of the mitral valve to create a dynamic left ventricular outflow tract (LVOT) obstruction. Nonobstructive HCM (nHCM) is primarily governed by severe diastolic dysfunction and elevated filling pressures. While oHCM standard-of-care management relies on negative inotropes and first-generation cardiac myosin inhibitors (CMIs) like mavacamten or aficamten to resolve the physical gradient, nHCM treatment remains strictly limited to palliative diuretics, underscoring a vast unmet need for therapies that improve relaxation without sacrificing systolic output. Edgewise’s EDG-7500 addresses this gap as an oral, selective cardiac sarcomere modulator that is designed to uniquely act during early diastole to slow contraction velocity and enhance myocardial relaxation. By precisely targeting the initial millisecond phase of early systole, EDG-7500 aims to alleviate LVOT obstruction in oHCM and ease stiffness in nHCM without triggering the class-wide drop in overall contractile force, successfully preserving baseline Left Ventricular Ejection Fraction (LVEF) and avoiding the severe ventricular safety risks of older CMIs.

The multi-center, open-label, dose-finding Phase 2 CIRRUS-HCM trial evaluated flexible once-daily oral doses of EDG-7500 (25–150 mg) over 12 weeks in 53 symptomatic patients split across parallel obstructive (oHCM, N=20) and nonobstructive (nHCM, N=33) cohorts, utilizing titrated dosing guided by LVOT gradient reductions or NT-proBNP levels, respectively. The trial achieved encouraging efficacy: 74% of oHCM patients and 88% of nHCM patients achieved NT-proBNP biomarker normalization (<150 pg/mL) or a ≥50% reduction from baseline, alongside a mean 65% NT-proBNP decline in the nHCM group. Notably, nHCM patients demonstrated a mean 13-point improvement in KCCQ-OSS, numerically outperforming the ~10-point KCCQ-CSS improvement observed with Cytokinetics’ aficamten in the Phase 3 ACACIA-HCM trial. On safety, across over 700 serial echocardiograms, there was no mathematical relationship between drug exposure and LVEF reductions, with zero patients dropping below the critical 50% LVEF threshold.

Following the conclusion of Part D, Edgewise is utilizing the PK/PD data to finalize its registrational dose cohorts. Armed with cash reserves bolstered by a recent $2.65 billion asset sale to Servier, Edgewise plans to initiate its global Phase 3 pivotal trials for EDG-7500 in late 2026. Patients completing the 12-week CIRRUS-HCM study will continue tracking in an open-label extension for up to 18 months to gather long-term durability and safety metrics.

Sources: Edgewise press release, Edgewise slide deck, Weekly Readout on Phase 3 ACACIA-HCM trial for Cytokinetics’ aficamten

Link to top ⬆️

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 17, 2026, Biogen announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, consisting of an upfront payment and, predominantly, payments contingent on the achievement of future clinical and regulatory milestones. This acquisition centers on their preclinical portfolio of oral small molecule immunology medicines designed to achieve biologic-like efficacy with the convenience of an oral pill:

• TNFa inhibitor

• STAT6 inhibitor

• JAK2 V617F inhibitor

• CCR4 inhibitor

Here, we dive into the injectable-to-oral arbitrage strategy deployed by RayThera and the serial home-runs scored by founder Qing Dong and Gene Hung.

Convenience-pilled

Developing oral small-molecule versions of highly successful, validated biologic or injectable drugs is one of the most lucrative strategies in modern biopharma corporate development. Historically, large biologics (like monoclonal antibodies or peptides) were required to hit complex, flat, or intracellular protein-protein interactions (PPIs). Today, advances in structural biology, computational chemistry, and targeted protein degradation allow companies to recapitulate or exceed that same clinical efficacy in a convenient pill. The primary advantage of this strategy is the elimination of target biology risk:

1. Validation: If a branded biologic (e.g., an anti-TNFa like Humira, or an anti-IL-4Ra like Dupixent) has already generated billions of dollars in revenue, the industry knows with absolute certainty that modulating that specific pathway safely treats the disease.

2. Arbitrage: By shifting the R&D risk away from biology and entirely onto chemistry (i.e., “Can we make a small molecule that safely hits this known target?”), companies significantly improve their probability of technical and regulatory success.

Oral small molecules both compete with established biologics for late-line patients and expand the total addressable market (TAM) by improving patient access. Many patients and primary care physicians delay initiating biologic therapy due to needle phobia or the logistical burden of specialty pharmacy distribution and cold-chain storage. Payers frequently mandate that patients fail oral systemic therapies (like methotrexate or JAK inhibitors) before approving expensive, injectable biologics. An oral small molecule with biologic-like efficacy can insert itself directly into this lucrative pre-biologic payor slot. Biologics are typically reserved for moderate-to-severe patients. A safe, oral option allows a pharma company to treat the massive mild-to-moderate patient segment. To replace a large molecule with a small molecule, drug hunters generally deploy one of three modern chemical strategies:

• Allosteric Modulation: Instead of competing directly with a massive cytokine (like TNFa) at its binding site, small molecules are engineered to bind to allosteric pockets. This distorts the receptor or cytokine structure, preventing signaling without needing to cover a massive, flat protein interface.

• Targeting Downstream Intracellular Nodes: If an extracellular cytokine receptor is too difficult to block with a small molecule, developers target the immediate, non-redundant intracellular signaling bottleneck. For example, instead of blocking the extracellular IL-4/IL-13 receptors with an antibody, companies use oral STAT6 inhibitors or degraders to shut down the exact same downstream transcription path inside the cell.

• Targeted Protein Degradation: Traditional small molecules must bind tightly to an active site to inhibit a protein continuously. Targeted protein degraders (TPDs) only need to bind briefly to eventuate the destruction of the target protein via the cell’s natural ubiquitin-proteasome system. This allows small molecules to successfully knock down historically hard-to-drug scaffolding proteins or transcription factors that biologics could never reach.

So, how does RayThera’s leverage this strategy? While their official pipeline remains undisclosed on their website, a cursory search of public patent filings assigned to the company suggests several areas of therapeutic interest that they may be pursuing. Let’s take a closer look at these hypothesized targets:

• TNFa inhibitor (patent, patent): This is one of the most commercially successful drug classes in biotech history with 8+ approved branded & biosimilar medicines and generates >$6.6 billion in annual revenue. While the anti-TNF space is saturated with injectable biosimilars, innovation continues around alternative delivery mechanisms (orals) and multi-specific targeting.

• STAT6 inhibitor (patent, patent): Currently, the Type 2 inflammation space is dominated by biologic agents like Dupixent (dupilumab), an anti-IL-4R mAb that generates >$19.5 billion in annual revenue. The clinical goal for STAT6 inhibitors, specifically oral degraders like KT-621, is to achieve biologic-like efficacy with the convenience of an oral pill. Preclinical data suggest that complete degradation of STAT6 can block IL-4/IL-13 signaling similar to Dupixent.

• JAK2 V617F inhibitor (patent, patent): Pan-JAK inhibitors likewise constitute a mature drug class with 11+ approved branded medicines and generates >$17 billion in annual revenue. Truly mutant-selective JAK2 V617F inhibitors represent a potential paradigm shift, aiming to achieve disease modification, deplete the variant allele frequency, and avoid the hematological toxicities of pan-JAK inhibition.

• CCR4 inhibitor (patent): In contrast to the other candidates, CCR4 is a relatively nascent drug class with only one approved drug (Poteligeo) generating almost $30 million in annual revenue despite being on the market for eight years (approved in August 2018). While Poteligeo is highly effective at clearing malignant cells from the blood and skin in CTCL, its wholesale systemic depletion of CCR4+ cells includes normal systemic T_regs. This can precipitate severe immune-related adverse events, most notably a distinct Mogamulizumab-Associated Rash (MAR) and other autoimmune toxicities that mimic graft-versus-host disease. Current pipeline efforts are focused on developing small-molecule antagonists that inhibit the receptor’s signaling/chemotaxis without triggering ADCC-mediated cell depletion, with the goal of preserving systemic T_reg safety margins while still blocking malignant T-cell migration or solid tumor immunosuppression.

For Big Pharma companies holding a blockbuster biologic that is nearing its patent cliff, developing an internal oral small-molecule successor is the ultimate lifecycle management play. Perhaps this explains the allure of RayThera in the eyes of Biogen. By focusing their small-molecule engine on clinically de-risked pathways, they’ve positioned themselves to disrupt multiple blockbuster markets simultaneously.

Three Times the Charm

To understand RayThera, you have to understand the proven partnership of its founders, Qing Dong and Gene Hung, M.D. Operating out of the fertile biotech ecosystem of San Diego, California, Dong and Hung have spent the 2020s cultivating incubating-to-exit biotechs. Qing Dong (RayThera Co-Founder & CEO) is a seasoned drug discovery executive and corporate strategist, Dong brings a razor-sharp clinical and business acumen to the partnership, serving as the operational and executive engine driving their ventures. Gene Hung, M.D. (RayThera Co-Founder & CSO) is a physician-scientist with deep roots in translation medicine, Hung provides the biological foresight to spot historically difficult, validated immunological drug pathways that are ripe for small-molecule disruption. Before RayThera was even a concept, Dong and Hung had already pulled off two remarkably swift and lucrative corporate exits in San Diego using the exact same strategy:

• FronThera: Founded to advance novel small molecules. Alumis Inc. acquired FronThera in 2021 to obtain its lead drug candidate ESK-001, a TYK2 inhibitor.

• XinThera: Launched immediately after, focusing on targeted oncology and immunology small molecules (PARP1 and MK2 inhibitors), it was acquired by Gilead Sciences in 2023 for an undisclosed amount.

With two consecutive multi-million-dollar exits under their belts, Dong and Hung had established an enviable reputation among elite life-science venture capitalists. They recognized Dong’s and Hung’s talent for building highly focused, nimble small-molecule engines designed to get assets to the brink of clinical trials and hand them off to Big Pharma.

In August 2023, fresh off the heels of the XinThera sale to Gilead, Dong and Hung wasted no time in executing their third act. They founded RayThera with a singular, hyper-focused mission: apply advanced structural chemistry and targeted protein modulation to develop next-generation oral small-molecule alternatives to blockbuster injectable biologics. Dong and Hung built a lean team of roughly 20-30 elite drug discovery experts, utilizing a highly capital-efficient model that favored outsourced execution and computational chemistry over sprawling internal infrastructure.Recognizing the pedigree of the founders, top-tier institutional investors moved quickly. RayThera secured a massive $110 million Series A financing round co-led by heavyweights Foresite Capital and OrbiMed Advisors, alongside TTM Capital. This funding allowed the company to rapidly progress three early-stage pipeline programs simultaneously, keeping their exact drug mechanisms heavily shrouded in stealth while quietly locking down essential patent families covering novel small-molecule for immunology.

By mid-2026, RayThera’s lead asset, a highly potent, undisclosed oral anti-inflammatory small molecule, had completed its IND-enabling studies and was structurally ready to enter Phase 1 human clinical testing. For Big Pharma companies facing imminent patent cliffs on their legacy biologics, RayThera’s pipeline represented the ultimate defensive asset. The race to acquire them culminated on June 17, 2026, when Biogen announced a definitive agreement to fully acquire RayThera in a transaction valued at up to $1 billion. The strategic fit was seamless. Biogen, historically known as a neuroscience powerhouse, was aggressively trying to diversify into immunology, anchored by its late-stage biologics litifilimab (anti-BDCA2 mAb) and felzartamab (anti-CD38 mAb). Acquiring RayThera gave Biogen an instant portfolio of next-generation oral small molecules. For Qing Dong and Gene Hung, the Biogen acquisition marked the third consecutive time they successfully turned a pre-clinical startup into a massive corporate exit in less than three years.

Conclusion

RayThera’s rapid journey from a stealthy 2023 startup to a 2026 blockbuster acquisition reads like a corporate thriller, but for Qing Dong and Gene Hung, it’s business as usual. Pulling off a third consecutive exit in under five years cements their playbook as one of the most efficient engines in modern drug discovery. They have shown once again that when you pair de-risked biology with elite structural chemistry, Big Pharma is more than happy to open up their billion-dollar check book. Ultimately, Biogen’s bet on RayThera shows that there is immense, untapped value in optimizing the blockbusters we already have. RayThera’s portfolio of oral TNFa, STAT6, JAK2 V617F, and CCR4 inhibitors represents the vanguard of this movement. If these candidates deliver on their preclinical promise in clinical trials and secure FDA authorization, the injectable-to-oral arbitrage will bring more convenient options to patients living with autoimmune disorders.

Love biotech? Check out Biotech Readout’s full content library, or navigate directly to a segment that interests you:

• Frontiers in Medicine: Exploring the frontiers of our understanding and treatments for disease.

• Medical History: Recovering forgotten relics in the history of medicine.

• Acquisitions: Exploring the innovation behind acquired companies.

• Weekly Readout: A digest of new clinical data from the past week.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 16, 2026, 4E Therapeutics, Inc. announced that it had been acquired by Eli Lilly and Company for an undisclosed amount. This acquisition centers on a preclinical pipeline of MNK inhibitors, developed as non-opioid painkillers:

• 4ET1103 (Neuropathic Pain): This is the company’s lead compound. It has completed a Phase 1 study, where it demonstrated a favorable safety profile.

• 4ET2124 (Migraine Pain): It is currently ready to begin IND-enabling studies.

• MNK-eIF4E (Acute Pain): This compound is currently in the Discovery phase.

This acquisition signals Eli Lilly’s focus on complementary non-opioid peripheral pain mechanisms. On May 2025, Eli Lilly acquired SiteOne Therapeutics for up to $1 billion in cash, in-housing their Na_v1.8 inhibitor STC-004, a voltage-gated sodium channel blocker designed to arrest electrical propagation in peripheral nerve. Lilly’s interest comes at an unprecedented time of need, as the United States grapples with the Opioid Crisis. From 1999-2023, approximately 806,000 people died in the United States from an opioid overdose according to the CDC, making it a national strategic priority.

In this article, I will focus on how the pioneering work of Ted Price led to 4E Therapeutics and may someday help combat the Opioid Crisis.

Lone Star Ranger

Growing up in Texas, Ted Price did not dream of slicing nerves or charting molecular pathways in a petri dish. Captivated by Carl Sagan’s Cosmos, he arrived at the University of Texas at Dallas (UTD) in the mid-1990s intending to become an astrophysicist. He wanted to map the stars, but science has a way of redirecting its most curious minds. Finding himself bogged down by the abstract mathematical architecture of advanced physics, Price sought counsel from his advisor. It was a serendipitous moment. UTD was quietly expanding a nascent neuroscience department, and his advisor nudged him to look inward rather than outward, suggesting that the human brain was an uncharted universe of its own. Price pivoted, becoming one of the very first undergraduates to graduate from UTD with a degree in neuroscience.

Afterwards, he moved on to the University of Texas Health Science Center at San Antonio for his Ph.D., immersing himself in pharmacology and the enigmatic behavior of peripheral pain, before packing his bags for a postdoctoral fellowship at McGill University in Montreal. It was at McGill, working alongside global leaders in pain mechanics, that Price began to challenge the orthodox medical view of chronic pain. For decades, medicine treated chronic pain as a wiring problem: an injury happens, a nerve fires, and the brain registers the signal. If the pain persisted, doctors assumed the injury hadn’t healed, or worse, that the patient was exaggerating. Price suspected the truth was far more insidious. He began investigating local translation machinery, the biological factories inside individual sensory neurons.

Through meticulous tracing, his lab discovered that a traumatic injury or a flood of inflammatory cytokines not only trigger an electrical impulse, but reprograms neurons through the MNK-eIF4E signaling pathway. In a healthy, uninjured state, baseline activity of the MNK-eIF4E pathway in sensory neurons is low. However, tissue injury, nerve damage, or metabolic distress triggers the pathway. Price’s work showed that the MNK pathway acts as a molecular crossroads where multiple, distinct upstream cascades converge in a three-step process:

1. The Cytokine/Growth Factor Influx: Peripheral injury floods the extracellular space with inflammatory cytokines (specifically IL-6 and TNF-alpha) and neurotrophins (like NGF).

2. The MAP Kinase Relays: These ligands bind to their respective receptors on nociceptors (such as gp130 for IL-6 and TrkA for NGF). This triggers two parallel intracellular signaling cascades: the ERK1/2 (extracellular signal-regulated kinase) pathway and the p38 MAPK pathway.

3. The MNK Convergence: Both active ERK and p38 physically bind to and phosphorylate Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2). Once phosphorylated, MNK1/2 becomes fully activated and primed to seek out its primary target: eIF4E.

The crux of the Price Lab’s research centers on what happens once MNK1/2 is activated. MNK’s sole well-characterized role in this context is the highly specific phosphorylation of eIF4E (eukaryotic translation initiation factor 4E) at a single, precise amino acid residue: Serine 209 (Ser209). Before Price’s discoveries, it was generally assumed that phosphorylating eIF4E simply cranked up global protein synthesis across the board. The Price Lab showed that there was more nuance to the mechanism than initially appreciated. When MNK phosphorylates eIF4E, it selectively triggers the rapid synthesis of proteins that dictate neuronal plasticity and pain hypersensitivity. These changes convert a normal, protective sensory alert system into a permanently damaged, hyper-reactive chronic circuit in three ways:

• Ion Channel Sinking: The newly translated proteins facilitate the rapid trafficking and insertion of voltage-gated sodium channels (like Na_v1.7 and Na_v1.8) and transient receptor potential channels (like TRPV1) directly into the nociceptor’s plasma membrane.

• Threshold Drop: With a vastly higher density of these channels embedded in the membrane, the resting membrane potential changes. The physical threshold required to trigger an action potential plummets.

• Allodynia and Hyperalgesia: Light touches that should feel benign (like clothing resting against the skin) are suddenly amplified into intense pain signals (allodynia). Minor painful stimuli are registered as excruciating (hyperalgesia).

While Price initiated his earliest exploratory research into localized protein synthesis while he was a postdoc at McGill (from 2004 to 2007), the heavy-lifting discovery, mapping, and human validation of the MNK-eIF4E axis occurred entirely after he returned to Texas and established his own independent labs. In 2014, Price was recruited back to his alma mater, UTD, as a star faculty member. Five years later in 2019, he became the founding director of the Center for Advanced Pain Studies (CAPS).

Of Mice and Men

In July 2017, Price published a foundational paper in The Journal of Neuroscience entitled “The MNK-eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain”. Prior to this publication, it was well known that activity-dependent mRNA translation via the mTORC1 and MAPK pathways drove pain sensitization. However, these upstream pathways are massive, complex, and regulate thousands of cellular functions. The Price Lab set out to isolate the exact step where these pathways converge to dictate hyperalgesic priming, or “pain memory” caused by molecular changes in neurons increase pain sensitivity. They hypothesized that the precise phosphorylation of the 5’ cap-binding protein eIF4E by its specific upstream kinase, MNK1/2, was the exact molecular switch responsible.

To investigate their hypothesis, the researchers designed a series of parallel experiments testing both genetic and pharmacological interventions across both male and female mice, confirming that the pathway operates identically across sexes. These studies involved the following key perturbations:

• eIF4E^S209A Knock-In Mouse: This was the study’s crown jewel. The team utilized mice engineered with a single point mutation that converted Serine 209 to Alanine (S209A). These mice have perfectly functional eIF4E proteins, but their eIF4E cannot be phosphorylated by MNK.

• Mnk1/2^-/- Knockout Mouse: These were mice completely lacking the genes that encode the MNK1 and MNK2 kinases.

• Cercosporamide: A small-molecule inhibitor of MNK1/2 used as a tool compound to see if the genetic models could be replicated chemically in wild-type (WT) animals.

Their first finding involved the injection of potent pain-stimulating and inflammatory agents, specifically Nerve Growth Factor (NGF), Interleukin-6 (IL-6), and carrageenan, into the hindpaws of the mice. In wild-type mice, the injections caused acute mechanical and thermal hypersensitivity, which eventually subsided. A subsequent injection of a low-dose inflammatory mediator (like PGE2) caused an immediate, severe, and prolonged return of pain behaviors. This fits the definition of hyperalgesic priming, cell signaling changes that sensitize mice to chronic pain. eIF4^ES209A Knock-In and Mnk1/2^-/- Knockout mice displayed normal acute reflexes to the initial injury, proving their baseline sensory warning systems were completely intact. However, they showed a profound reduction in secondary mechanical and thermal hypersensitivity, decreased affective pain behaviors (measured via facial grimacing scales), and completely failed to trigger molecular signaling associated with hyperalgesic priming. The biological memory of the pain couldn’t be formed so long as the interaction between eIF4 and Mnk1/2 was absent. The paper also looked at peripheral nerve injury (PNI) via a surgical model. They discovered that the intense, long-lasting cold hypersensitivity typically brought on by direct structural nerve damage was heavily attenuated in both the eIF4ES209A Knock-In and Mnk1/2-/- Knockout mice, as well as in WT mice treated systemically with cercosporamide.

To understand why the behavior changed, the team performed whole-cell patch-clamp recordings and Ca²⁺ imaging on small-diameter dorsal root ganglion (DRG) neurons, the primary pain-sensing cells. Exposing wild-type DRG neurons to NGF or IL-6 caused a massive surge in ramp current-evoked action potential spiking. The nerves became hyper-excitable, firing rapidly at minor stimulation thresholds. Neurons isolated from eIF4^ES209A mice showed almost no increase in excitability when exposed to NGF or IL-6. The threshold for firing remained at healthy, baseline levels. Similarly, treatment of wild-type DRG neurons with the MNK inhibitor cercosporamide blocked the hyperexcitability induced by NGF and IL-6, matching the genetic mouse findings.

A subsequent 2023 bioRxiv preprint entitled “MNK inhibitor eFT508 (Tomivosertib) suppresses ectopic activity in human dorsal root ganglion neurons from dermatomes with radicular neuropathic pain” bridged the mouse-to-human translational gap. A key part of this study lies in its procurement and utilization of viable human tissue, a logistical feat managed by the Center for Advanced Pain Studies (CAPS) at UT Dallas in collaboration with surgical teams, such as those at MD Anderson Cancer Center. The team recovered human dorsal root ganglion (DRG) tissue from patients undergoing complex thoracic vertebrectomy surgeries (procedures involving the partial removal of vertebrae to relieve severe spinal cord or dorsal root compression). The tissue was harvested specifically from patients with radiculopathy (pinched, inflamed spinal nerves causing severe, radiating nerve pain along designated dermatomes). These neurons were compared directly against healthy DRG tissue recovered from organ donors who did not have a history of chronic neuropathic pain.

Once the human DRGs were surgically extracted, the Price Lab immediately transported and dissociated the tissue to culture live human sensory neurons. They utilized whole-cell patch-clamp electrophysiology to record the real-time electrical signatures of these cells. In preclinical models, a damaged nerve cell generates Spontaneous Activity (SA) or ectopic activity, meaning it fires action potentials continuously without any external heat, touch, or chemical trigger. This paper sought to determine whether human radiculopathy neurons possessed this same pathological firing and if an MNK inhibitor could silence it. When researchers applied 25 nM of Tomivosertib (a MNK1/2 inhibitor) directly onto the firing human radiculopathy neurons, it suppressed the pathological spontaneous firing within minutes. Crucially, when the drug was washed out of the cellular bath, the spontaneous activity slowly returned over time. This demonstrated a direct, reversible pharmacological engagement rather than a toxic, permanent killing of the cell.

By studying the precise shape of the action potentials before and after tomivosertib application, the team characterized how acute translation blockade alters electrical propagation:

• Decreased Action Potential Amplitude: The peak height of the nerve’s electrical spike shrank.

• Altered Afterhyperpolarization (AHP) Currents: The magnitude of the resetting current after a cell fires was significantly modified.

• The Ion Channel Connection: These changes strongly indicated that blocking MNK immediately modifies the functional activity and deployment of voltage-gated Sodium (Na⁺) and Potassium (K⁺) channels embedded in the human pain nerves.

Spurring it Forward

Ted Price never believed that a scientist’s job ended with a published paper. He openly maintained that if you discover a way to alleviate human suffering, you have a moral obligation to get it to patients. This spirit, combined with high-quality neurobiology, led him to serial entrepreneurship.

First came CerSci Therapeutics, a company he co-founded to develop small-molecule catalysts for neuropathic pain. CerSci was founded in 2015 alongside his frequent UT Dallas collaborator Dr. Gregory Dussor and then-graduate student Lucas Rodriguez, who drafted the business plan during an entrepreneurship course. The company was built to intercept acute and postoperative pain before it could necessitate opioid exposure. CerSci acquired and optimized a lead small-molecule compound, CT-044, a novel peroxynitrite decomposition catalyst. Rather than dulling pain centrally in the brain or binding to dangerous opioid receptors, the molecule worked peripherally to damp down the oxidative stress and inflammatory cascades that cause nociceptors to flare post-surgery. After raising nearly $20 million in venture capital and securing essential NIH Small Business Innovation Research (SBIR) grants, CerSci proved the safety and mechanics of its platform. In August 2020, the startup was acquired by Acadia Pharmaceuticals for $52.5 million upfront, with total development and commercial milestones pushing the deal’s potential value up to $525 million.

Following the acquisition of CerSci, Price co-founded 4E Therapeutics to commercialize his lab’s definitive breakthrough: the MNK-eIF4E translational axis. Led by CEO T. Craig Benson and VP of Drug Development James Sahn, the startup aimed to silence the biological printer that writes chronic pain memory into sensory nerves. While systemic MNK inhibitors had been tested in oncology, they crossed the blood-brain barrier, triggering central toxicities like depression. 4E Therapeutics engineered 4ET1103, a highly optimized, peripherally restricted oral small molecule MNK inhibitor. By isolating the drug’s effects strictly to the dorsal root ganglia (DRG), they could arrest pathological protein translation while minimizing central nervous system or addictive side effects. After advancing 4ET1103 through a Phase 1 trial, Eli Lilly agreed to acquire 4E Therapeutics and absorb its pipeline of MNK inhibitors into their expanding non-opioid pain portfolio.

Recognizing that the standard industry practice of using rodent models was the primary reason most pain drugs failed in clinical trials, Price co-founded Doloromics. Doloromics functions as a proprietary, data-driven drug discovery platform. Instead of testing random compounds on mice, the company leverages the massive, high-resolution human datasets generated by the Center for Advanced Pain Studies (CAPS). By utilizing comparative human transcriptomics, specifically sequencing healthy human DRGs against tissue from donors who suffered from chronic conditions like diabetic neuropathy, Doloromics employs machine learning to identify entirely new, highly specific cell-surface targets unique to human pain pathways, licensing these pristine targets out to broader pharmaceutical developers.

Demonstrating his agility across different commercial scales, Price also launched Ted’s Brain Science Products to address localized pain at the skin level. Born out of his early academic research into the metabolic management of pain, this venture commercializes over-the-counter topical pain creams. The formulations utilize resveratrol and metformin to activate AMP-activated protein kinase (AMPK). Price’s lab had previously discovered that AMPK acts as a natural brake on nociceptor amplification. By delivering these activators topically, the cream helps reset hyperactive nerve endings in the skin without systemic drug interaction.

Conclusion

Eli Lilly’s acquisition of 4E Therapeutics is a landmark in a thirty-year scientific journey that began when an undergraduate student in Dallas pivoted from astronomy to neuroscience. By backing Dr. Ted Price’s vision, Lilly is betting on a new mechanism for chronic pain. For decades, the pharmaceutical industry tried to solve pain by overriding the brain with central opioids, an approach that triggered a devastating public health crisis. As 4E Therapeutics enters into a collaboration with a global pharmaceutical giant, the industry moves one step closer to a future where chronic pain is no longer a permanent sentence, but a neuronal memory that can be rewritten.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

Did you really think that I would only write about biotech? Well, if you did, you are correct. I will only write about biotech. This piece is a rare exception.

I’m going off-script to write this piece about artificial Intelligence (AI) due, in part, to its ever-present rise, but also because I believe that I have something new to add to the conversation that hasn’t already been said before. AI has, without a doubt, set off a chain of events that will lead humanity to a new place, but what does that place look like? Dream or doom? Eden or Erebus?

Humanity has seen this story before, or at least different flavors of it. First, here is what what I will not talk about:

• I will not aim to characterize AI as “good” or “bad”

• I will not aim to disseminate propaganda perspectives advanced by specific AI labs

• I will not aim to promote one political ideology over another

Instead, I aim to objectively unpack historical case studies and surface conclusions from first principles. I aim to sift through the past to determine what could be in store for humanity in the age of artificial intelligence (AI), focusing on the decline of artisanal labor and the rise of new forms of labor.

ChatFYI

To make sure we are all on the same page, I will briefly summarize the development of AI as we know it today. Feel free to skip this section if you are familiar with AI, or want to go straight to the history of technological innovation.

The formal birth of AI began in the mid-20th century, driven by the belief that human thought could be reduced to the manipulation of symbols and logic. In 1950, Alan Turing published Computing Machinery and Intelligence, asking the question, “Can machines think?” He proposed the Imitation Game (now called the Turing Test) as a benchmark for machine intelligence. Six years later, John McCarthy, Marvin Minsky, Nathaniel Rochester, and Claude Shannon organized a summer research project at Dartmouth College. This is where the term Artificial Intelligence was officially coined. Early success came from “Good Old-Fashioned AI” (GoFiAI). Programs like the Logic Theorist and later Expert Systems used strict “if-then” rules programmed by human experts to solve specific problems. The field was born, but by the mid-1970s, early optimism collapsed. Computers lacked the processing power and memory to handle real-world complexity, leading to severe funding cuts.

As rule-based systems stalled, a rival philosophy emerged: Connectionism. Instead of programming rules, researchers wanted to mimic the structure of the human brain using artificial neural networks. A methodology called backpropagation was popularized by Geoffrey Hinton, David Rumelhart, and Ronald Williams in 1986. This mathematical algorithm allowed neural networks to learn from their mistakes by adjusting the weights of their connections backward through the network. The 1990s shifted focus toward specific, isolated tasks using probabilistic models and machine learning. This era culminated in 1997 when IBM’s Deep Blue defeated world chess champion Garry Kasparov.

For decades, neural networks were limited because they couldn’t be trained effectively at a large scale. In the late 2000s, three ingredients changed everything: Compute (GPUs), Data (The Internet), and Algorithmic Breakthroughs. Alex Krizhevsky, Ilya Sutskever, and Geoffrey Hinton entered a neural network called AlexNet into the ImageNet visual recognition competition in 2012. It crushed traditional computer vision methods, proving that Deep Learning (networks with many hidden layers) powered by GPUs was the future. For language, researchers used Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks. These processed text sequentially (word by word), which was a major step forward for machine translation but struggled with long paragraphs and couldn’t be easily parallelized on hardware.

The modern era of AI began with a single, foundational paper entitled Attention Is All You Need was published by Google researchers in 2017. This paper introduced the Transformer architecture. Instead of reading text word-by-word, Transformers use a mechanism called Self-Attention to process an entire sequence of text simultaneously. It tracks the relationships between words across vast distances in a text, allowing for massive parallel processing on GPUs. OpenAI and other labs realized that if you made Transformer models larger (more parameters) and fed them more data, they began to show emergent abilities like reasoning, coding, and roleplaying. While raw Large Language Models (LLMs) were powerful, they were unpredictable. The key unlock for the public was making them conversational and aligned with human intent. By using Reinforcement Learning from Human Feedback (RLHF), developers trained models to act as helpful assistants rather than just text-completers.

In November 2022, OpenAI released ChatGPT (built on GPT-3.5), bringing conversational AI to the mainstream and triggering a global tech race. It combined a massive Transformer model with seamless conversational alignment. It became the fastest-growing consumer application in history, sparking the current AI arms race.

Today, the market has matured beyond just raw size, splitting into distinct frontiers of optimization:

• ChatGPT (OpenAI): The pioneer, moving heavily into advanced multi-modal capabilities (voice, vision) and complex reasoning architectures (like the o1/Strawberry series) that “think” before they respond.

• Claude (Anthropic): Founded by former OpenAI researchers, Anthropic focused heavily on AI safety, steerability, and structural alignment (Constitutional AI), resulting in models highly praised for nuanced writing, coding, and large context windows.

• Gemini (Google): Built from the ground up as a native multi-modal model, deeply integrated into an ecosystem with massive data advantages and pioneered incredibly massive context windows (millions of tokens).

• Grok (xAI): Elon Musk founded xAI to build Grok, an LLM integrated closely with real-world data from the X (formerly Twitter) platform, designed with a more witty, unfiltered personality.

Growing Pains

In the arc of history, technological innovation has been the harbinger of a sort-of industrial cycle. A new technology triggers the sunsetting of “old” industries while simultaneously birthing “new” industries.

Scientists will recognize this process as a paradigm shift, an idiom popularized by the American historian Thomas Kuhn in his book The Structure of Scientific Revolutions. For Kuhn, a paradigm is a complete worldview that encompasses a universally recognized framework that a community shares. Once a paradigm is established, scientists enter a phase Kuhn called Normal Science, in which the paradigm’s core rules are taken for granted and the theory is extended (ex. radioactivity is an established paradigm so we discover more radioactive elements and expand its applications to cancer biology). Inevitably, normal science encounters anomalies, experimental results that contradict the expectations of the paradigm. Initially, these anomalies are ignored, dismissed as experimental error, or swept under the rug with minor tweaks to the existing theory. However, as anomalies pile up and begin to undermine the core tenets of the framework, the scientific community loses confidence. The discipline enters a state of crisis, characterized by professional insecurity, philosophical debates, and the emergence of competing, radical theories (ex. religious organizations denounce Galileo’s theory that the Earth orbits the Sun). The crisis is resolved when a completely new paradigm emerges that can not only explain all the successes of the old paradigm but also neatly resolve the critical anomalies that caused the crisis. This transition from the old worldview to the new one is the paradigm shift. It is not a gradual transition; it is a sudden, sweeping revolution that fundamentally changes how scientists see the world. However, paradigm shifts largely concern the acceptance of technological innovation by experts. How does technological innovation percolate through society?

This process is recognized by techies as creative destruction, a term popularized by the Venezuelan economist Carlotta Perez in her book Technological Revolutions and Financial Capital. Every cycle starts with a cheap, ubiquitous key input (like oil, microchips, or steel) that changes the logic of how everything is produced. Perez divides the industrial cycle (typically 50-60 years) into three distinct phases:

1. The Installation Period: This is the initial, highly disruptive phase of creative destruction. The new technology erupts into an economy dominated by mature, stagnant industries. Since established institutions and banks are hesitant to back unproven technologies, speculative financial capital (venture capitalists, investment banks) steps in. Financial capital pours immense amounts of money into building the new infrastructure. This creates a massive economic divergence: a booming, high-tech sector versus a decaying, obsolete “old economy.” This inevitably culminates in a massive asset bubble (e.g., the Railway Mania of the 1840s or the Dot-com bubble of 2000).

2. The Turning Point: The frenzy phase always ends in a financial crash. However, Perez argues this crash is a necessary part of creative destruction. The bubble, while destructive, leaves behind a fully built infrastructure (e.g., thousands of miles of fiber-optic cables or railway tracks) that is now cheap to use. The Turning Point is a period of political and social choice. For creative destruction to move forward, the state must step in to regulate the financial markets and establish new institutional frameworks to guide the new technology.

3. The Deployment Period: Once the rules of the game are established, the economy enters a new golden age. The focus shifts from financial speculation to production capital, actual businesses using the new technology to generate real goods and services. The new technology is no longer a disruptive outsider; it becomes the standard operating fabric of the entire global economy (e.g., the post-WWII boom of mass production, or the widespread integration of the internet across all industries in the 2010s). Eventually, the technology matures, markets saturate, and growth slows down. Financial capital begins looking for the next big thing, setting the stage for the next technological revolution to emerge and destroy the current order.

The Gartner Hype Cycle is a great visual depiction of creative destruction, mapping out its initial frenzy, crash, and gradual re-expansion.

Labors of Love

For millennia, stretching from the ancient world through the medieval period and into the 18th century, virtually every manufactured object was the product of an artisan. Whether it was a horseshoe, a wool cloak, a wooden chair, or a glass vial, goods were made by hand, using localized, highly specialized knowledge. In medieval Europe and many other global cultures, artisanship was strictly regulated by guilds, powerful associations of master craftsmen. The guild system structured a worker’s entire life through a strict hierarchy:

• Apprentice: A young person bound to a master for several years, working for room and board while learning the mysteries of the trade.

• Journeyman: A skilled worker who had completed their apprenticeship and earned a wage, often traveling to study under different masters to perfect their craft.

• Master: A craftsman who had produced a masterpiece judged worthy by the guild, allowing them to open their own shop, train apprentices, and sell goods.

The earliest guilds trace their roots back to ancient Mesopotamia (starting 2200 BCE). While they weren’t called guilds, highly structured associations of artisans existed under the Akkadian and Babylonian empires. King Naram-Sin of Akkad standardized weights, measurements, and lengths specifically to unify the work of artisan groups across cities. Later, the Code of Hammurabi (1750 BCE) explicitly laid down legal wage protections and standard rates for specific trades, such as fixed shipbuilder wages and ferry rates, indicating an organized, state-recognized class of skilled laborers. The original Code is inscribed on a basalt slab on display at the Louvre (called “The Louvre stele”).

Guilds endured through the Roman Republic & Empire (“Collegium”) and survived in the Byzantine Empire after the Western Roman Empire collapsed. As Europe stabilized after the Dark Ages, early versions of the modern word guild began to appear (likely derived from the Anglo-Saxon gylta or the Germanic gild, meaning “to pay” or “sacrifice”), although they were closer to religious fraternities than business cartels. By the 11th and 12th centuries, the revival of trade, the growth of independent medieval cities, and the emergence of a money economy caused these religious fraternities to split into the highly structured, economically dominant institutions we know today. They divided into two strict categories:

• Merchant Guilds: As international trade routes reopened, merchants traveling between towns faced immense dangers from bandits, pirates, and predatory feudal lords. Merchants banded together into Merchant Guilds for physical protection on the road. Once they grew wealthy, these guilds bought charters from kings or lords. These charters granted the guild a total monopoly on trade within a specific city. If you weren’t a member of the local Merchant Guild, you could not sell goods retail, you were hit with massive taxes, or you were banned from the city gates entirely.

• Craft Guilds: As cities grew, the population of craftsmen inside the walls exploded, leading to intense specialization. Craft fields broke away from the broader merchant guilds to form their own specific Craft Guilds (e.g., the Weavers, the Blacksmiths, the Goldsmiths, the Shoemakers). It was these 12th-century Craft Guilds that perfected the iconic three-tier career progression designed to tightly control the quality of goods and protect their economic security (apprentice, journeyman, master). By enforcing this structure, the first true craft guilds ensured that no rogue operator could flood the city with cheap, low-quality products, effectively establishing the stable, localized economic paradigm that dominated human manufacturing.

By the 17th century, the domestic system emerged alongside guilds. Merchant-capitalists would distribute raw materials (like raw wool) to rural families and independent artisans, who would spin, weave, or fashion the goods in their own cottages using their own tools. The merchant would then return to buy the finished product and sell it on the market. Under both systems, the artisan possessed holistic knowledge. They understood the entire production process from raw material to finished good. They owned their tools, set their own hours, worked from home or small shops, and took deep personal pride in their unique stamp of quality. Technological innovation would soon shake this 4000+ year tradition to its core.

1st Industrial Revolution and the Luddites

The First Industrial Revolution (roughly 1760 to 1840) shattered the guilt system by separating the artisan from both their tools and their autonomy. The revolution was driven by a synergistic loop of mechanical innovation, a new energy source, and the discovery of better raw materials. To understand its scale, we have to look at the specific cluster of breakthrough technologies that drove it, and the precise, often devastating ways they impacted the artisanal class.

Before the revolution, textile production was a slow, decentralized cottage industry. A series of inventions rapidly mechanized the two core stages: spinning raw fiber into yarn, and weaving yarn into cloth. In 1733, John Kay invented the Flying Shuttle, which automated the weaving process, allowing a single weaver to weave much wider fabrics at double the speed. This created a massive yarn shortage, as weavers outpaced traditional hand-spinners. James Hargreaves would build on the idea with his 1764 debut of the Spinning Jenny, a hand-powered machine that allowed one worker to spin multiple spools of thread simultaneously. Five short years later in 1769, Richard Arkwright invented the Water Frame, which bypassed human muscle entirely by using water power to drive spinning machines. It produced yarn faster and stronger than the Jenny, but the machines were too massive for a home. They required a dedicated building next to a fast-flowing river, effectively birthing the modern factory. The final straw yarn came in 1785, when Edmund Cartwright invented the Power Loom and mechanized the weaving side to catch up with the abundance of machine-spun yarn, fully automating textile production from raw material to finished fabric.

While water power launched the factory system, it tied factories to rural, rushing rivers. The steam engine liberated manufacturing from geography. Building on Thomas Newcomen’s primitive pump design, James Watt added a separate condenser and converted the engine’s linear motion into rotational power, resulting in the Rotary Engine (1776–1781). This enabled factories to be built anywhere, specifically near coal fields, shipping ports, and booming urban labor pools. Steam power ran dozens of mechanical looms and jennies simultaneously via complex systems of ceiling shafts, belts, and pulleys.

Machines and steam engines required stronger materials than wood and animal fat. Abraham Darby discovered how to use coke (purified coal) rather than scarce wood charcoal to smelt iron ore. Henry Cort invented a way to refine pig iron into high-quality wrought iron on an industrial scale (The Cort Process/Puddling). This provided the durable, cheap metal needed to construct heavy machinery, steam boilers, bridges, and eventually, railways.

For centuries, the artisan was the backbone of production. They owned their tools, possessed holistic knowledge of their craft, managed their own schedules, and dictated the price of their goods. The First Industrial Revolution systematically dismantled this entire lifestyle through three structural shifts:

• Separation from the Means of Production: Under the traditional domestic system, an artisan weaver or spinner worked out of their own cottage. They owned their spinning wheel or handloom. Since steam engines and iron power looms were incredibly expensive and physically massive, no individual artisan could afford to buy or house them. Capitalist entrepreneurs bought the technology and built the factories. Since hand-turned tools could not compete with the speed, volume, and low cost of steam-driven machinery, the artisan’s tools became economically worthless overnight. To survive, artisans had to sell the only asset they had left: their time and labor as wage workers inside someone else’s factory.

• Extreme Deskilling and Wage Depression: In the guild and artisanal systems, value was tied to human skill. A master weaver spent a lifetime learning how to handle different fibers, adjust yarn tension by touch, and execute complex patterns. The factory system flipped this dynamic. The skill was transferred from the human to the machine. A power loom did the precise work of weaving automatically. The factory owner no longer needed an expensive master craftsman. They could hire an untrained laborer (frequently women and children, who were paid drastically lower wages) to perform simple, repetitive maintenance tasks like sweeping debris, clearing jams, or tying broken threads. The artisan class saw their wages plummet as their highly specialized knowledge was rendered obsolete.

• The Loss of Freedom and the Tyranny of the Clock: Artisans were used to a task-oriented rhythm. They worked until the job was done, took breaks when they wished, and historically celebrated “Saint Monday”, taking Mondays off to recover from the weekend or tend to their family gardens. Factories replaced this natural rhythm with the tyranny of the clock and the machine. Workers were bound to the relentless speed of the steam engine. If the belts were turning, the human had to keep pace. Factory bells dictated precisely when to arrive, when to eat, and when to leave. Systems of strict fines were introduced for being minutes late, talking on the shop floor, or looking out a window. The artisan went from being an independent creator who took pride in a finished masterpiece to an interchangeable, highly policed machine tender, suffering what philosophers and economists termed profound psychological alienation from their labor.

This disruption did not happen quietly. Between 1811 and 1816, displaced textile artisans in England organized a violent, underground resistance movement. Invoking the name of a mythical leader, Edward Ludd, these Luddites broke into factories at night to systematically smash wide-frame knitting straight-edges and power looms with sledgehammers. Contrary to the modern misuse of the term, the Luddites were not blindly afraid of technology. In reality, the original Luddites were highly skilled, deeply literate artisanal cloth dressers, weavers, and knitters in northern England who were protesting how automated machinery was being used to bypass fair wages, degrade standard working conditions, and flood the market with cheap, poorly made goods, destroying their communities and autonomy in the process.

According to folklore, Edward Ludd was a young weaver’s apprentice who, in a fit of rage against a cruel master in the late 18th century, took a sledgehammer and smashed two knitting frames. The rebels adopted his name, turning him into a phantom folk hero. Letters threatening factory owners were signed by “Ned Ludd from Sherwood Forest.” Since “Ned Ludd” didn’t exist, the state could never capture the leader of the rebellion. The Luddites operated as a clandestine, oath-bound secret society. They utilized complex handshakes, code words, and night-time drills on the dark moors of northern England. Their primary weapon was the Enoch, a massive, custom-forged sledgehammer manufactured by the local blacksmithing firm Enoch & James Taylor. In a brilliant twist of dark irony, the Taylor firm also manufactured the iron shearing frames used in the factories. The Luddites’ rallying cry became: “Enoch made them, and Enoch shall break them!” Crucially, the Luddites were highly selective. If a factory owner paid fair wages and used traditional, high-quality production methods, the Luddites would march right past his facility without touching a single brick. But if an owner used automated frames to undercut human labor, his machinery was systematically reduced to scrap iron.

By 1812, the rebellion had escalated from property damage to open warfare. Luddites began ambushing factory owners, leading to bloody shootouts at fortified mills, such as the famous attack on Rawfolds Mill in Yorkshire. Terrified of a French-style revolution on British soil, the government reacted with unprecedented ferocity. The British State deployed more than 12,000 soldiers to the industrial north to hunt down the Luddites. To put this in perspective, this domestic occupation force was larger than the army the Duke of Wellington commanded during the opening of the Peninsular War against Napoleon. Passed in February 1812, the Frame Breaking Act made the destruction of mechanized looms an offense punishable by death. During the parliamentary debate over the bill, the romantic poet Lord Byron stood up in the House of Lords as one of the very few public figures to defend the workers, famously declaring:

“I have been in some of the most oppressed provinces of Turkey; but never, under the most despotic of infidel governments, did I behold such squalid wretchedness as I have seen since my return in the very heart of a Christian country... Is there not capital enough in your life-blood? And must a frame be placed in the scale with the life of a man?”

Lord Byron

The deployment of the army, combined with a vast network of paid government spies, eventually broke the resistance movement. In 1813, the state held a series of high-profile show trials in York. Dozens of suspected Luddites were convicted. Seventeen men were publicly [redacted], and dozens more were packed onto prison ships and transported to penal colonies in Australia for life. By 1816, the mass [redacted], coupled with a slight easing of the economic depression, brought a quiet, bitter end to the uprising.

The Luddites lost because they were outgunned by the state machinery of the world’s most powerful empire. Their true legacy is not a rejection of technology, but a profound question about progress: Who does innovation serve? The Luddites argued that if a machine creates immense wealth for one factory owner while throwing an entire community into starvation and poverty, that technology isn’t a benefit to civilization. Rather, it is a weapon and and instrument of subjugation. This debate that directly echoes through our modern anxieties surrounding AI.

2nd Industrial Revolution and the Communists

The Second Industrial Revolution (roughly 1870 to 1914) was a phase of rapid industrialization that took the breakthroughs of the first revolution and scaled them into a massive, globally integrated system. If the First Industrial Revolution was defined by coal, iron, and local textile mills, the Second was defined by electricity, steel, chemicals, and giant corporations. For the remaining artisanal classes, this era both challenged their wages and systematically dismantled the intellectual & structural concept of skilled craftsmanship.

Before the 1870s, steel was a luxury metal, difficult and expensive to manufacture in large quantities. The Bessemer process (and later the open-hearth furnace) allowed for the mass purification of pig iron into high-quality steel by blowing air through molten metal to burn off impurities. Steel production skyrocketed, while costs plummeted. This cheap, ultra-strong metal allowed for the construction of transcontinental rail networks, massive steamships, skyscrapers, and heavy industrial machinery that could withstand immense pressure.

The reliance on centralized steam engines running massive, dangerous belt-and-pulley systems gave way to two far more flexible power sources. The development of alternating current (AC) grids allowed electricity to be transmitted over vast distances. Factories no longer needed to be built near coal fields or rivers. They could be placed anywhere. Furthermore, small, efficient electric motors could be attached to individual machines, making factory layouts far safer and more efficient. Fueled by newly refined petroleum, this technology laid the groundwork for automobiles, aviation, and decentralized mechanical power.

Numerous other industries evolved rapidly. The birth of synthetic dyes, plastics, artificial fertilizers, and pharmaceuticals transformed agriculture, healthcare, and consumer goods. The telegraph, telephone, and transatlantic cables allowed corporations to coordinate logistics, supply chains, and market prices globally in real time.

By 1870, the independent cottage weaver was largely a thing of the past. However, a vast class of highly skilled, proud craftsmen still dominated other sectors: machinists, blacksmiths, gunsmiths, clockmakers, carriage builders, and toolmakers. These artisans retained high status because assembling complex machines still required human judgment, hand-filing, and custom fitting. The Second Industrial Revolution targeted this final stronghold of artisanal pride through three crushing corporate and managerial strategies:

• Ultra-Precise Interchangeable Parts: Historically, if a machine component was slightly off, an artisan machinist used a file to custom-fit the gear or piston by hand. Every complex product was slightly unique. The invention of heavy, electrified, ultra-precise machine tools (like automated lathes and milling machines) allowed factories to stamp out millions of parts that were perfectly identical down to a fraction of a millimeter. The need for an artisan’s unique touch, judgment, and fitting skill vanished. Components could be dumped into a bin and bolted together by anyone. The artisan’s hand was replaced by the machine tool’s precision.

• Taylorism (Scientific Management or “white collar” work): Pioneered by mechanical engineer Frederick Winslow Taylor, Taylorism treated human beings as biological cogs in a larger machine. Taylor argued that the biggest drain on factory efficiency was worker autonomy. Management explicitly stole the “brainwork” from the craftsman. Engineers used stopwatches to analyze a master craftsman’s movements, stripped away any “wasted” motion, and broke a complex, holistic job down into its smallest, most mindless components. Under Scientific Management, the worker was explicitly instructed not to think, innovate, or self-pace. The comprehensive knowledge of how to build an entire product from scratch was abstracted away into a corporate manual, completely separating the execution of labor from the conception of labor.

• The Moving Assembly Line: Pioneered by Henry Ford for the Model T in 1913, the moving assembly line was the logical conclusion of Taylorism and the ultimate disintermediation of the worker. Instead of a group of skilled workmen gathering around a stationary product to build it, a motorized conveyor belt dragged the product past stationary, completely deskilled laborers. On a Ford assembly line, the worker lost control over their own physical pacing. The machine, regulated by the factory’s electricity, dictated exactly how fast the human had to move. A worker might spend ten hours a day doing nothing but turning a single nut on a chassis as it passed by. If they paused for a few seconds, the entire global supply chain stalled.

The Second Industrial Revolution required massive capital to build steel mills, transcontinental railroads, and electrical grids. This led to the rise of the first mega-corporations, trusts, and monopolies managed by Robber Barons (like Andrew Carnegie, John D. Rockefeller, and J.P. Morgan). While corporate titans amassed fortunes that rivaled the GDP of entire nations, the workers who operated the machinery lived in cramped, disease-ridden tenements, working 12-to-14-hour days with zero job security, health insurance, or pensions. The contrast between opulent wealth and squalid poverty was impossible to ignore.

As Taylorism and scientific management stripped workers of their intellectual ownership of labor, work became profoundly monotonous and dehumanizing. Workers felt a deep sense of psychological alienation. They no longer saw themselves in the products they created. A worker on an assembly line was merely an appendage to an electrified machine. Events like the Haymarket Affair (1886) and the Homestead Strike (1892) in the United States, alongside brutal crackdowns on striking miners and factory workers across Europe, showed that governments would readily deploy the military, police, and private militias (like the Pinkertons) to shoot striking workers and protect corporate property.

By the dawn of World War I, the artisan had been thoroughly transformed into the modern industrial proletariat, a wage laborer who owned no tools, possessed no unique monopoly on skill, and performed highly repetitive, specialized tasks. The pride of saying “I made this” was replaced by the bleak observation of “I operate the machine that makes this.” This alienation from the holistic process of creation fueled the massive, organized labor union movements of the late 19th and early 20th centuries, as workers realized their only remaining leverage was no longer their individual talent, but their collective numbers. The story of modern communist theory does not begin in a grand parliament or on a smoky battlefield, but in the damp, soot-choked streets of industrial Europe during the 1840s. It is a narrative driven by an unlikely partnership between two brilliant German minds: Karl Marx, a penniless, fiercely academic radical philosopher, and Friedrich Engels, the wealthy son of a conservative textile tycoon. Together, they looked at the smoking factories of the First Industrial Revolution and saw not just a change in technology, but a structural prison that was tearing the human soul apart.

In 1842, Karl Marx was a young, combative journalist in Cologne, editing a radical newspaper. He was deeply steeped in the abstract philosophy of Georg Wilhelm Friedrich Hegel, who argued that history progressed through a clash of ideas, a thesis colliding with an antithesis to create a new synthesis. However, Marx was growing frustrated with pure abstraction. He noticed that the local government was passing laws criminalizing poor peasants for collecting fallen firewood from private forests. Marx began to realize that the driving force of human society was economics and property law, not merely spirit or ideas. Meanwhile, across the North Sea, a twenty-two-year-old Friedrich Engels was being sent by his father to Manchester, England, to help manage the family cotton mill, Ermen & Engels. The senior Engels hoped the trip would cure his son of his radical political leanings. It had the opposite effect.

Guided by Mary Burns, a fierce working-class Irish factory hand who became his lifelong partner, Engels walked through the squalid slums of Manchester. He smelled the open sewers, saw children missing limbs from factory machines, and witnessed families crammed ten to a room. In 1845, he published The Condition of the Working Class in England, a devastating piece of investigative journalism. Engels provided something Marx lacked: raw, empirical, firsthand evidence of how industrial capitalism operated on the factory floor. When Marx and Engels met at the Café de la Régence in Paris in August 1844, they talked for ten days straight. They realized their thoughts were complementary. Marx had the philosophical framework and Engels had the economic framework. A lifelong intellectual brotherhood was born.

Marx and Engels set out to build a new theory of human history that was grounded entirely in the physical world. Marx famously stated that he found Hegel’s philosophy standing on its head, and that he chose to turn it right side up. They called their approach Historical Materialism. They argued that the foundation of any human society is its economic base, the “forces of production” (tools, technology, factories) and the “relations of production” (who owns them and who works them). Everything else (religion, law, politics, art, and philosophy) was merely a superstructure built on top of that economic foundation, designed to protect the interests of the ruling class. From this, they deduced that human history was not a peaceful evolution, but a recurring cycle of class warfare. In ancient times, it was Master versus Slave. In the Middle Ages, it was Feudal Lord versus Serf. Now, under the Industrial Revolution, the conflict had been distilled into its final, purest form: the Bourgeoisie (the capitalist factory owners) versus the Proletariat (the working class).

By 1847, Marx and Engels had joined a small, underground network of radical European workers called the League of the Just, which they promptly convinced to rename itself The Communist League. The League asked the duo to write a document explaining their secretive philosophy to the world. Working through the winter in a frantic burst of energy, they produced a slim, forty-page pamphlet. Published in London in February 1848, it opened with a line that sent a shiver through the courts of Europe: “A spectre is haunting Europe; the spectre of communism.”

The Communist Manifesto was an electrifying synthesis of their theory. It praised capitalism for its staggering productive power, noting that it had accomplished wonders far surpassing Egyptian pyramids and Roman aqueducts. However, it prophesied that, like Mary Shelley’s Frankenstein, the bourgeoisie had conjured a monster it could no longer control. By packing thousands of resentful, exploited workers onto factory floors and into dense urban slums, capitalism was organizing and weaponizing its own executioners. The Manifesto laid out a radical roadmap: the proletariat would rise up, overthrow the bourgeoisie, centralize the means of production in the hands of a worker-led state, and systematically abolish private property. Eventually, as class distinctions faded, this transitional socialist state would wither away entirely, leaving behind a classless, stateless, communist society based on a simple maxim: “From each according to his ability, to each according to his needs.”

Just days after the Manifesto was printed, revolutions broke out across Europe, in France, Germany, Italy, and Austria. For a moment, it seemed Marx and Engels’ prophecies were coming true. However, the uprisings of 1848 were brutally crushed by the old aristocratic and monarchical regimes. Marx was exiled to London, where he spent the rest of his life living in deep poverty, supported almost entirely by the financial allowance Engels sent him from his Manchester textile business. Sitting day after day in the Reading Room of the British Museum, Marx poured his remaining energy into a massive, multi-volume economic autopsy of the capitalist system: Das Kapital. When Marx died in his armchair in 1883, the global communist movement was still small and fragmented. Engels spent his remaining twelve years organizing Marx’s messy, handwritten notes to publish the final volumes of Das Kapital, ensuring their shared life’s work would survive.

The divergence between the twentieth-century communist experiments and the trajectory of capitalist economies offers one of the most significant case studies in modern political economy. While Marxist theory promised a stateless, classless paradise of abundance, its twentieth-century implementations in places like the Soviet Union (USSR), East Germany (GDR), Vietnam, and North Korea consistently led to economic stagnation, bureaucratic paralysis, and authoritarian control. Conversely, the regulated, state-supported capitalist models of the United States, Western Europe, Europe, post-WWII Japan, and South Korea managed to generate unprecedented wealth and foster robust, prosperous middle classes.

Capitalism recognized that a mass-production economy requires a mass-consumption society. This feedback loop, famously catalyzed by Henry Ford’s decision to pay his workers enough to afford the cars they built, became the bedrock of the post-WWII middle class. When workers earn disposable wages, they buy homes, automobiles, and electronics. This massive consumer demand drives corporate profits, which incentivizes businesses to innovate, scale up, and hire more workers, steadily lifting millions out of poverty and into a stable economic center.

The defining feature of the middle class in the West and East Asia was the ability to build intergenerational wealth, primarily through homeownership and private capital investments. Programs like the U.S. GI Bill and state-backed mortgage systems allowed average citizens to buy property on credit. Owning a home provided families with equity, financial stability, and collateral to start small businesses. In a communist system, where all land and property belonged to the state, citizens could never convert their decades of hard work into transferable personal wealth.

The economic miracles of Japan (post-WWII) and South Korea (the “Miracle on the Han River”) demonstrate that the rise of the middle class was heavily accelerated by strategic cooperation between the state and the private sector. Rather than running the economy themselves, governments in Tokyo and Seoul used tax incentives, infrastructure investments, and credit guidance to back giant, competitive private conglomerates (like Toyota and Sony in Japan, or Samsung and Hyundai in South Korea). During the Cold War, the United States opened its massive consumer markets to Japanese and South Korean exports while pouring billions in aid and security into these nations to ensure they stood as prosperous, capitalist bulwarks against regional communist expansion.

Despite the backlash to the 1st and 2nd Industrial Revolutions, new industries rose to replace the disrupted industries:

• 1st Industrial Revolution: Hand-spinners, cottage weavers, traditional blacksmiths, and small-scale farmers were disrupted. They were replaced with industrial machinists, boiler makers, and mechanical engineers in factories. The building and operation of railroads became one of the largest employers in the world. It absorbed millions of displaced agricultural workers and former artisans, employing them as track-layers, locomotive engineers, station masters, and cargo handlers. Mass production led to the rise of wholesaling, warehousing, and modern retail industries.

• 2nd Industrial Revolution: Specialized machinists, custom carriage-makers, independent farmers, and small-scale merchants were disrupted. In their wake, rose the professional middle class (“white collar”), technical blue-collar workers (plumbers, electricians, etc.), and the modern hospitality, entertainment, and commercial service industries.

Conclusion

When we look at the trajectory of human innovation through the lenses of Kuhn, Perez, and the historical wreckage of the Industrial Revolutions, a striking pattern emerges. We are living through the early, volatile Installation Period of a brand-new paradigm of artificial intelligence (AI). The parallels are impossible to ignore. The 1st Industrial Revolution separated the artisan from their physical tools, moving labor from the home cottage to the water-powered loom. The 2nd Industrial Revolution separated the artisan from their intellectual workflow, using Taylorism and the assembly line to strip away autonomous judgment and turn humans into cogs. The Generative AI Revolution represents the ultimate abstraction: it is beginning to separate the worker from their cognitive execution. Tasks that once required years of specialized training (drafting code, analyzing data, or rendering illustration) can now be autocompleted in seconds by a Transformer architecture trained on the collective output of human history.

If we blindly follow the script of the past, this looks like a familiar doom, the ultimate deskilling of cognitive labor, creating a deeply alienated white-collar proletariat. When an LLM can instantly generate a legal brief, a diagnostic summary, or a software script, the modern professional risks being disintermediated just like the Nottinghamshire weavers of 1811. However, history also offers a profound note of optimism. Creative destruction is cyclical. Just as the assembly line accidentally funded and organized a middle class and birthed entirely new industries in corporate strategy, technical maintenance, and leisure. Like Revolutions of the past, the AI transition will force labor to evolve. Today, we stand at the Turning Point. The choices we make now will determine whether the age of AI becomes a centralized, corporate Erebus of algorithmic replacement, or a collaborative Eden that supercharges human creativity.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of professional independence. To ensure full transparency regarding the technology infrastructure and semiconductor market segments discussed in this report, please note that at the time of publication, the author holds personal financial positions/long equity in Alphabet Inc. (Google), Taiwan Semiconductor Manufacturing Company (TSMC), and diversified S&P 500 index funds. Aside from these broad-market and specific technology holdings, the author holds no direct financial interest, equity, or options in any other individual companies mentioned in this report. No compensation has been received from any third party to feature, mention, or analyze specific corporate entities or therapeutic candidates.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

The American Diabetes Association (ADA) 86th Scientific Sessions, held in New Orleans, Louisiana, from June 5–8, 2026, served as the premier global stage for groundbreaking research, clinical advances, and therapeutic shifts in diabetes care, obesity management, and metabolic health. Bringing together tens of thousands of clinicians, scientists, and industry leaders from around the world, the 2026 conference marked a definitive turning point in metabolic medicine. Unsurprisingly, the overarching theme of this year’s sessions focused on next-generation obesity/diabetes therapies.

This week, we discuss selected ADA 2026 datasets for:

• Injectable Obesity Medicines ⬇️

• Oral Obesity Medicines ⬇️

Injectable Obesity Medicines

The absolute ceiling for weight loss at the conference was established by Eli Lilly’s retatrutide, a GIP/GLP-1/Glucagon triple receptor agonist (GGG). In the Phase 3 TRIUMPH-1 trial for non-diabetic obesity, retatrutide achieved historic, deep weight reductions of -28.3% at 80 weeks and -30.3% at 104 weeks. In the parallel Phase 3 TRANSCEND-T2D-1 trial evaluating a comorbid T2D population, the drug drove a 16.6% weight loss at 40 weeks. On the glycemic front, it allowed 90% of patients to cross the finishing line of an HbA1c < 7.0%.

Boehringer Ingelheim & Zealand Pharma countered with survodutide, a dual GLP-1/Glucagon receptor agonist. In the Phase 3 SYNCHRONIZE-1 trial for obesity, survodutide demonstrated a robust weight loss profile of -13-16.6% at 76 weeks. While it showed a minor numerical HbA1c drop of -0.2% from a normal baseline, the clinical focus of its dual-agonist mechanism heavily emphasized fat quality reduction rather than pure glucose lowering.

Pfizer utilized its Phase 2b VESPER program to showcase berobenatide, an investigational ultra-long-acting GLP-1 receptor agonist explicitly designed to challenge the industry’s standard weekly injection paradigm by evaluating both weekly and monthly regimens. The VESPER-1 trial evaluated a once-weekly (QW) subcutaneous dose, reaching a non-placebo-adjusted weight reduction of -15.9% at 32 weeks at the 2.4mg dose level. The VESPER-2 trial proved its glucose-lowering capabilities in a combined T2D and obesity population, delivering a strong -2.2% reduction in HbA1c at 28 weeks. The pivotal proof-of-concept came from the VESPER-3 obesity trial. By testing a once monthly (QM) maintenance strategy, Pfizer proved that patients transitioning to a 4.8mg once-monthly shot could successfully maintain their trajectory, clocking a -14.9% weight loss at 60 weeks without a plateau.

Novo Nordisk focused its presentations on leveraging the combination of amylin and GLP-1 pathways, showcasing two distinct molecular approaches to maximize metabolic control. In a Phase 2b dose-finding trial for type 2 diabetes, Zenagamtide (single-molecule GLP-1/Amylin dual agonist) turned heads by achieving a -14.6% weight reduction in just 36 weeks. This was paired with a -1.71% reduction in HbA1c, with 89.1% of patients achieving the target threshold of < 7.0%. Novo also presented Phase 3 data for CagriSema, a co-formulation of the amylin analog cagrilintide and semaglutide. In the REIMAGINE 1 trial (evaluating adults with T2D and obesity), the fixed-dose combo met its primary and secondary endpoints simultaneously, demonstrating a -13.8% weight loss alongside a -1.8% drop in HbA1c at 40 weeks.

Link to top ⬆️

Oral Obesity Medicines

The data from the oral medicine table maps out a fiercely competitive, small-molecule injectable to oral shift presented at ADA 2026. The readouts demonstrate that oral GLP-1 receptor agonists are attempting to close the efficacy gap with injectables, focusing heavily on maximizing convenience while maintaining glycemic control and weight loss.

Eli Lilly anchored the oral small-molecule landscape with comprehensive Phase 3 data from its highly anticipated ATTAIN clinical trial program for orforglipron. In the Phase 3 ATTAIN-1 trial targeting adults with obesity, the daily pill demonstrated strong, sustained efficacy, driving a -12.4% weight loss at 72 weeks at the maximum dose. In the parallel ATTAIN-2 trial, orforglipron showed impressive dual efficacy in a historically harder-to-treat diabetic population. It delivered a ‒10.5% weight loss at 72 weeks, closely mirrored by a substantial -1.82% drop in HbA1c recorded at the 40-week milestone.

AstraZeneca emerged as a primary challenger in the oral small-molecule sector, showcasing mid-to-late stage data from its elecoglipron clinical program. The Phase 2b VISTA trial tracking pure obesity demonstrated a highly competitive profile, pushing out to a -11.8% weight reduction at 36 weeks without showing an immediate plateau. The parallel Phase 2b SOLSTICE trial underscored the molecule’s glycemic potency. Elecoglipron achieved a powerful -1.9% reduction in HbA1c at 26 weeks, enabling an impressive 90% of enrolled patients to reach the ADA’s target threshold of < 7.0%.

Two China-based biotechs discussed presented data for their oral GLP-1 agonists. Innovent turned heads with a striking Phase 1 multiple ascending dose readout. In a pure obesity cohort, IBI3032 triggered a rapid -10.11% body weight reduction in just 4 weeks. This double-digit drop in a single month suggests an exceptionally potent kinetic and bioavailable profile. Ascletis rounded out the oral landscape by presenting Phase 2 data for ASC30. In its obesity cohort, the asset demonstrated a steady, linear therapeutic trajectory, delivering a -7.7% weight loss at 13 weeks at the maximum dose tested.

Link to top ⬆️

Getting Up to Speed on Obesity?

Check out my two-part Frontiers in Medicine series here:

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 9, 2026, GSK announced that it has entered an agreement to acquire Nuvalent, Inc. for $10.6 billion (GSK press release, GSK slide deck, Nuvalent press release). This acquisition centers on three targeted oncology assets:

• Zidesamtinib (ROS1 inhibitor, PDUFA 9/18/2026)

• Neladalkib (ALK inhibitor, PDUFA 11/27/2026)

• NVL-330 (HER2 inhibitor, Phase 1 ongoing)

While most biotech buyouts focus on a single crown jewel, GSK has acquired a diversified “stable” of molecules that hits three mutations associated with non-small cell lung cancer (NSCLC). At first glance, a general industry analyst might look at the pie chart and question the value proposition: ALK+ (4%), ROS1+ (2%), and HER2 (2%) combined represent a seemingly small slice (~8%) of the total non-small cell lung cancer (NSCLC) market. Large-cap pharmaceutical companies traditionally target broad populations like KRAS mutations (25%) or the massive “Unknown/Other” chemotherapy and immunotherapy pools.

However, GSK’s expansion layout highlights the under-appreciated commercial value of this 8% slice. Patients with KRAS mutations or unknown drivers are subjected to standard chemotherapy combined with immuno-oncology (IO) regimens. These markets are highly crowded, hyper-competitive, and prone to rapid therapy switching due to inconsistent durability. By acquiring Nuvalent’s portfolio (neladalkib, zidesamtinib, and NVL-330), GSK aims to establish a strategic position across three distinct, biomarker-defined segments. In precision medicine, dominating three highly validated, 2% to 4% niches with potential best-in-class assets could yield more predictable, high-margin revenue than competing in a broad, fragmented market. GSK expects the acquisition “to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies and reprioritisation.”

Here, we dive into the M&A strategy that GSK highlighted in their presentation, the discovery & drug development generations for ALK & ROS1 inhibitors, and the corporate history of Nuvalent.

Share

A Peek Into GSK’s M&A Strategy

During GSK’s presentation regarding its $10.6 billion acquisition of Nuvalent, Chief Executive Officer Luke Miels emphasized that this transaction represents a direct continuation of their established Business Development (BD) framework. The slide above highlighted previous examples where GSK acquired companies that they deemed to have a “validated target” that fixed an “efficacy or tolerability gap”:

• Sierra Oncology / Momelotinib (Oncology): The standard of care for myelofibrosis (like ruxolitinib) relies heavily on JAK1/JAK2 inhibition, which routinely suppresses bone marrow production and causes severe, treatment-limiting anemia and thrombocytopenia. Momelotinib uniquely inhibits ACVR1 (in addition to JAK1/JAK2), downregulating hepcidin to actually restore iron homeostasis and red blood cell production, fixing the anemia gap.

• BELLUS Health / Camlipixant (Respiratory): Early-generation P2X3 antagonists developed for refractory chronic cough suffered from a major tolerability issue: they frequently blocked the P2X2 receptor subtype, causing severe taste disturbance (dysgeusia) or total taste loss, leading to high clinical discontinuation rates. Camlipixant was engineered as a highly selective P2X3 antagonist that spares P2X2, preserving normal taste sensation while maintaining potent cough-reflex suppression.

• Aiolos Bio / LA-TSLP (Respiratory): Approved anti-TSLP antibodies for severe asthma (such as tezepelumab) require frequent subcutaneous injections every 4 weeks. This high treatment burden impacts long-term patient adherence and lifestyle flexibility. LA-TSLP is a long-acting monoclonal antibody designed with an extended half-life to enable every-6-month dosing, converting a frequent clinical intervention into a twice-a-year maintenance regimen.

• IDRx / Velzatinib (Oncology): Existing tyrosine kinase inhibitors (TKIs) used for gastrointestinal stromal tumors (GIST), such as imatinib, inevitably succumb to resistance. Over 90% of progressing patients develop highly heterogeneous, secondary resistance mutations in exons 13, 14, 17, or 18 of the KIT gene, which standard TKIs fail to cover simultaneously. Velzatinib (IDRX-42) was specifically engineered to broadly inhibit the entire spectrum of clinically relevant primary and secondary KIT mutations, closing the evasion gap that causes tumor relapse.

• RAPT Therapeutics / Ozureprubart (Immunology): Omalizumab (Xolair), the standard anti-IgE biologic for severe food allergies and chronic spontaneous urticaria (CSU), requires painful injections every 2 to 4 weeks. Additionally, a strict dosing ceiling leaves up to 25% of patients with high body weights or exceptionally high baseline IgE levels entirely ineligible for treatment. Ozureprubart is a half-life extended anti-IgE antibody engineered to allow dosing intervals of 8 to 12 weeks while boasting a broader therapeutic window capable of treating the high-weight/high-IgE patient populations previously locked out of therapy.

• 35Pharma / HS235 (Respiratory): First-generation activin signaling inhibitors used in pulmonary hypertension inadvertently cross-react with BMP9 and BMP10 ligands. This off-target binding causes structural vascular fragility, manifesting as a high risk of severe bleeding and telangiectasia (broken blood vessels), a major danger for patients concurrently taking blood thinners. HS235 features enhanced structural selectivity that deliberately spares BMP9 and BMP10, which could lower bleeding risks while adding distinct metabolic perks like fat-selective weight loss and improved insulin sensitivity.

Nuvalent also fits this paradigm. Early-generation ALK and ROS1 inhibitors for non-small cell lung cancer (NSCLC) fall short on three fronts:

1. Selectivity Gap: They cause severe neurological toxicities (dizziness, weight gain, cognitive changes) because they inadvertently inhibit the structurally similar TRK receptor family.

2. Efficacy Gap: When non-small cell lung cancer (NSCLC) is treated with early-generation inhibitors, the tumor cells adapt by developing secondary “solvent-front” or “gatekeeper” mutations. These mutations physically alter the shape of the binding pocket, blocking older drugs from entering.

   1. ALK resistance: In ALK-positive lung cancer, successive lines of treatment (like crizotinib followed by alectinib or brigatinib) force the tumor to evolve highly complex single and compound ALK mutations. The most aggressive of these is the G1202R solvent-front mutation, as well as double mutations like 1151T/G1202R.

   2. ROS1 resistance: The most notorious resistance adaptation in ROS1-positive NSCLC is the ROS1 G2032R solvent-front mutation. When this mutation occurs, standard therapies like crizotinib or entrectinib lose virtually all potency, leaving patients with no targeted options.

3. Delivery Gap: Up to 40% to 50% of patients with advanced ROS1- or ALK-positive NSCLC either present with or develop brain metastases during their treatment journey. Early-generation TKIs are poor substrates for crossing the blood-brain barrier, or they are actively pumped out of the brain by P-glycoprotein (P-gp) efflux pumps.

Both zidesamtinib and neladalkib were engineered to potentially address these limitations:

1. Selectivity Fix: Nuvalent designed both zidesamtinib and neladalkib to be highly TRK-sparing. They possess macrocyclic structures that are macro-selectively tuned to fit perfectly into the ATP-binding pockets of mutated ROS1 or ALK, but are structurally hindered from binding to TRK. This allows patients to stay on the highest therapeutic dose of the drug while minimizing debilitating cognitive or physical neurological side effects.

2. Efficacy Fix: Zidesamtinib was specifically engineered with a compact, rigid structure designed to avoid steric clash with the mutated, bulky arginine residue at position 2032. It binds tightly to both wild-type ROS1 and the mutated G2032R variant, shutting down the tumor’s primary resistance mechanism. Neladalkib is a potent, fourth-generation ALK inhibitor designed with a low molecular weight and optimized conformation that fits deeply into the ALK kinase domain. It maintains extreme potency across a broad spectrum of single and compound ALK mutations that render even third-generation inhibitors like lorlatinib ineffective.

3. Delivery Fix: Both molecules were built from the ground up to maximize cerebrospinal fluid (CSF) penetrance. They possess optimal lipophilicity and molecular weight profiles that bypass standard cellular efflux mechanisms. By achieving high, sustained concentrations inside the central nervous system, they are able to aggressively shrink existing brain metastases and prevent new intracranial lesions from forming, all while maintaining the TRK-sparing safety profile outlined above.

By targeting clinically validated oncology pathways, Nuvalent’s engineering has overcome the resistance and neurological tolerability gaps that limited earlier generations of TKIs. But, how did we find these “validated targets” in the first place?

(A)ttacking (L)ung (K)ancer

The ALK gene was first discovered in 1994 by researchers studying anaplastic large-cell lymphoma (ALCL), a rare form of non-Hodgkin lymphoma. They identified a recurring chromosomal translocation, designated as t(2;5)(p23;q35), which abnormally fused the ALK gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5. This historic finding established ALK‘s capability to act as an oncogene when structurally rearranged. However, because ALCL is relatively rare, the wider scientific community initially viewed ALK as a niche, disease-specific driver rather than a major target in solid tumors. For over a decade, it remained largely isolated to hematologic research.

In 2007, a team of Japanese scientists including Dr. Manabu Soda and Dr. Hiroyuki Mano at the University of Tokyo revealed that there was more to the story. Emboldened by the recent discovery of EGFR mutations in non-small cell lung cancer (NSCLC), the team was systematically screening clinical specimens from lung adenocarcinoma patients to isolate novel transforming genes. Using a retroviral cDNA expression library generated from a patient’s tumor, they identified a crucial genetic error: a small, cryptic intrachromosomal inversion on the short arm of chromosome 2 (2p). This structural inversion disrupted and fused two adjacent genes:

• The amino-terminal portion of Echinoderm Microtubule-Associated Protein-Like 4 (EML4)

• The intracellular kinase domain of Anaplastic Lymphoma Kinase (ALK)

To prove this new EML4-ALK fusion was a true driver mutation, rather than an innocent bystander, the researchers forced its expression in mouse 3T3 fibroblasts. The cells rapidly formed transformed foci in culture and grew into large tumors when injected into nude mice, proving the fusion protein possessed potent, autonomous oncogenic competence. Simultaneously, a separate team utilized a global phosphoproteomic screen to independently identify identical ALK fusions across a broad screen of lung cancer cell lines.

Biochemically, the native, wild-type ALK receptor is a transmembrane tyrosine kinase that requires a specific extracellular ligand to activate. When the EML4-ALK fusion occurs, the extracellular ligand-binding domain and the transmembrane segment of ALK are entirely replaced by the amino-terminal coiled-coil domain of EML4. This specific structural region of EML4 has a natural, powerful tendency to pair up (dimerize). As a result, the attached ALK kinase domains are pulled together into a state of perpetual, ligand-independent dimerization and autophosphorylation. This unleashes a continuous, uncontrolled downstream signaling cascade through the RAS/MAPK, PI3K/AKT, and STAT3 pathways, forcing the lung cell into rapid, unhalted proliferation and cell survival.

As screening protocols expanded globally via fluorescence in situ hybridization (FISH) and RT-PCR assays, a distinct clinicopathologic profile emerged. While EGFR mutations were highly prevalent in East Asian women, the EML4-ALK fusion was found to be highly enriched in a completely distinct, distinct subset comprising roughly 3% to 7% of all NSCLC patients. The typical ALK-positive patient was significantly younger (often in their 40s or 50s, compared to a median lung cancer diagnosis age in the late 60s) and predominantly had a history of being a light smoker or having never smoked at all. This stark clinical demarcation transformed how the industry approached drug design. It suggested that advanced lung cancer could be a molecularly defined disease, paving a direct path for the immediate clinical deployment and rapid approval of targeted ALK inhibitors.

The ALK story began in earnest when crizotinib, originally developed as a MET inhibitor, was discovered to have potent activity against the EML4-ALK fusion oncogene. It cleared the regulatory hurdle in 2011, providing an immediate, dramatic alternative to cytotoxic chemotherapy. While revolutionary, crizotinib had two flaws. First, it was a poor substrate for crossing the blood-brain barrier, leaving the central nervous system (CNS) as a wide-open sanctuary for brain metastases. Second, tumors rapidly evolved single, acquired point mutations in the ALK kinase domain (like the L1196M gatekeeper mutation), which physically blocked crizotinib from binding and triggered clinical relapse in under a year.

Second-generation ALK inhibitors were designed from the ground up to address crizotinib’s shortfalls. They featured altered chemical scaffolds that achieved significantly greater potency against primary resistance mutations and, crucially, were engineered to optimize central nervous system (CNS) penetrance. Alectinib eventually emerged as the undisputed king of this generation. As shown on the chart, the landmark ALEX trial demonstrated an unprecedented 34.8 months of mPFS, effectively delaying tumor progression for nearly three years in the front-line setting while aggressively preventing or shrinking brain metastases. Despite this massive step forward, tumors eventually outsmarted second-generation TKIs by developing a highly aggressive, bulky “solvent-front” mutation known as ALK G1202R. This mutation structurally altered the binding pocket, causing steric clash that blocked alectinib, brigatinib, and ceritinib entirely.

To crack the G1202R mutation, Pfizer engineered lorlatinib, a highly compact, macrocyclic 3rd-generation ALK inhibitor designed to fit deeply into the altered ALK binding pocket regardless of standard solvent-front mutations. The updated 7-year data from the CROWN trial represents an absolute summit in solid-tumor oncology: an astonishing 55% of patients remain progression-free at the 7-year mark in the first-line setting. However, lorlatinib’s structural triumph created a massive, distinct double-gap:

• Compound Mutations: When tumors finally breakthrough lorlatinib, they do so by stacking mutations atop one another, developing complex compound mutations (such as G1202R combined with L1196M or I1171T) that no approved drug can inhibit.

• Off-Target TRK Inhibition: Lorlatinib’s small, rigid structure lacks macro-selectivity. It inadvertently binds heavily to the TRK receptor family in the brain. This off-target binding causes severe, treatment-limiting neurological toxicities, including profound cognitive impairment, memory loss, severe mood fluctuations, and massive, rapid weight gain.

This brings the narrative to the modern era and GSK’s recent strategic acquisition of Nuvalent’s portfolio. Neladalkib (formerly NVL-655) represents the fourth generation of ALK inhibition, engineered specifically to pick up where lorlatinib’s limitations begin. Neladalkib utilizes a novel macrocyclic scaffold that is deliberately optimized to maintain extreme potency against the entire spectrum of single and compound resistance mutations (including the dreaded lorlatinib-resistant lines). Crucially, its structure is TRK-sparing, allowing it to achieve deep brain penetrance to treat intracranial disease without triggering the debilitating cognitive and neurological side effects that limit lorlatinib’s utility. With the global Phase 3 ALKAZAR trial actively evaluating neladalkib head-to-head against alectinib in the front-line setting, the timeline projects a future where the red shaded bar intends to redefine the ceiling of long-term survival by offering a highly differentiated, TRK-sparing safety profile and potent coverage against known resistance mutations for ALK-positive patients.

Bringing ROS1 into Focus

Unlike many oncogenes discovered directly in human tissue, ROS1 was first identified via veterinary virology. In 1981, researchers isolating the transforming component of the UR2 avian sarcoma virus, a retrovirus that caused tumors in chickens, discovered a unique viral oncogene sequence they named v-ros. By 1986, molecular biologists cloned the human cellular homolog, identifying the normal proto-oncogene on chromosome 6 (6q22.1) and labeling it c-ros (now standardized as ROS1). Phylogenetic analysis revealed that ROS1 encodes a massive, type I transmembrane receptor tyrosine kinase belonging to the insulin receptor superfamily. It is evolutionarily linked to the sevenless (sev) gene in Drosophila.

Despite its identification, ROS1 was designated an orphan receptor, a receptor with an unidentified endogenous ligand. Even today, no physiological, native ligand has been definitively established for human ROS1, making wild-type functional research notoriously difficult. Knockout mice models showed that missing the receptor entirely resulted in perfectly healthy, viable animals, save for localized epithelial defects causing male infertility.

The oncogenic capability of ROS1 in humans was first identified in 1987. Researchers trying to identify transforming DNA from human tumor lines transfection-isolated a unique chromosomal deletion in the U118MG glioblastoma (brain cancer) cell line. This microdeletion on chromosome 6 fused a gene called FIG (now standardized as GOPC) to the kinase domain of ROS1. The resulting GOPC-ROS1 fusion protein was localized to the Golgi apparatus, where it drove downstream signaling. However, much like the early ALK discoveries in lymphoma, glioblastoma fusions were deemed a rare, niche phenomenon, and ROS1 receded from the therapeutic spotlight for two decades.

A defining moment for ROS1 in solid tumors arrived in 2007, coincidentally the exact same year the EML4-ALK fusion was uncovered in lung cancer. Instead of focused gene sequencing, a team of global scientists utilized a cutting-edge, high-throughput phosphoproteomics screen to map out global tyrosine kinase signaling across dozens of non-small cell lung cancer (NSCLC) cell lines and patient tumors. They were looking for cells completely saturated with abnormal survival signaling. In a distinct subset of lung adenocarcinoma samples that tested completely negative for known drivers like EGFR, KRAS, or ALK, the screen detected massive, aberrant phosphorylation clustering directly on the ROS1 kinase domain. Genetic sequencing of these samples revealed brand-new, somatic chromosomal translocations that fused the 3’ region of the ROS1 gene (encoding the intact intracellular tyrosine kinase domain) to the 5’ regions of completely unrelated driver partners.

The most prominent of these newly discovered lung cancer fusions was CD74-ROS1, alongside others like SLC34A2-ROS1. The structural architecture of these fusions explains their ruthless oncogenic drive. The fusion partner (e.g., CD74) provides a structured domain, typically a coiled-coil or WD40 repeat domain, that naturally forces proteins to cluster together (multimerize). This forces the attached, intracellular ROS1 kinase domains into a state of perpetual, ligand-independent autophosphorylation. Locked permanently in the “on” position, the mutant ROS1 engine floods the cell with continuous, hyperactive signaling through the STAT3, PI3K/AKT/mTOR, and RAS/RAF/MAPK pathways, bypassing cellular checkpoints to drive rapid proliferation.

As large-scale epidemiological screening expanded, the ROS1 archetype crystallized. Comprising roughly 1% to 2% of all NSCLC cases, ROS1-positive patients matched the ALK clinical profile almost perfectly: they were typically younger (median age around 50), disproportionately female, and had little to no smoking history. Since the ATP-binding pocket of the ROS1 kinase domain shares massive amino acid homology with ALK, clinicians realized that small-molecule inhibitors designed to fit into the ALK pocket could likely cross-react and shut down ROS1. This biochemical crossover allowed crizotinib, already FDA-approved for ALK in 2011, to be rapidly deployed in clinical trials for ROS1 patients. By 2016, crizotinib secured expanded approval as the first targeted therapy for ROS1-positive NSCLC, setting off the targeted therapeutic arms race.

Much like its story in ALK, crizotinib fell short on two fronts. It suffered from poor blood-brain barrier penetrance, allowing brain metastases to emerge or progress unchecked. Furthermore, tumors rapidly escaped crizotinib by developing the ROS1 G2032R solvent-front mutation. This mutation introduces a bulky arginine residue that physically blocks crizotinib from entering the binding pocket. Approved in 2019, second-generation ROS1 inhibitor entrectinib was intentionally designed to be a potent, CNS-active inhibitor of both ROS1 and TRK. In the STARTRK-2 trial, it established strong efficacy against baseline brain metastases, addressing crizotinib’s delivery flaw. Despite its superior brain penetrance, entrectinib’s overall first-line mPFS (~16.8 months) didn’t eclipse crizotinib due to early resistance. More critically, entrectinib remained entirely inactive against the emergent G2032R solvent-front mutation. Additionally, because it explicitly targets the TRK receptor family, patients frequently suffered from off-target neurological toxicities like severe dizziness, cognitive changes, and paresthesia.

To tackle the crizotinib- and entrectinib-resistant tumors, the third generation ROS1 inhibitors introduced highly rigid, smaller macrocyclic or rigid chemical structures designed to squeeze past the bulky G2032R mutation. This generation raised the ROS1 efficacy ceiling. Repotrectinib delivered an impressive 35.7 months mPFS, while taletrectinib pushed the frontier even further to an astonishing 46.1 months mPFS in TKI-naive patients. Both drugs offered potent, dual-pronged protection: they effectively shut down the primary G2032R resistance mutation and demonstrated exceptional intracranial activity. Even with this elite efficacy, a double-gap remained:

• Next-Gen Resistance: Under the selective pressure of 3rd-generation TKIs, tumors inevitably adapt by developing novel, complex compound mutations or specific “gatekeeper” and “solvent-front” doublets (such as L2026M or G2032R combinations) that these drugs fail to inhibit.

• TRK Co-Inhibition: Repotrectinib is a highly potent pan-TRK inhibitor. Its rigid, compact structure binds tightly to TRK receptors in the brain, making side effects like profound dizziness (ataxia), dysgeusia (taste distortion), and paresthesia a significant, chronic management challenge for patients.

This culminates in the modern frontier and GSK’s strategic acquisition of Nuvalent’s portfolio. Zidesamtinib (formerly NVL-520) was engineered from the ground up as a 4th-generation ROS1 inhibitor, a TRK-sparing macrocycle. Nuvalent designed zidesamtinib’s structure to fit cleanly into both wild-type ROS1 and the mutated G2032R pocket, but gave it a precise conformation that causes structural clash with TRK receptors. This is intended to allow zidesamtinib to maintain high potency against specific resistance mutations and exhibit deep brain penetrance with reduced TRK-mediated neurological side effects relative to earlier-generation therapies. With its PDUFA date fast approaching on September 18, 2026, and the first-line ARROS-1 trial underway, the timeline represents a future where the red shaded bar aims to redefine long-term, toxicity-free survival for ROS1-positive patients.

Making Resistance Futile

The story of Nuvalent is a story of precision chemistry, born out of a desire to overcome drug resistance. James Porter, an exceptional medicinal chemist, and Alexander Fraley founded Nuvalent with a deceptively simple observation: early-generation tyrosine kinase inhibitors (TKIs) were leaving too many patients behind. In the rush to develop targeted therapies for oncogene-driven cancers, like ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC), the industry had settled for structural compromises. Backed by the company creation experts at Deerfield Management, Nuvalent set to crafting rigid, low-molecular-weight molecules from the ground up.

By 2021, Nuvalent was ready to show its hand. Under the leadership of Chief Executive Officer Dr. Christopher Turner, the company went public in a highly successful $174 million IPO. The capital allowed them to transition from a fascinating chemistry hypothesis into a clinical-stage reality. Their twin lead candidates, NVL-520 (later named zidesamtinib) for ROS1 and NVL-655 (later named neladalkib) for ALK, entered the clinic. Over the next three years, data from their ARROS-1 and ALKAY can clinical trials began trickling out at major medical conferences like ASCO and ESMO. The oncology community watched with mounting excitement as the data proved Porter’s thesis correct. In reported clinical cohorts, these candidates demonstrated encouraging objective response rates, including intracranial activity, accompanied by a highly differentiated safety profile characterized by low rates of TRK-associated neurological adverse events. Nuvalent had successfully built TRK-sparing inhibitors that could outsmart the most notorious resistance mutations, like ROS1 G2032R and ALK G1202R. By early 2024, the FDA recognized the profound potential of this platform, granting Breakthrough Therapy designations to both lead assets. Nuvalent transformed into a formidable oncology contender racing toward the regulatory finish line.

As 2025 turned into 2026, Nuvalent entered its most intense operational phase. The company advanced a third asset, NVL-330, into Phase 1 clinical trials to target HER2-mutant lung cancers, proving that their design philosophy could be replicated across multiple distinct oncogenes. Zidesamtinib’s New Drug Application (NDA) was accepted by the FDA with a critical PDUFA action date set for September 18, 2026, and neladalkib was swiftly moving through a global Phase 3 trial (ALKAZAR) while its own priority review clock ticked toward a November 2026 deadline. Nuvalent had reached the ultimate crossroads for a successful independent biotech: it possessed a validated, multi-asset pipeline, but lacked the global commercial muscle required to launch three oncology drugs simultaneously.

The climax of the Nuvalent story arrived in June 2026. Recognizing the rare brilliance of a pipeline that had systematically “solved” the biggest efficacy and tolerability gaps in thoracic oncology, pharmaceutical giant GSK stepped forward. In a definitive $10.6 billion acquisition, GSK absorbed Nuvalent, framing the transaction to their investors as the ultimate “multiple assets in one deal” strategic victory. What began eight years prior as a chemist’s conviction in a Boston laboratory concluded as one of the most successful biotechnology narratives of the decade, handing GSK a ready-made, powerhouse lung cancer franchise and cementing Nuvalent’s legacy as the team that redefined the limits of targeted precision medicine.

Conclusion

The $10.6 billion acquisition of Nuvalent stands as an informative case study, demonstrating that the ultimate value in drug development often lies not in discovering a brand-new target, but in mastering the molecular architecture required to fix its flaws. By securing a powerhouse trio of potentially best-in-class assets in zidesamtinib, neladalkib, and NVL-330, GSK circumvents foundational biological uncertainty, establishes immediate commercial scale, and seamlessly anchors its broader thoracic oncology footprint. As the regulatory clocks tick closer to the late-2026 PDUFA dates for both zidesamtinib and neladalkib, the industry will be watching closely. What began as a chemist’s conviction in a Boston laboratory has officially evolved into a premier lung cancer franchise, one that is poised to redefine the upper limits of long-term, toxicity-free survival for patients worldwide.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 8, 2026, Incyte announced a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion in upfront payments and up to $750 million in additional payments upon the achievement of sales milestones, for total potential consideration of up to $2.0 billion subject to customary closing adjustments. This acquisition centers on VGA039, a first-in-class monoclonal antibody currently in Phase 3 trials for the treatment of von Willebrand disease (VWD).

Here, we dive into the founding of Vega Therapeutics and its TopCo (Star Therapeutics), as well as the novel biology that enabled them to buck the trend of me-too R&D and pioneer a new drug class for treating von Willebrand disease (VWD).

The Second Spoke

The story of Vega Therapeutics is a textbook modern biotechnology narrative: an elegant concept of novel biology incubated inside an innovation engine, spun out into a laser-focused entity, and ultimately acquired in a multi-billion-dollar deal. The story begins in San Francisco in 2018 with the founding of Star Therapeutics, LLC by scientist and entrepreneur Adam Rosenthal, Ph.D. Rather than operating as a traditional biotech pursuing a single molecule, Star was designed as a “hub-and-spoke” company, a corporate structure where a central parent organization (the hub) provides capital, operational infrastructure, and shared expertise to incubate and manage a portfolio of distinct, specialized subsidiary companies (the spokes). Its core philosophy was to discover best-in-class antibody therapies targeting novel biological pathways, utilizing a unique pipeline-in-a-product strategy.

While mapping out overlooked gaps in hematology, the Star team recognized a critical unmet need in bleeding disorders, specifically von Willebrand disease (VWD), the most common inherited bleeding disorder in the world. The existing standard of care required patients to undergo burdensome, multi-weekly intravenous (IV) infusions of clotting factor to manage or prevent debilitating bleeds. Star’s scientists discovered a way to elegantly bypass this by engineering a monoclonal antibody, VGA039, designed to target Protein S. By modulating Protein S, the antibody could effectively rebalance the body’s natural coagulation cascade and improve hemostasis. Crucially, it was engineered to be administered as a convenient, once-monthly subcutaneous injection.

In late 2022, Star officially spun out Vega Therapeutics, Inc. as a dedicated home for its bleeding disorder portfolio, backing the new entity with an initial $40 million in internal financing. This was the second company (spoke) spun out of Star Therapeutics, following the formation of Elektra in early 2022 (focused on anti-SIRP mAb ELA026 for a rare hyper-inflammatory condition called Secondary Hemophagocytic Lymphohistiocytosis). Vega operated with a lean, specialized team, sharing the broader scientific and operational infrastructure of Star. Over the next two years, Vega quietly developed VGA039. The U.S. FDA recognized the therapeutic potential of the mechanism, granting VGA039 Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

Star Therapeutics’ presentation of interim data for VGA039 at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025 provided promising clinical efficacy signals. The presentation highlighted findings from an ongoing Phase 1/2 multi-dose study. Crucially, it included cohorts that captured patients across all major subtypes of von Willebrand disease (Type 1, Type 2, and Type 3). This is a critical regulatory and clinical differentiator, as standard-of-care options vary widely depending on the patient’s specific VWF defect. The most compelling data came from patients who transitioned to VGA039 from standard-of-care intravenous (IV) clotting factor replacement regimens (which typically require highly burdensome IV infusions multiple times per week). In this subgroup, switching to monthly subcutaneous injections of VGA039 achieved a 73-100% reduction in Annualized Bleeding Rate (ABR), suggesting that some patients achieved complete bleed freedom. Achieving up to a 100% reduction by targeting Protein S proves that bypassing the body’s natural brakes on clotting works incredibly well, regardless of the patient’s specific genetic subtype of von Willebrand disease (VWD). Armed with this data and bolstered by Star’s massive $125 million Series D financing round in September 2025, Vega pushed its lead asset into a registrational trial. In October 2025, it initiated the global VIVID-6 study, a Phase 3 pivotal trial evaluating subcutaneous VGA039 across all types of VWD.

By the spring of 2026, Vega’s Phase 3 asset had captured the attention of the broader biopharmaceutical industry. Star Therapeutics and its premier venture capital backers and began working with financial advisors to explore a public listing (IPO) for the company. However, the rapid progression of the VIVID-6 trial coincided perfectly with a strategic shift at a major pharmaceutical peer: Incyte Corporation. Incyte’s newly appointed CEO, Bill Meury, was actively hunting for a late-stage hematology asset. Vega’s asset fit the bill exactly. On June 8, 2026, the narrative reached its climax. Incyte and Star Therapeutics announced a definitive agreement for Incyte to acquire Vega Therapeutics in an all-cash equity transaction.

Following the close of the transaction (expected in the third quarter of 2026), Vega Therapeutics will fully integrate into Incyte’s commercial hematology footprint, ensuring that the global scale of a major biopharma engine powers the remaining development of VGA039. Meanwhile, Star Therapeutics will continue to operate as an independent entity in San Francisco, retaining its remaining pipeline of complement-directed antibody therapies and validating its unique corporate model of incubating, proving, and successfully spinning out high-value biotech breakthroughs.

The Courage of First-in-Class

In a May 2025 article entitled Biotech Wisdom Of The Crowds: Competition And Capitalism, Bruce Booth (Partner at Atlas Venture) addresses the staggering level of “therapeutic crowding” in the biotech industry. Therapeutic crowding occurs when a massive influx of biotechnology and pharmaceutical companies simultaneously rush to develop drugs against the exact same biological target or disease indication. Driven by a herd mentality following a major scientific breakthrough or clinical validation, this intense duplication leads to a market saturated with me-too or fast-follower drugs. Notable examples include over 200 GLP-1 obesity programs and 300+ PD-1/PD-L1 cancer programs in development in early 2025.

The reason for crowding is incredibly clear. Uncovering new biology is high-risk, incredibly slow, and prone to failure, which is precisely why the industry defaults to crowding around known targets. In a separate essay published in 2017 and entitled Four Decades Of Hacking Biotech And Yet Biology Still Consumes Everything, Booth emphasizes that the primary failure mode in drug R&D is that human biology is massively complicated. We frequently pick the wrong target to interrogate, leading to massive attrition in Phase 2 trials when the hypothesis fails in humans.

Since trailblazing into unmapped biology is terrifyingly high-risk, Booth notes that capitalism naturally pushes a large portion of the industry toward “safer” fast-follower strategies. He points out that discovering and validating a brand-new biological pathway within academia is extraordinarily difficult. Translating that novel science into a structured industry setting requires drug hunters with a specific mindset who have no fear of failure, because exploring new biological frontiers means dealing with constant, iterative failure before finding a signal. When a biotech company decides to explore a completely unmapped biological mechanism, it cannot rely on off-the-shelf tools. They must build bespoke cell-based assays and find specialized contract research organizations (CROs) capable of running highly customized animal or cellular models. While global CROs are highly adept at standard, commoditized readouts, they routinely struggle with the nuanced, unscripted biology required to validate a brand-new therapeutic hypothesis.

In Booth’s view, the extreme financial reward of being the first to drug a novel target is the only thing that justifies the brutal, slow, and expensive process of uncovering new biology. When companies choose instead to join a “therapeutic crowd,” they are actively trading the steep scientific risks of unmapped biology for the intense commercial and clinical trial risks of a hyper-competitive market.

So, how did Vega Therapeutics pull off the impossible improbable? Despite generating robust proof-of-concept data, Vega Therapeutics is still the only company with a drug in clinical development specifically targeting Protein S for von Willebrand disease (VWD) as of June 2026.

For decades, VWD was viewed strictly through the lens of VWF replacement. In April 1924, a Finnish physician named Erik Adolf von Willebrand was consulted about a five-year-old girl named Hjördis Sundblom, who lived on a remote island in the Åland archipelago between Sweden and Finland. Upon investigation, Dr. von Willebrand mapped her family pedigree and discovered a terrifying hereditary pattern: 6 of her 10 siblings suffered from the same bleeding condition, and three of her sisters had already bled to death (tragically, Hjördis herself would later bleed to death at age 14 during her fourth menstrual period). In 1926, von Willebrand published his landmark paper, Hereditär pseudohemofili (”Hereditary Pseudohemophilia”).

In the 1950s, researchers in Sweden discovered that plasma from healthy individuals contained a mysterious “plasma factor” that could correct the bleeding time in Åland islanders. By the 1970s and 1980s, this massive glycoprotein was officially isolated, cloned, and named von Willebrand Factor (VWF). Scientists realized VWF plays two indispensable roles in normal hemostasis:

1. When a blood vessel is damaged, VWF acts as molecular double-sided tape. It binds to the exposed subendothelial collagen on one side and hooks onto the receptors (GPIb) of passing platelets on the other, forcing them to stop and form a plug.

2. In circulation, VWF binds to Factor VIII (the clotting factor missing in Hemophilia A), stabilizing it and protecting it from rapid degradation.

Today, VWD is recognized as the most common inherited bleeding disorder in humans, categorized into Type 1 (partial quantitative deficiency), Type 2 (qualitative/functional defects), and Type 3 (near-total absence of VWF, which is what Hjördis Sundblom suffered from).

Separately in 1977, pediatric hematologist Richard DiScipio and his colleagues first isolated and characterized Protein S but it was mistakenly pigeonholed as an anti-coagulant that acted independently of VWF for more than thirty years. The first cracks in this siloed view began to appear in the late 2000s and early 2010s, as vascular biologists began utilizing advanced microfluidic chambers that could simulate the immense mechanical forces inside living blood vessels. Scientists knew that VWF was a massive, tightly coiled polymer composed of over 40 to 100 linked monopers. Under normal, lazy blood flow, it drifted along like a crumpled ball of yarn. But when a blood vessel was ruptured, the local blood flow became turbulent and incredibly fast, a state known as high shear stress. This mechanical force literally yanked the VWF molecule open, unraveling it into long, sticky, linear strands. This highly specific, deeply hidden domain that acted like a molecular magnet for Protein S. The evolutionary elegance of this “molecular kidnapping” was breathtaking: by localizing and neutralizing the anti-coagulant brake (Protein S) exactly where the injury occurred, VWF allowed a localized explosion of thrombin generation.

This discovery re-wrote the pathology of von Willebrand disease. For a century, scientists believed that VWD patients bled simply because they lacked the duct tape to catch platelets. Now, they realized VWD was actually a catastrophic double-whammy. The patient lacked functional VWF, so platelets couldn’t anchor to the damaged blood vessel wall. Since there was no VWF to unravel and kidnap Protein S, the local injury site was flooded with unchecked, free-floating Protein S. The biological “brakes” were being slammed down completely wide open at the exact moment the body desperately needed to accelerate clotting.

By 2018, academic proof-of-concept papers began floating an audacious hypothesis: if a VWD patient is suffering because free Protein S is suppressing their clotting capacity, what happens if we inhibit Protein S? This was the intellectual spark that ignited Star Therapeutics. Their drug hunters realized that trying to synthetically replace massive, fragile VWF molecules via lifelong intravenous infusions was an uphill battle. They engineered VGA039, a monoclonal antibody designed to bind to Protein S and block its ability to interact with its anti-coagulant partners, TFPI and APC, mimicking the role of VWF under shear stress. When Vega Therapeutics took this molecule into human trials in the early 2020s, the narrative came full circle. By deliberately disabling the Protein S brake, the drug allowed the coagulation cascade to generate robust, stable fibrin plugs entirely on its own. The body no longer needed VWF to sequester the brake because the drug had already neutralized it. When Vega presented its stunning multi-dose data at the ASH annual meeting in December 2025, showing up to a 100% reduction in annualized bleeding rates, they beat the odds and vaulted over the chasm of death between basic biology and translational drug discovery.

Conclusion

The story of Vega Therapeutics is both a massive financial win for Star Therapeutics and a high-impact proof of concept for the future of drug development. In an industry where capital naturally retreats to the relative safety of therapeutic crowding, Vega’s journey proves that the steep risks of unmapped biology can still yield the highest rewards. By transforming an elegant physiological insight into a Phase 3 asset, Vega has the potential to rewrite the standard of care for how we treat bleeding disorders. By daring to look away from crowded targets and zeroing in on the nuanced mechanics of Protein S, Vega demonstrated the viability of a completely novel therapeutic approach for patients with von Willebrand disease (VWD). As VGA039 transitions into Incyte’s commercial engine, it leaves behind a rich legacy of translating basic biology for the next generation of drug hunters and for Star Therapeutics’ other spokes.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 8, 2026, Johnson & Johnson (J&J) announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. This is not your average acquisition. Firefly is co-founded by Nobel laureate Carolyn Bertozzi, an American chemist widely recognized for founding the field of bioorthogonal chemistry.

Firefly’s foundational technology is the Firelink™ degrader antibody conjugate (DAC) platform, a new therapeutic class that combines the cellular targeting of traditional antibodies with the intracellular protein-cleaving power of degraders to treat solid tumors more effectively. Firefly’s lead program targets KRAS-driven cancers, which have historically been difficult to treat with conventional medicine.

Here, we dive into Carolyn Bertozzi’s rock & roll past and path to the Nobel Prize in Chemistry, as well as her collaboration with Versant-incubated startup Firefly Bio.

Rock You Like a Nobel Laureate

Growing up in Lexington, Massachusetts, science was practically the family business. Carolyn Bertozzi’s father, William Bertozzi, was a nuclear physics professor at MIT. The expectation in the household was clear: his daughters would go to MIT and pursue the hard sciences. Carolyn, however, possessed a fiercely independent streak, leaning heavily toward music. When she entered Harvard University in 1984, she genuinely considered majoring in it. The early 1980s were an explosive era for electronic synthesizers, keyboard production, and new wave rock, and Bertozzi leaned heavily into the campus music scene, joining several underground student bands.

Her most famous musical chapter opened when she crossed paths with Tom Morello, a fiercely political social studies undergraduate who happened to be a virtuosic, highly experimental guitarist. Together, they formed a satirical, high-energy rock group called Bored of Education. True to the mid-1980s, Morello frequently performed in tight spandex, delivering aggressive, heavy riffs. Bertozzi stood behind the electronic keyboards, anchoring the rhythm, synthesizing brass and bass lines, and shaping the band’s new wave/rock fusion sound. In 1986, during Morello’s senior year, Bored of Education entered and won the Ivy League Battle of the Bands, cementing them as the top student act across the entire conference.

Shortly after their big win, Morello graduated and moved to Los Angeles, where he would eventually form Rage Against the Machine and later Audioslave, transforming the landscape of modern rock with his politically charged, genre-bending guitar style. Bertozzi stayed at Harvard for two more years, where her focus began to shift decisively toward organic chemistry, though her love for late-night synthesizer jamming never quite left her.

So, what led Bertozzi to chemistry? Everything shifted during her sophomore year when she walked into an organic chemistry lecture. While many pre-med students viewed the subject as a brutal weed-out class, Bertozzi saw an intricate, logical, and breathtakingly beautiful puzzle. She changed her major and graduated summa cum laude in 1988. Determined to forge her own path, she moved west for graduate school at the University of California, Berkeley. It was here that she fell in love with glycans, the complex, forest-like structures of sugar chains that coat the surface of every living cell. Biologists knew these sugars were crucial for cellular communication, but because they were incredibly difficult to track, they were largely ignored. Bertozzi wanted to change that. After completing her Ph.D. at Berkeley and a postdoctoral fellowship at UCSF, Bertozzi joined the UC Berkeley faculty in 1996. She set her sights on a daunting goal: mapping glycans directly inside a living creature.

To do that, she needed a way to attach a glowing molecular tag to the sugars. The problem was the environment. Cells are highly sensitive, crowded, watery spaces packed with thousands of proteins, lipids, and nucleic acids. If you introduce an artificial chemical reaction into a cell, one of two things usually happens:

1. The cellular environment destroys or ignores the chemical.

2. The chemical destroys the cell.

Bertozzi realized she needed a reaction that was utterly invisible to the cell’s native biology. In 2003, she coined a new term for this concept: Bioorthogonal Chemistry, meaning chemistry that runs on a completely separate, non-intersecting axis to the chemistry of life. Around the same time, scientists Barry Sharpless and Morten Meldal had discovered click chemistry, a method where two molecular components could reliably snap together like a seatbelt buckle. It was a revolutionary concept, but it had a fatal flaw for biology: it required a copper catalyst. In living systems, copper is highly toxic, causing cells to wither and die.

Bertozzi sought a workaround that eliminated the need for copper entirely. She found her answer by looking into the deep history of organic chemistry and weaponizing physical strain. She designed an eight-membered carbon ring called a cyclooctyne, forcing it into a severely bent, uncomfortable shape. This process came to be known as strain-promoted alkyne-azide cycloaddition (SPAAC). Since the molecule was packed with stored energy, like a tightly coiled spring, it was desperate to burst open. When it encountered a specific target molecule (an azide) embedded in a cell’s glycans, the spring released, and the two snapped together instantly. No toxic copper required. Using this “copper-free click chemistry,” Bertozzi did what many thought impossible: she successfully fed modified sugars to living cells, watched the cells mount them onto their surfaces, and then snapped glowing tags onto those sugars inside living zebrafish and mice. For the first time, scientists could watch the sugar coats of living, developing organisms change in real time.

In 2015, Bertozzi moved her laboratory to Stanford University, stepping into her current role as the Baker Family Director of Sarafan ChEM-H. Her focus expanded from simply looking at biology to fixing it. She realized that cancer cells use their thick coating of glycans as a sort of “invisibility cloak” to hide from the human immune system. Armed with bioorthogonal chemistry, she began building new biological therapeutics. Her lab co-founded multiple biotechnology companies to engineer molecules that act like lawnmowers, specifically shaving the deceptive sugars off cancer cells so the immune system can detect and destroy the tumor. Her entrepreneurial work also yielded breakthroughs like LYTACs (Lysosome-Targeting Chimeras), an entirely new therapeutic modality designed to drag disease-causing proteins out of the bloodstream and drop them into the cell’s garbage disposal (the lysosome) to be shredded.

On an October morning in 2022, Carolyn Bertozzi’s phone rang at 3:00 AM. It was the call from Stockholm. She had been awarded the 2022 Nobel Prize in Chemistry, sharing it with Sharpless and Meldal. At 56, she became one of only a handful of women in history to win the prestigious honor. Beyond the ultimate scientific validation, the award shone a spotlight on Bertozzi as a transformative figure in academic culture. Upon hearing the news, Bertozzi’s old bandmate Tom Morello immediately took to social media to celebrate his former keyboardist:

In a podcast with NobelPrize.org, Bertozzi reflected on how her musical background directly influenced her scientific creativity. She views both organic chemistry and music as structural languages driven by composition, creativity, and lateral thinking. To Bertozzi, designing a bioorthogonal chemical reaction inside a cell is not unlike writing a piece of music. You have to understand how different components (or notes) interact, ensure they don’t create destructive interference (or dissonance) with the background environment, and arrange them so they “snap” together in perfect harmony. The egalitarian, expressive nature of being in a band also heavily influenced her approach to leadership. Her laboratory at Stanford is famous for its vibrant, highly inclusive, and non-hierarchical culture. Rather than acting as a strict, top-down director, she operates more like a bandleader, bringing diverse talents together, encouraging improvisation, and letting every researcher take their own solo.Body

You Would Not Believe Your Eyes, If One Billion Fireflies, Lit Up the World as I Fell Asleep

In the high-stakes theater of modern biotechnology, certain ideas bubble just beneath the surface for years, waiting for the technology and the perfect team to catch up. Such was the case for Firefly Bio, a company born from a simple question: What happens when you marry the precise navigation of an antibody with the cellular destructive power of a protein degrader?

By 2022, the oncology landscape was being dominated by Antibody-Drug Conjugates (ADCs). These therapies worked like molecular smart missiles: an antibody navigated through the bloodstream, latched onto a cancer cell, and dropped a toxic chemical payload inside. But ADCs had a flaw. Their payloads were traditionally brutal chemical toxins. If the drug leaked into healthy tissue before reaching the tumor, it caused severe, dose-limiting side effects. Meanwhile, a parallel revolution was happening in protein degraders. Instead of poisoning a cell, these molecules hijacked the cell’s own disposal system to shred specific, disease-causing proteins. They were incredibly elegant and catalytic, but they lacked a targeting system so they couldn’t reliably find the tumor tissue on their own. The solution seemed obvious on paper: attach a protein degrader payload to an antibody, creating a Degrader-Antibody Conjugate (DAC).

Yet, execution was an entirely different beast. Bridging these two modalities required an incredibly stable “linker” molecule that wouldn’t fall apart prematurely in the bloodstream. Recognizing the massive hurdle, venture capital firm Versant Ventures decided to incubate the concept inside their Ridgeline Discovery Engine in Basel, Switzerland. Over months of careful waiting, Versant pulled together a dream team:

• The Academic Maven: They brought in Stanford professor and 2022 Nobel Laureate Carolyn Bertozzi. As the pioneer of bioorthogonal chemistry, Bertozzi was the world’s foremost expert on safely snapping complex molecules together inside living systems.

• The Industry Veterans: They recruited John Flygare, who had led ADC teams at Genentech and Merck, to serve as Chief Scientific Officer (CSO) and Bernhard Geierstanger, a veteran of Novartis and Merck, to serve as Chief Technology Officer (CTO).

• The Business Architect: To captain the ship, they tapped Scott Hirsch, an executive with a deep operational pedigree at Genentech and AbbVie, to step in as CEO.

With the team in place, Firefly Bio was quietly incorporated in late 2022. The founders chose the name “Firefly” because the bug’s natural glowing abdomen reminded them of an ADC’s glowing payload, a small burst of energy navigating the dark. For over a year, Firefly operated in complete secrecy, working to engineer a proprietary linker technology called Firelink™. The goal was to swap out traditional chemical toxins for protein degraders, ensuring the payload would hitch a ride safely on the antibody until it was precisely inside the cancer cell.

In February 2024, Firefly Bio officially broke stealth. Backed by a massive $94 million Series A funding round co-led by Versant Ventures and MPM BioImpact, with participation from Decheng Capital and pharmaceutical giant Eli Lilly, the company went public with its vision. CEO Scott Hirsch announced to the world that Firefly would leverage their DAC platform to, “hit biologically validated targets with minimal collateral damage.”

While many oncology platforms target specific mutations (like the single amino acid swap in KRAS G12C), Firefly leveraged its platform to go after a pan-KRAS approach. This means targeting all major variants of the mutated KRAS oncogene, which drives roughly a quarter of all human cancers, including up to 90% of pancreatic ductal adenocarcinomas (PDAC) and significant portions of colorectal and non-small cell lung cancers (NSCLC). Historically, KRAS has been deemed “undruggable” due to its smooth surface, which lacks deep pockets for traditional small-molecule inhibitors to lock into. Firefly’s preclinical candidates were designed to bypass this issue by leveraging a key feature of degraders. By changing the goal from inhibiting the protein’s active site to completely degrading the entire protein structure via the cell’s ubiquitin-proteasome system, Firefly achieved “significant reductions in tumor volume at very low doses” in preclinical solid tumor models. Meanwhile, the antibody component could expand the drug’s therapeutic window, plowing the degrader into cancer cells while aiming to avoid healthy cells.

Conclusion

The story of Firefly Bio is a testament to what happens when scientific creativity is given the room to jam. By pairing the targeting precision of an antibody with the catalytic, destructive power of a protein degrader, Firefly aims to introduce a new approach to the oncology arsenal. For Johnson & Johnson, the $1 billion acquisition represents a significant strategic bet on the potential of Firefly’s degrader antibody conjugate (DAC) technology and its pan-KRAS lead program. As Firefly’s platform transitions from a nimble, VC-backed syndicate into J&J’s massive development pipeline, throws down the gauntlet for competing biotechs rushing to target the ubiquitin-proteasome pathway. It’s a four horse race between J&J/Firefly (preclinical pan-KRAS degrader ADC), Gilead per their recent acquisition of Tubulis (two preclinical candidates with undisclosed targets), Prelude Therapeutics (preclinical CDK9 degrader ADC for CALR mutated MPN), and Fortitude Biomedicines (3 preclinical programs with undisclosed targets). The industry will be watching closely to see how DACs perform in human trials. While clinical translation always carries inherent risks and unpredictability, if the clinical data ultimately mirrors the elegance of the preclinical composition, the oncology landscape could get a whole lot brighter.

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

The European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London just wrapped up (held from June 3–6, 2026), delivering significant Phase 3 readouts, head-to-head data, and updates across key immunology portfolios. It stands alongside the American College of Rheumatology (ACR) convergence as one of the two premier global medical conferences dedicated to breakthroughs in rheumatic and musculoskeletal diseases (RMDs).

Here, we review the following hand-picked clinical data presented at EULAR 2026:

• Potentially best-in-disease UCB - Bimzelx (anti-IL-17A/F mAb) versus Skyrizi (anti-IL23 mAb) / Phase 3b (PsA) ⬇️

• Potentially first-in-class Biogen - Dapirolizumab (anti-CD40L mAb) / Phase 3 (SLE) ⬇️

• Potentially first-in-disease Novel mechanism Zenas BioPharma - Obexelimab (CD19 x FcγRIIb mAb) / Phase 3 (IgG4-RD) ⬇️

• Potentially first-in-disease Novartis - Ianalumab (anti-BAFF mAb) / Phase 3 (Sjögren’s disease) ⬇️

• Aurinia - Lupkynis (calcineurin inhibitor) / Phase 3 (LN) ⬇️

• Novartis - Rapcabtagene autoleucel (CD19 CAR-T) / Phase 2 (IIL, SSc) ⬇️

UCB - Bimzelx (anti-IL-17A/F mAb) versus Skyrizi (anti-IL23 mAb) / Phase 3b (PsA)

Potentially best-in-disease

This was arguably the most talked-about oral presentation of the congress. It provided a direct, head-to-head clinical evaluation pitting the dual IL-17A/F mechanism against the dominant IL-23 path in active psoriatic arthritis (PsA).

• Indication: Psoriatic Arthritis (PsA) is a prominent, highly heterogeneous type of spondyloarthritis that occurs in about 30% of patients with psoriasis. It uniquely blends this spinal and entheseal inflammation with painful peripheral joint swelling (often causing “sausage digits” or dactylitis), skin lesions, and nail dystrophy, driven by an overactive immune response typically mediated by the IL-17/IL-23 cytokine pathways.

• Mechanism: The trial represents a strategic mechanistic clash between upstream cytokine inhibition (IL-23) and direct, downstream dual-isoform blockade (IL-17A/F).

  • Bimzelx (bimekizumab): A humanized IgG1 monoclonal antibody that dual-inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). IL-17A and IL-17F are homodimers (and IL-17A/F heterodimers) that share structural homology and cooperate synergistically to drive the tissue inflammation, enthesitis, and new bone formation characteristic of spondyloarthritis. Dual blockade achieves a deeper suppression of downstream inflammatory genes than blocking IL-17A alone.

  • Skyrizi (risankizumab): A humanized IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). By inhibiting IL-23, it prevents the differentiation, proliferation, and survival of pathogenic Th17 cells upstream, thereby reducing the production of IL-17 and other downstream effectors.

• Trial design: The Phase 3b BE BOLD Trial was a randomized, multicenter, open-label, assessor-blinded (PROBE design), active-controlled, head-to-head superiority trial in adults with active, moderate-to-severe Psoriatic Arthritis (PsA) who met the CASPAR criteria, had ≥3 tender and ≥3 swollen joints, and had an inadequate response or intolerance to at least one conventional synthetic DMARD (csDMARD) or anti-TNF therapy. Patients were randomized to either Bimzelx or Skyrizi. The primary endpoint was the proportion of patients achieving an ACR50 response at Week 16 (signifying a 50% improvement in core American College of Rheumatology joint disease metrics).

• Data (press release):

  • Efficacy: The oral presentation (Abstract LB0001) demonstrated distinct superiority for the dual IL-17A/F approach in rapid and deep joint responses. Bimzelx achieved a statistically significant and clinically meaningful superiority over Skyrizi, with 49.1% of patients achieving ACR50 at Week 16 compared to 38.4% in the Skyrizi arm (p < 0.05). A dramatic kinetic separation was observed as early as Month 1. At Week 4, 19.9% of Bimzelx patients had already reached an ACR50 response, versus just 7.2% of Skyrizi patients. While both agents are highly effective skin clearance tools, Bimzelx held the edge at Week 16 with 53.4% of patients achieving completely clear skin (PASI 100) compared to 46.6% for Skyrizi.

  • Safety: No new safety signals were observed. Treatment-emergent adverse events (TEAEs) were broadly comparable. As expected with the class, mild-to-moderate oral candidiasis (thrush) rates were numerically higher in the Bimzelx arm due to IL-17F’s role in mucosal fungal surveillance, but these rarely led to treatment discontinuation.

• Impact:

  • Potentially Redefining First-Line Biologic Selection: In the highly fragmented PsA market, these data challenge the growing adoption of IL-23 inhibitors as the default first-line biologic over older anti-TNFs. Demonstrating superior joint efficacy against the market-leading IL-23 (Skyrizi) establishes Bimzelx as an ultra-potent option when rapid joint stabilization is a priority.

  • The “4-for-4” Moniker: With this readout, UCB has achieved a clean sweep of head-to-head trials, having previously demonstrated Bimzelx‘s superiority over Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab). This robust comparative data package strengthens its position in commercial formulary negotiations and clinical guidelines.

• Next steps: The immediate next step for the BE BOLD trial is the readout of longer-term data (Weeks 24 and 52) to evaluate whether Bimzelx‘s early joint and skin superiority maintains its separation or if Skyrizi catches up once steady-state dosing is sustained out to a year. Publication of detailed secondary metrics focusing specifically on enthesitis (inflammation where bone meets tendon) and dactylitis (sausage digits) resolution, two highly debilitating manifestations of SpA where IL-17 biology plays a critical localized role.

Link to top ⬆️

Biogen - Dapirolizumab (anti-CD40L mAb) / Phase 3 (SLE)

Potentially first-in-class

Systemic Lupus Erythematosus (SLE) has historically been a graveyard for clinical assets. Simultaneous with its presentation at EULAR 2026, full data from the PHOENYCS GO trial evaluating this novel, Fc-free anti-CD40L pegylated Fab fragment was published in The Lancet.

• Indication: Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous autoimmune disease driven by a profound loss of immune tolerance to self-antigens. Its pathophysiology centers on defective clearance of apoptotic cellular debris, which leads to an accumulation of nuclear antigens; these self-antigens trigger B-cell hyperactivation and the subsequent production of pathogenic antinuclear autoantibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA). These autoantibodies bind to self-antigens and form immune complexes that deposit in vital tissues—such as the kidneys, skin, joints, and blood vessels—activating the complement cascade and driving relentless, type I interferon (IFN)-mediated tissue inflammation and organ damage. The clinical standard of care (SOC) aims to suppress this inflammation, prevent acute flares, and minimize long-term organ toxicity. The foundational therapeutic backbone for all patients is hydroxychloroquine (an antimalarials drug), which is layered with systemic glucocorticoids (corticosteroids) for acute flare management, alongside traditional immunosuppressants like mycophenolate mofetil (MMF), methotrexate, or azathioprine for moderate-to-severe or organ-threatening disease. For patients with inadequate disease control, targeted biologic therapies—specifically belimumab (an anti-BAFF monoclonal antibody) or anifrolumab (an anti-type I interferon receptor antibody)—are integrated into the regimen to facilitate steroid tapering and protect long-term organ function.

• Mechanism: Dapirolizumab pegol is a novel, investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment that selectively targets and inhibits CD40 Ligand (CD40L / CD154). CD40L is primarily expressed on activated T cells and platelets, binding to CD40 on B cells and antigen-presenting cells (APCs). Inhibiting this costimulatory pathway effectively disrupts pathogenic T-cell/B-cell crosstalk, which downregulates B-cell activation, diminishes type I interferon (IFN) secretion, and limits downstream autoantibody production. Historical attempts by the industry to target CD40L were completely halted due to severe thromboembolic (blood clotting) safety issues. Those older antibodies possessed an intact Fc region that bound to platelets, triggering aggregation. Because DZP is Fc-free, it is designed to avoid binding platelet Fc-gamma-RIIa receptors, aiming to mitigate the mechanism of vascular toxicity seen in historical candidates.

• Trial design: The Phase 3 PHOENYCS GO Trial was designed to evaluate the safety and efficacy of dapirolizumab added to standard of care (SOC) in Systemic Lupus Erythematosus (SLE). The trial recruited 321 adults with moderately-to-severely active SLE despite receiving standard-of-care (SOC) background therapy (antimalarials, corticosteroids, and/or immunosuppressants). Patients were randomized in a 2:1 ratio to receive either dapirolizumab pegol plus SOC (n=213) or placebo plus SOC (n=108). The primary endpoint was the proportion of patients achieving a BICLA response at Week 48 (British Isles Lupus Assessment Group-based Composite Lupus Assessment).

• Data (Biogen press release, UCB press release, Lancet paper):

  • Efficacy: The drug demonstrated broad, statistically significant improvements across both clinical endpoints and serological markers. At Week 48, 50% (103/208) of patients treated with dapirolizumab pegol achieved a BICLA response compared to 35% (37/106) in the placebo group (p = 0.011). Sapirolizumab significantly reduced the frequency of severe flares and enabled the tapering of steroids. Among patients entering the trial on a baseline corticosteroid dose >7.5 mg/day (prednisone equivalent), a significantly greater proportion in the active arm successfully tapered to ≤7.5 mg/day while maintaining absolute disease control through Week 48. For patients with abnormal baselines, DZP led to significant reductions in anti-dsDNA autoantibodies alongside meaningful increases in complement proteins C3 and C4, validating the drug’s upstream mechanism.

  • Safety: Treatment-emergent adverse events (TEAEs) were slightly higher in the active arm (82.6% vs 75.0%), but crucially, serious TEAEs were less frequent with DZP than with placebo (10% vs 14.8%). Discontinuations due to adverse events remained low across both groups (4.7% vs 3.7%), and no thromboembolic signal was observed.

• Impact:

  • Graveyard Defied: Systemic lupus is notoriously heterogeneous, making successful Phase 3 assets incredibly rare. This successful readout validates CD40L inhibition as a viable, safe, and highly efficacious pathway when engineered correctly.

  • Paradigm Shift Away from Steroids: Showing that patients can successfully taper down to safe steroid thresholds (≤ 7.5 mg/day) without triggering flares addresses one of the single largest unmet needs in lupus management, preventing cumulative, drug-induced organ damage.

• Next steps: Per standard FDA requirements for broad SLE indications, Biogen and UCB are currently executing a second, parallel confirmatory Phase 3 registrational trial titled PHOENYCS FLY. The positive PHOENYCS GO data will serve as the anchor for global regulatory dossiers (BLA/MAA), which will be filed sequentially as soon as the confirmatory FLY data reads out and solidifies the safety-to-efficacy matrix.

Link to top ⬆️

Zenas BioPharma - Obexelimab (CD19 x FcγRIIb mAb) / Phase 3 (IgG4-RD)

Potentially first-in-disease Novel mechanism

The presentation of the Phase 3 INDIGO trial at the EULAR 2026 Congress in London. It was simultaneously published in The New England Journal of Medicine (NEJM). This data marks a significant milestone for Zenas BioPharma and the management of IgG4-Related Disease (IgG4-RD).

• Indication: IgG4-Related Disease (IgG4-RD) is a chronic, immune-mediated fibro-inflammatory condition characterized by a unique immune cascade where activated T-follicular helper (T_FH) cells and type 2 helper T (T_H2) cells drive the continuous hyper-activation and expansion of B-cell lineages, specifically IgG4-positive plasmablasts and plasma cells. These cells infiltrate vital organs (such as the pancreas, salivary glands, retroperitoneum, and lymph nodes), triggering severe local tissue swelling and a distinctive “storiform” pattern of progressive fibrosis and obliterative phlebitis that can cause irreversible organ damage or failure. The clinical standard of care (SOC) focuses on quickly arresting this destructive inflammation. Systemic glucocorticoids (corticosteroids) remain the universal first-line treatment to induce rapid clinical remission; however, because IgG4-RD has an exceptionally high relapse rate upon tapering, patients often require long-term, toxic steroid maintenance. To mitigate steroid-induced metabolic and bone toxicities, clinicians integrate traditional steroid-sparing immunosuppressants like mycophenolate mofetil (MMF), azathioprine, or methotrexate.

• Mechanism: Obexelimab is a first-in-class, humanized, bifunctional monoclonal antibody that selectively targets B-cell lineage cells through a unique inhibitory rather than depleting strategy. The antibody is engineered to simultaneously bind CD19 and the inhibitory Fc receptor Fc-gamma-RIIb (CD32B), both of which are broadly co-expressed across the B-cell lineage (including naive B cells, memory B cells, and plasmablasts). By cross-linking CD19 with Fc-gamma-RIIb, obexelimab co-opts the immune system’s natural negative-feedback loop. This mechanical engagement downregulates B-cell receptor (BCR) signaling, effectively paralyzing and inhibiting B-cell activation, proliferation, and downstream autoantibody secretion. Unlike standard B-cell therapies (e.g., anti-CD20 mAbs like rituximab), obexelimab does not deplete B cells. This leaves the patient’s underlying humoral immune landscape intact, allowing for a rapid return to immune baseline upon drug cessation and mitigating the long-term severe infection risks tied to cellular depletion.

  

• Trial design: The Phase 3 INDIGO study stands as the largest randomized, double-blind, placebo-controlled registrational trial ever conducted in IgG4-RD. The trial recruited 194 adults with newly diagnosed or recurrent, active, multi-organ IgG4-RD who met the 2019 ACR/EULAR classification criteria and required immediate systemic glucocorticoid (GC) intervention. Participants were randomized 1:1 to receive either obexelimab (250 mg via subcutaneous injection, weekly) or matching placebo for 52 weeks. To isolate the true therapeutic effect of the biologic, all patients were mandatory-started on an aggressive, protocol-driven background glucocorticoid (prednisone) taper at Day 1, down to 0 mg by Week 8. The primary endpoint was the time to the first IgG4-RD disease flare during the 52-week randomized controlled period, as determined by an independent, blinded Adjudication Committee (AC) and clinical investigators (flares requiring rescue therapy were managed with an open-label glucocorticoid intervention).

• Data (press release, NEJM paper):

  • Efficacy: The INDIGO trial achieved a definitive, highly statistically significant clean sweep across its primary and all four key secondary endpoints. Obexelimab demonstrated a striking 56% reduction in the risk of IgG4-RD disease flares over 52 weeks compared to placebo (HR = 0.443, p = 0.0005; see graph below). This significantly prolonged time to flares requiring rescue therapy (p = 0.0001) and dropped the absolute number of rescue-dependent flares (p = 0.0008). A significantly higher proportion of patients in the active arm achieved and maintained complete remission at Week 52 (p = 0.0049). Obexelimab drove a substantial reduction in cumulative glucocorticoid rescue therapy use (p = 0.0042), translating to lower measurable glucocorticoid-induced organ toxicity.

    

  • Safety: Overall treatment-emergent adverse events (TEAEs) were balanced (97.9% obexelimab vs. 95.9% placebo). Crucially, Grade ≥3 TEAEs were nearly halved with obexelimab (11.3% vs. 23.7%), and serious adverse events (SAEs) favored the drug at 10.3% vs. 18.6%. Total infections were actually lower in the obexelimab group (53.6% vs. 62.9%), validating the safety profile of an inhibitory versus depleting approach. Injection-site reactions occurred in a modest 3.5% of total active doses, and there were zero deaths in the obexelimab cohort.

• Impact:

  • Establishing the First Standard: There are currently zero FDA-approved targeted therapies for IgG4-RD. Clinicians have been forced to rely on long-term, high-dose steroids (which drive irreversible metabolic and bone damage) or B-cell depletion (rituximab). If approved, some clinical analysts suggest obexelimab could reshape the paradigm as a first-line targeted standard of care.

  • The Shift to At-Home Care: Rituximab requires resource-intensive, in-clinic intravenous infusions. Obexelimab’s formulation allows for an autonomous, self-administered at-home subcutaneous injection regimen, massively lowering systemic healthcare utilization costs and improving patient quality of life.

  • Validation of the Non-Depleting B-cell Hypothesis: This robust Phase 3 win serves as a major de-risking event for the broader field of B-cell inhibition, demonstrating that turning B cells “off” can match or exceed the efficacy of killing them, without the associated long-term immunosuppressive safety penalties.

• Next steps: Zenas BioPharma executed swiftly around this data, submitting its Biologics License Application (BLA) to the FDA in Q2 2026. The next major catalyst will be the regulatory decision, alongside a planned Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) in H2 2026. Patients exiting the 52-week randomized trial have transitioned into a 3-year Open-Label Extension (OLE) study to monitor long-term safety, sustained remission durability, and tissue damage prevention over a multi-year horizon. With the B-cell inhibition mechanism clinically validated in IgG4-RD, Zenas is actively advancing obexelimab into other high-unmet-need autoimmune indications, including an active Phase 2 trial (SunStone) in Primary Sjögren’s Syndrome and other closely aligned rheumatological conditions.

Link to top ⬆️

Novartis - Ianalumab (anti-BAFF mAb) / Phase 3 (Sjögren’s disease)

Potentially first-in-disease

The presentation of ianalumab (VAY736) at EULAR 2026 represents a historic milestone for Sjögren’s disease, the second most prevalent rheumatic autoimmune condition which has historically suffered from a complete lack of approved disease-modifying therapies. Building upon the landmark Phase 3 primary endpoints revealed in late 2025, Novartis showcased critical long-term Week 108 interim extension data at EULAR 2026, anchoring its regulatory pathway toward a global launch.

• Indication: Sjögren’s disease is a chronic, systemic autoimmune disorder characterized by a progressive loss of immune tolerance that leads to the targeted destruction of exocrine glands, primarily the salivary and lacrimal glands. Its pathophysiology centers on a profound lymphocytic infiltration (chiefly CD4+ T cells and hyperactive B cells) into glandular tissues, driven by the chronic overexpression of B-cell activating factor (BAFF) and type I interferons (IFNs). This chronic inflammatory environment induces secretory epithelial cell dysfunction, leading to severe exocrine hypofunction, tissue fibrosis, and the classic sicca symptoms of xerostomia (profound dry mouth) and keratoconjunctivitis sicca (profound dry eyes), while also predisposing a subset of patients to systemic extraglandular manifestations (e.g., vasculitis, peripheral neuropathy, interstitial lung disease) and a significantly elevated risk of B-cell lymphoma. Because there are historically no approved disease-modifying therapies (DMARDs), the clinical standard of care (SOC) is heavily polarized between localized, reactive palliation and systemic immunosuppression. For sicca features, management relies entirely on symptomatic alleviation via artificial tears, lubricating ophthalmic ointments, topical cyclosporine eye drops, and oral sialagogues like pilocarpine or cevimeline to stimulate residual salivary flow. For patients presenting with severe systemic or extraglandular disease, clinicians escalate to off-label systemic regimens—predominantly utilizing oral glucocorticoids (corticosteroids) for acute flare control, layered with traditional immunosuppressants such as hydroxychloroquine for arthralgias, or methotrexate, azathioprine, and off-label rituximab for severe organ-threatening complications.

• Mechanism: Ianalumab is an ADCC-active anti-BAFF antibody that features a unique dual mechanism of action engineered to maximize B-cell eradication and suppression. The antibody is afucosylated (engineered lacking fucose sugar units on its Fc portion). This structural modification dramatically increases its binding affinity to CD16 receptors on Natural Killer (NK) cells. As a result, ianalumab triggers highly potent antibody-dependent cellular cytotoxicity (ADCC), eliminating circulating and, crucially, tissue-infiltrated B cells within the exocrine glands with 40- to 70-fold greater potency than legacy anti-CD20 agents like rituximab. Concurrently, ianalumab binds directly to the B-cell activating factor receptor (BAFF-R). By physically blocking BAFF from attaching to its receptor, it cuts off the essential survival and activation signaling pathways for any remaining or nascent autoreactive B cells, inhibiting their downstream proliferation and autoantibody production.

• Trial design: The registrational clinical package consisted of two global, randomized, double-blind, placebo-controlled Phase 3 trials and their subsequent open-label extensions (NEPTUNUS-1 & NEPTUNUS-2 trials). They included a combined enrollment of 779 adult patients across 35 countries with active, moderate-to-severe primary Sjögren’s disease (characterized by systemic disease burden and exocrine glandular dysfunction). Patients were randomized to receive subcutaneous injections of either ianalumab 300 mg monthly, ianalumab every 3 months, or matching placebo for 52 weeks. The primary endpoint was The change from baseline in the ESSDAI score (EULAR Sjögren’s Syndrome Disease Activity Index) at Week 48. The EULAR 2026 presentation focused on long-term efficacy, structural salivary preservation, and safety data capturing patient exposure through an interim Week 108 extension phase.

• Data:

  • Efficacy: Following the successful Week 48 readouts (where monthly ianalumab met the primary endpoint with a statistically significant, rapid, and sustained reduction in ESSDAI score, p = 0.0031), the new Week 108 interim data (Abstract OP0126) added crucial durability metrics. Significant improvements were maintained out to 108 weeks across key patient-reported outcomes, including patient-rated symptom diaries measuring global dryness, chronic widespread pain, and debilitating fatigue (ESSPRI indices). A highly impactful sub-analysis showed that in patients who maintained a baseline stimulated salivary flow rate of ≥0.4 mL/min, ianalumab therapy successfully halted further deterioration of glandular function and reduced objective oral dryness over the 108-week horizon compared to historical placebos.

  • Safety: Extended exposure did not yield any new safety signals. Total incidence of treatment-emergent adverse events (TEAEs) and serious infections remained thoroughly comparable to the placebo baseline, validating the targeted safety window of BAFF-R blockade over non-selective immunosuppression.

• Impact:

  • Potentially First-in-disease: Having zero approved competitors grants Novartis an open runway. With an estimated 50% of the Sjögren’s population currently going undiagnosed due to limited historical treatment options. Like lupus, Sjögren’s disease has been notoriously difficult to treat, causing decades of failed clinical trials. Ianalumab stands as the first targeted biologic in history to hit its primary endpoints in Phase 3 trials for this indication.

  • Disease-Modifying Potential: Rather than just masking symptoms with eye drops or artificial saliva, ianalumab treats the underlying pathology. This shifts the clinical standard from reactive, symptomatic palliation to active, long-term organ and tissue preservation.

• Next steps: Backed by an FDA Breakthrough Therapy Designation awarded in January 2026, Novartis has initiated global regulatory filings, with a target FDA approval decision and subsequent European Medicines Agency (EMA) submission timelines running throughout late 2026 and early 2027. Continued monitoring of the NEPTUNUS open-label extension cohorts out to their final protocol endpoints to evaluate long-term safety, immunoglobulin recovery kinetics, and potential impacts on reducing lymphoma risk (Sjögren’s patients carry a 5% to 10% lifetime risk of developing B-cell lymphoma). Utilizing the validated dual BAFF-R/ADCC backbone, Novartis is actively progressing ianalumab across a wide, corporate-wide multi-indication footprint, including ongoing trials in Systemic Lupus Erythematosus (Phase 2 data also highlighted at EULAR 2026), Lupus Nephritis, Immune Thrombocytopenia (ITP), and Diffuse Cutaneous Systemic Sclerosis.

Link to top ⬆️

Aurinia - Lupkynis (calcineurin inhibitor) / Phase 3 (LN)

At EULAR 2026, Aurinia Pharmaceuticals presented a highly impactful, new long-term time-to-event safety and efficacy analysis from its landmark AURORA 1 Phase 3 study of Lupkynis (voclosporin). While Lupkynis is already FDA-approved, this new data package significantly elevates its clinical profile by demonstrating a massive reduction in “hard” clinical endpoints, such as kidney failure and death, solidifying its competitive positioning in the crowded lupus nephritis (LN) landscape.

• Indication: Lupus Nephritis (LN) is a severe, organ-threatening manifestation of SLE occurring in up to 50% of patients, driven by an autoimmune assault where circulating anti-dsDNA autoantibodies and nuclear antigens form immune complexes that deposit directly within the renal glomeruli. This intrarenal deposition activates the complement cascade, triggering a massive influx of inflammatory cells, podocyte injury, and severe structural damage across the glomerular basement membrane. If left unchecked, this localized inflammatory cascade progresses to glomerulosclerosis, interstitial fibrosis, and irreversible chronic kidney disease (CKD) or end-stage renal disease (ESRD). The clinical standard of care (SOC) aims to rapidly halt this renal inflammation to maximize nephron preservation while minimizing drug toxicity. Standard therapy is divided into an intensive induction phase to achieve complete renal response—historically utilizing a heavy backbone of systemic high-dose glucocorticoids (corticosteroids) paired with mycophenolate mofetil (MMF) or intravenous cyclophosphamide—followed by a lower-dose maintenance phase using MMF or azathioprine to prevent relapses. Modern clinical guidelines now heavily favor upfront multi-target or triple-therapy regimens for active LN, layering advanced targeted biologics like belimumab (anti-BAFF mAb) or adding a next-generation oral calcineurin inhibitor like voclosporin (Lupkynis) to the background MMF/steroid regimen to accelerate proteinuria reduction and facilitate aggressive, organ-protecting steroid tapering.

• Mechanism: Lupkynis (voclosporin) is a next-generation, structurally modified oral calcineurin inhibitor (CNI). Compared to older CNIs like cyclosporine or tacrolimus, Lupkynis exhibits a predictable pharmacokinetic-pharmacodynamic relationship. This eliminates the operational burden of routine therapeutic drug monitoring (TDM) and minimizes standard CNI toxicities (such as severe lipid or glucose metabolic derangements).

• Trial design: The data presented at EULAR 2026 evaluated a post-hoc, time-to-event clinical analysis of the pivotal AURORA 1 Phase 3 trial. The trial recruited 356 randomized adult patients with active, biopsy-proven Class III, IV, or V Lupus Nephritis (178 on Lupkynis, 178 on placebo). All patients received a multi-target background standard of care consisting of mycophenolate mofetil (MMF) and an aggressive, low-dose oral corticosteroid taper. Patients were randomized 1:1 to receive either Lupkynis (23.7 mg twice daily) or matching placebo layered onto the background SOC for 52 weeks. A rigorous composite time-to-event endpoint measuring the safety population’s risk of a renal-related event or death, tracking components including treatment failure, worsening proteinuria, and all-cause mortality.

• Data (press release, poster):

  • Efficacy: The newly presented analysis (led by Dr. Amit Saxena) demonstrated that adding Lupkynis to MMF and steroids dramatically alters long-term renal outcomes. Treatment with Lupkynis was associated with a highly statistically significant 53% reduction in the risk of a renal-related event or death compared to placebo (HR = 0.47, p = 0.0007). Lupkynis drove a 78% reduction in the risk of progressive proteinuria (HR = 0.22, p < 0.0001), highlighting immediate, sustained podocyte protection. Associated with a 55% reduction in the risk of clinical treatment failure (HR = 0.45, p = 0.0062). Demonstrated a strong trend favoring the active arm with an 81% reduction in the risk of death (HR = 0.19, p = 0.0929). The presentation reiterated that Lupkynis remains the only oral option to show statistically significant improvements in Complete Renal Response (CRR) in as short as 6 months within a randomized Phase 3 setting.

    

  • Safety: The FDA-approved label for Lupkynis (voclosporin) carries a Boxed Warning regarding an increased risk for developing serious infections (including bacterial, viral, fungal, and opportunistic infections that can lead to hospitalization or death) and malignancies (such as lymphoma and skin cancers) due to its potent immunosuppressive nature. According to its clinical safety profile, the most common adverse reactions (≥3%) include decreased estimated glomerular filtration rate (eGFR), hypertension, diarrhea, headache, anemia, cough, urinary tract infections, and abdominal pain. Additionally, because it is a calcineurin inhibitor, Lupkynis can cause acute, dose-dependent nephrotoxicity and neurotoxicity (such as tremors, seizures, or altered mental status), can prolong the QT interval when combined with other QT-prolonging drugs, and may cause hyperkalemia. It is also contraindicated for co-administration with strong CYP3A4 inhibitors (like ketoconazole) due to a substantial increase in drug exposure.

• Impact:

  • Payer and Provider Leverage: Showing a 53% reduction in hard endpoints like renal degradation and death shifts the clinical conversation from a surrogate biomarker (proteinuria reduction) to concrete organ preservation, which is vital for winning commercial payer coverage and formulary placement.

  • Defending Market Share: The LN space is intensely competitive, with Lupkynis going toe-to-toe with GSK’s intravenously/subcutaneously infused Benlysta (belimumab) and Roche/Genentech’s newly reading-out Phase 3 anti-CD20 mAb obinutuzumab (REGENCY trial). Confirming that an entirely oral multi-target regimen prevents long-term renal failure strengthens Lupkynis‘s foothold among community nephrologists and rheumatologists.

• Next steps: Aurinia is pushing for these long-term hard outcome data points to be formally incorporated into upcoming EULAR, ACR, and KDIGO clinical management guidelines for lupus nephritis, positioning early oral CNI introduction as a gold standard. Growing the Lupkynis franchise allows Aurinia to fund and advance its second preclinical/clinical pipeline asset, aritinercept (a dual BAFF/APRIL inhibitor aimed at broader autoimmune diseases) reducing the company’s reliance on a single marketed product.

Link to top ⬆️

Novartis - Rapcabtagene autoleucel (CD19 CAR-T) / Phase 2 (IIL, SSc)

At EULAR 2026, Novartis presented highly anticipated data from its cell therapy pipeline, highlighting its autologous CD19-directed CAR-T cell therapy, rapcabtagene autoleucel (rap-cel, formerly YTB323). The spotlight fell on an oral presentation detailing preliminary analysis from the AUTOGRAPH-IIM and AUTOGRAPH-SSc trials, marking a push to transition oncology-born CAR-T architectures into severe, life-threatening autoimmune diseases.

• Indication: Idiopathic Inflammatory Myopathies (IIM / Myositis) and Systemic Sclerosis (SSc / Scleroderma) are severe, chronic systemic autoimmune diseases characterized by profound immune dysregulation that leads to progressive organ dysfunction and tissue scarring. In IIM, the pathophysiology centers on cellular and humoral autoantibody attacks (such as anti-synthetase or myositis-specific antibodies) directly targeting skeletal muscle fibers and small vasculature, inducing muscle cell necrosis, severe symmetric proximal muscle weakness, and extra-muscular inflammation of the skin, joints, and lungs. In SSc, the pathophysiology involves a devastating triad of microvascular injury, intense autoimmune hyperactivation (marked by anti-Scl-70 or anti-centromere antibodies), and massive, uncontrolled overproduction of extracellular matrix proteins by myofibroblasts, causing a characteristic thickening and hardening of the skin (fibrosis) alongside progressive, life-threatening scarring of internal organs like the lungs (interstitial lung disease), heart, and gastrointestinal tract. The clinical standard of care (SOC) for both conditions heavily prioritizes aggressively suppressing active immunologic inflammation to arrest downstream tissue degradation. For IIM, treatment begins with high-dose systemic glucocorticoids (corticosteroids), rapidly layered with traditional steroid-sparing immunosuppressive DMARDs such as methotrexate, azathioprine, or mycophenolate mofetil (MMF), and escalated to intravenous immunoglobulin (IVIG) or rituximab for severe or refractory cases. For SSc, management is highly organ-specific due to the lack of a universal disease-modifying cure; it utilizes MMF or cyclophosphamide to combat progressive interstitial lung disease, often combined with the antifibrotic tyrosine kinase inhibitor nintedanib, while peripheral vascular complications like Raynaud’s phenomenon are managed with vasodilators (calcium channel blockers, PDE-5 inhibitors) and hypertensive renal crises are aggressively treated with ACE inhibitors.

• Mechanism: Rapcabtagene autoleucel is an autologous, CD19-targeted Chimeric Antigen Receptor (CAR) T-cell therapy, engineered utilizing Novartis’s proprietary T-Charge rapid manufacturing platform. They seek out and deeply deplete pathogenic B-cell populations not just in the peripheral blood, but deep within affected target tissues. As the CAR-T cells contract, a completely “naive” and un-primed B-cell population repopulates from the bone marrow, effectively resetting the patient’s immune tolerance. Traditional oncology CAR-T manufacturing takes weeks, leading to cell exhaustion. Novartis’s T-Charge platform reduces the ex vivo culture time to less than two days.

• Trial design: The Phase 2 data presented at EULAR emerged from two parallel, open-label, multi-center, single-arm clinical studies evaluating the feasibility, safety, and early efficacy of rap-cel. AUTOGRAPH-IIM enrolled adult patients with Severe Refractory Idiopathic Inflammatory Myopathies (IIM) (including polymyositis, dermatomyositis, and anti-synthetase syndrome) who displayed active muscle weakness and inadequate responses to standard high-dose corticosteroids and multiple traditional immunosuppressive or biologic DMARDs. AUTOGRAPH-SSc enrolled adult patients with active, severe Diffuse Cutaneous Systemic Sclerosis (dcSSc / scleroderma) characterized by rapidly progressive skin fibrosis and a high risk of or existing internal organ involvement (such as interstitial lung disease). Patients underwent a standard 3-day lymphodepletion conditioning regimen consisting of fludarabine and cyclophosphamide, followed immediately by a single intravenous infusion of rap-cel.

• Data:

  • Efficacy: The oral abstract presentation (Abstract OP0077) provided a critical preliminary peek into the expansion kinetics, tissue clearance, and safety profiles of rap-cel in these non-oncology populations. Rap-cel demonstrated a robust, predictable expansion wave, tracking a distinct in vivo peak within 14 to 21 days post-infusion, followed by gradual contraction. This kinetic wave triggered immediate, complete peripheral B-cell aplasia alongside rapid clearance of baseline autoimmune serum biomarkers. In IIM, patients demonstrated early, meaningful improvements in Total Improvement Scores (TIS), characterized by stabilization or recovery of proximal muscle strength and reductions in muscle enzyme levels (e.g., creatine kinase). In SSc, early multi-domain stabilization was observed, highlighted by reductions in the Modified Rodnan Skin Score (mRSS) measuring skin tightness, and early stabilization of pulmonary metrics (Forced Vital Capacity) in individuals presenting with baseline interstitial lung disease.

  • Safety: Crucially for an autoimmune population, rap-cel exhibited a manageable safety profile. Cytokine Release Syndrome (CRS) was overwhelmingly restricted to mild-to-moderate (Grade 1 or 2) transient events, resolving rapidly with standard protocols (such as tocilizumab). Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and unexpected off-target toxicities were remarkably rare or absent, confirming that the ultra-low cell dose facilitated by the T-Charge™ platform acts as an effective safety buffer.

• Impact:

  • Moving Past Temporary Palliation: Current standard therapies for IIM and SSc merely dampen inflammation or slow tissue scarring. Early cohort data highlights the investigational potential of a functional cure or long-term drug-free remission via an intensive, one-time treatment intervention.

  • Strategic Differentiation: The data positions Novartis at the forefront of the highly competitive “Autoimmune CAR-T Race” (see our CAR-T, Part 3 piece for more on the landscape), keeping stride with rival academic data (such as the landmark Erlangen cohorts) and specialized biotechs (like Kyverna’s KYV-101 or Cabaletta’s CABA-201).

  • The Long-Term Durability Question: Independent registry meta-analyses presented during the same sessions (Abstract OP0076) noted that across all historical global autoimmune CAR-T recipients, a minority (~12%) eventually experienced clinical relapses (median 13 months), which occurred more frequently in IIM than in SLE or SSc. Novartis’s data acts as a baseline to prove whether the unique, stem-like properties of T-Charge manufactured cells provide superior long-term remission durability over standard manufacturing methods.

• Next steps: Novartis is scaling recruitment for its global, randomized, open-label, active-controlled Phase 2 trial (NCT06665256), which aims to randomize approximately 123 patients to directly test rapcabtagene autoleucel against investigator’s choice of standard background comparator therapies in severe IIM. Concurrently, Novartis presented 24-month long-term tracking data in severe refractory SLE patients treated with rap-cel (Abstract POS0303), establishing a blueprint for the multi-year long-term follow-up (LTFU) protocols mandatory for the IIM and SSc arms to observe the precise timelines of B-cell reconstitution. Refining the precise, minimal dose requirements and lymphodepletion intensities needed to guarantee absolute tissue-level B-cell clearance while minimizing the neutropenic infection window for fragile, multi-organ compromised scleroderma patients.

Link to top ⬆️

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Press ⬇️ to go down to a section and ⬆️ to go back up to the Table of Contents

Table of Contents

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which wrapped up this past week (May 29 - June 2) in Chicago, centered on the theme “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.” With over 44,000 global oncology professionals in attendance, the meeting delivered several massive, potentially practice-changing clinical datasets.

This week, I present the ASCO 2026 Awards, which are based on my personal opinion of patient impact and strictly for fun:

• GOLD Revolution Medicines - Daraxonrasib (pan-RAS inhibitor) / Phase 3 (mPDAC) ⬇️

• SILVER Celcuity - Gedatolisib (Pan-PI3K/mTOR inhibitor) / Phase 3 (HR+ HER2- mBC) ⬇️

• BRONZE Ideaya - Darovasertib (PKC inhibitor) / Phase 2/3 (MUM) ⬇️

My Honorable Mention includes the emerging field of in vivo CAR-T therapy, which stole the spotlight at ASCO 2026 and is a rapidly growing theme that we covered in CAR-T, Part 2. By programming T-cells directly inside the patient’s body, these therapies circumvent apheresis, weeks-long ex vivo manufacturing delays, and the toxicities of lymphodepleting chemotherapy.

• Honorable Mention Kelonia / Eli Lilly - KLN-1010 (in vivo BCMA CAR-T) / Phase 1/2 (MM) ⬇️

GOLD Revolution Medicines - Daraxonrasib (pan-RAS inhibitor) / Phase 3 (mPDAC)

The Phase 3 RASolute 302 trial data for daraxonrasib (RMC-6236) presented at ASCO 2026 and concurrently published in the New England Journal of Medicine represents a historic moment for a disease context that has been notoriously refractive to targeted therapies.

• Indication: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive malignancy driven by a dense, immunosuppressive desmoplastic stroma and near-ubiquitous driver mutations, most notably in the KRAS oncogene (>90% of cases), alongside inactivating mutations in tumor suppressors like TP53, CDKN2A, and SMAD4. This rich fibroinflammatory microenvironment creates high interstitial fluid pressure and profound hypoxia, severely impairing drug delivery and rendering the tumor largely resistant to standard immunotherapy. Consequently, systemic therapy relies on combination cytotoxic chemotherapy backbones. The frontline standard of care is determined by patient performance status, typically utilizing either FOLFIRINOX (or modified FOLFIRINOX) or gemcitabine plus nab-paclitaxel. For the small subset of patients harboring specific genomic alterations, targeted strategies are integrated, such as PARP inhibitors (olaparib) for germline BRCA1/2 mutations or pembrolizumab for MSI-H/dMMR tumors, while second-line regimens generally rotate the alternative chemotherapy backbone (e.g., liposomal irinotecan plus 5-FU/LV following gemcitabine failure) or capitalize on newly emerging targeted options like pan-KRAS inhibitors.

• Mechanism: Daraxonrasib is a first-in-class, oral, non-covalent, multi-selective RAS(ON) inhibitor. It acts by binding to an abundant intracellular chaperone protein, cyclophilin A, to form a binary complex. This complex then selectively docks onto the active, GTP-bound state of both mutant and wild-type RAS isoforms (KRAS, HRAS, and NRAS). Unlike pioneering KRAS^G12C inhibitors, daraxonrasib targets a broad spectrum of RAS variants common in PDAC (G12D, G12V, G12R, etc.), successfully shutting down downstream MAPK signaling regardless of the specific driver mutation or compensatory wild-type RAS activation.

  

• Trial design: The Phase 3 RASolute 302 trial was designed to evaluate the safety and efficacy of daraxonrasib in 501 patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had progressed on exactly one prior systemic line of therapy (typically FOLFIRINOX or Gemcitabine + nab-paclitaxel). Patients had an ECOG performance status of 0 or 1. Patients were randomized 1:1 to either daraxonrasib monotherapy administered orally at 300 mg once daily (the established RP2D) in 21-day cycles or investigator’s choice of standard-of-care (SOC) second-line chemotherapy backbones (e.g., liposomal irinotecan + 5-FU/LV, FOLFOX, or Gem/nab-paclitaxel depending on frontline exposure). The primary endpoint was Progression-Free Survival (PFS) and Overall Survival (OS) evaluated in both the overall Intent-to-Treat (ITT) population and the subset with RAS^G12 mutations.

  

• Data (press release, slide deck, NEJM paper):

  • Efficacy: The trial delivered highly mature, definitive survival benefits that met both primary (mOS 13.2 months dara versus 6.7 months SOC, HR 0.4, P < 0.001; mPFS 7.2 months dara versus 3.6 months SOC) and secondary endpoints (ORR 47% dara versus ~11% SOC) with remarkable statistical significance. Furthermore, daraxonrasib delayed the median time to cancer-related symptom worsening to >9 months compared to <4 months in the chemotherapy control arm.

    

  • Safety: Daraxonrasib exhibited a vastly improved therapeutic index compared to cytotoxic options. Grade ≥3 treatment-related adverse events occurred in 43.6% of the daraxonrasib cohort vs. 57.5% in the chemotherapy arm. The primary toxicities were manageable, on-target class effects: skin rash and mouth sores (stomatitis), which were easily mitigated with standard topicals or antibiotics. Crucially, the treatment discontinuation rate due to toxicities was just 1.2% for daraxonrasib compared to 11.2% for chemotherapy.

  

• Impact:

  • Potentially Best-in-Disease for 2L mPDAC: A 60% reduction in the risk of death (HR 0.40) and an absolute mOS extension of 6.5 months is unprecedented in second-line mPDAC, where historical increments are measured in weeks. If approved, daraxonrasib has the potential to emerge as a preferred option over standard cytotoxic single- or doublet-chemotherapy choices in the second-line setting. Shifting patients from toxic, center-based intravenous chemotherapeutic infusions to a once-daily, highly tolerable oral pill could further improve patient quality of life. This data were presented to a room full of oncologists who have seen thousands of pancreatic cancer patients die months after diagnosis, who will soon have a new tool in their tool belt; it was impressive enough to merit a standing ovation!

  • Validation of the pan-RAS Strategy: This success delivers robust clinical proof-of-concept for pan-RAS(ON) inhibition, demonstrating that wild-type sparing/multi-selectivity can achieve deep efficacy without creating unmanageable systemic toxicity.

• Next steps: Having secured FDA Breakthrough Therapy and Orphan Drug designations, and being enrolled in the FDA Commissioner’s National Priority Voucher (CNPV) pilot program, a formal NDA filing is imminent. Revolution Medicines anticipates approval and commercial launch are anticipated within the next 1 to 2 months. On May 1, 2026, the FDA cleared an Expanded Access Program (EAP) protocol, allowing immediate pre-approval clinical access to the drug for eligible relapsed mPDAC patients who cannot wait for the final commercial rollout. Revolution Medicines is already actively enrolling the global, Phase 3 RASolute 303 trial. This study is evaluating daraxonrasib combined with standard chemotherapy versus chemotherapy alone as a first-line intervention for metastatic PDAC, aiming to move the molecule into treatment-naive settings. Driven by the pan-RAS profile, Phase 3 registrational studies are simultaneously underway for daraxonrasib in other major RAS-addicted indications, specifically advanced RAS-mutant non-small cell lung cancer (NSCLC) and colorectal cancer.

Link to top ⬆️

SILVER Celcuity - Gedatolisib (Pan-PI3K/mTOR inhibitor) / Phase 3 (HR+ HER2- mBC)

At ASCO 2026, the Phase 3 VIKTORIA-1 trial established gedatolisib as a major clinical success by cutting the risk of disease progression in half (HR=0.50) and doubling median PFS to 11.1 months, delivering an efficacy triumph.

• Indication: Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is fundamentally driven by luminal mammary epithelial proliferation fueled by hyperactive estrogen receptor (ER) and/or progesterone receptor (PR) transcription factors, alongside deregulated cyclin D-CDK4/6-Rb and PI3K/AKT/mTOR signaling pathways that promote uncontrolled cell cycle progression and survival. Over time, selective therapeutic pressure inevitably induces acquired resistance mechanism mutations, such as ESR1 ligand-binding domain mutations (enabling ligand-independent ER activation) or PIK3CA, AKT1, and PTEN alterations that hyperactivate downstream survival cascades. To counter this biology, the frontline standard of care (SOC) couples endocrine therapy—principally a non-steroidal aromatase inhibitor (letrozole or anastrozole)—with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib), which dramatically delays disease progression. Upon subsequent progression, the second-line SOC pivots sharply based on liquid biopsy or genomic profiling: tumors harboring ESR1 mutations are prioritized for next-generation oral selective estrogen receptor degraders (SERDs) like elacestrant; those exhibiting PIK3CA, AKT1, or PTEN mutations transition to targeted inhibitor combinations (e.g., capivasertib or alpelisib plus fulvestrant, or multi-PAM agents like gedatolisib); while patients with germline BRCA1/2 mutations utilize PARP inhibitors (olaparib, talazoparib). Once endocrine-refractory states develop or visceral crisis is imminent, sequential cytotoxic chemotherapy or heavily targeted antibody-drug conjugates (ADCs) like sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) are deployed to sustain survival.

• Mechanism: Gedatolisib is a highly potent, intravenously administered pan-PI3K/mTOR inhibitor designed for absolute vertical suppression of the PI3K/AKT/mTOR (PAM) pathway. Unlike single-node inhibitors (e.g., the α-selective PI3K inhibitor alpelisib), gedatolisib simultaneously targets all four class I PI3K isoforms (α, β, γ, δ) as well as both mTORC1 and mTORC2 complexes. By blocking both upstream (PI3K) and downstream (mTOR) nodes, it preempts the compensatory cross-activation and adaptive resistance loops that typically blunt the efficacy of single-target single-agent options.

  

• Trial design: The Phase 3 VIKTORIA-1 trial was designed to evaluate the safety and efficacy of gedatolisib in 362 patients with HR+ HER2- mBC whose disease had progressed during or after standard frontline treatment with a CDK4/6 inhibitor and an aromatase inhibitor. Patients were randomized 3:3:1 to one of three treatment arms (see below). The primary endpoint was Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) for the triplet vs. active control. A key secondary endpoint evaluated the doublet vs. active control.

  

• Data (press release, slide deck):

  • Efficacy: The trial met its primary and key secondary endpoints with high statistical significance, though the baseline numbers missed “lofty” expectations established by small, earlier phase trials (where a historical mPFS had hovered around 14.6 months).

    

  • Safety: Gedatolisib demonstrated a far superior metabolic and GI toxicity index compared to alpelisib. Grade ≥3 on-target metabolic toxicities were radically lower for gedatolisib. the gedatolisib arms saw markedly lower rates of hyperglycemia (11.5-15% geda versus 57.9% alpelisib), diarrhea (9.6-15% geda versus 40.1% alpelisib), and discontinuation Rates due to treatment-related adverse events (2.6-3.8% geda versus 7.1% alpelisib). The trade-off toxicity for gedatolisib was stomatitis (mouth inflammation), appearing in ~61% of patients across both gedatolisib arms versus 34.2% in the alpelisib arm.

• Impact:

  • Efficacy Nearly Doubling over Standard of Care: Clinically, cutting the risk of disease progression or death by half (HR = 0.50) and doubling the mPFS from 5.6 to over 11 months represents a massive win for a second-line, post-CDK4/6 inhibitor mutant population.

  • Potentially Broad Label: Since gedatolisib is equally potent in both PIK3CA-mutant and PIK3CA-wild-type contexts, it could avoid the niche labeling restrictions of single-node competitors, pending regulatory review.

• Next steps: The FDA is currently reviewing its NDA for the PIK3CA wild-type (WT) advanced breast cancer cohort (based on prior VIKTORIA-1 data that showed a 7.3-month PFS advantage over fulvestrant alone). The assigned PDUFA goal date is July 17, 2026. Celcuity has confirmed plans to submit this newly presented PIK3CA-mutant data package to the FDA in an sNDA during Q3 2026 to expand the commercial label broadly across both mutational categories. In the clinic, oncologists will need to dissect the overlapping utility of the triplet vs. the doublet. Given the nearly identical PFS curves and the cleaner hematologic safety profile of the doublet, real-world positioning may favor dropping the CDK4/6 backbone in patients sensitive to cytopenias, while utilizing the triplet for highly aggressive kinetics where maximizing the initial ORR (48.9%) is paramount.

Link to top ⬆️

BRONZE Ideaya - Darovasertib (PKC inhibitor) / Phase 2/3 (MUM)

At ASCO 2026, the late-breaking oral presentation of the randomized Phase 2/3 OptimUM-02 trial (Abstract LBA9503) positioned IDEAYA Biosciences and Servier’s darovasertib + crizotinib combination as the definitive new frontline standard of care for HLA-A*02:01-negative metastatic uveal melanoma (mUM), a historically recalcitrant population with zero approved targeted or systemic options.

• Indication: HLA-A*02:01-negative metastatic uveal melanoma (mUM) is a molecularly distinct ocular malignancy predominantly driven by early, mutually exclusive, activating mutations in the G-protein α subunit genes GNAQ or GNA11 (occurring in over 90% of cases). These driver mutations constitutively hyperactivate the downstream Protein Kinase C (PKC) and MAPK/MEK pathways, fueling rapid cellular proliferation and a profound tropism for hepatic metastasis, where the tumor manipulates a dense, immunosuppressive microenvironment characterized by low tumor mutational burden (TMB) and poor T-cell infiltration. Because of this non-inflamed “cold” tumor phenotype, standard cutaneous melanoma treatments like single-agent anti-PD-1 blockades are largely ineffective. For the roughly 55% of patients who test HLA-A*02:01-negative, the bispecific gp100-directed T-cell engager tebentafusp (Kimmtrak) is biologically restricted and unavailable. Consequently, the historical standard of care has defaulted to combination immune checkpoint inhibition with ipilimumab plus nivolumab or enrollment in clinical trials utilizing liver-directed therapies (such as hepatic artery infusion or percutaneous hepatic perfusion), though response rates to standard immunotherapy remain dismally low (~5%) and prognoses poor. This therapeutic void has positioned newly validated molecular targeted strategies, such as dual vertical inhibition of the PKC and c-Met pathways, as the definitive frontline standard to directly intercept the underlying GNAQ/11 biology in this underserved population.

• Mechanism: Darovasertib is a first-in-class, oral small-molecule Protein Kinase C (PKC) inhibitor. Up to 95% of uveal melanomas harbor activating mutations in the G-protein subunits GNAQ or GNA11. This oncogenic mutation continuously hyperactivates the downstream PKC signaling pathway, fueling tumor proliferation. While single-agent PKC inhibition faces feedback resistance, combining it with crizotinib (Xalkori), an oral c-Met/MET inhibitor—blocks parallel pathway activation triggered by hepatic growth factor (HGF) and MET overexpression. Because mUM heavily metastasizes to the liver (a high-HGF environment), this dual vertical inhibition significantly enhances synthetic lethality and prevents tumor escape.

  

• Trial design: The Phase 2/3 OptimUM-02 trial was designed to evaluate the safety and efficacy of darovasertib in 313 patients with treatment-naive (first-line) patients with histologically or cytologically confirmed metastatic uveal melanoma who tested HLA-A*02:01 negative. Patients were randomized to either darovasertib (300 mg BID) + crizotinib (200 mg BID) administered orally in continuous cycles or investigator’s Choice of Therapy reflective of current real-world checkpoint inhibitor use (~77% received the doublet ipilimumab + nivolumab; others received pembrolizumab or dacarbazine). The primary endpoint of the Phase II portion was Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR). The dual primary endpoint of the ongoing Phase 3 portion is Overall Survival (OS).

• Data (press release, slide deck):

  • Efficacy: The ASCO presentation reported a clinically meaningful and statistically significant improvement in PFS with darova + criz vs control, with a 58-64% reduction in the risk of disease progression or death (p < 0.0001) for BICR and investigator assessments (see below). OS data are not yet mature, but a pre-specified interim look demonstrated an early trend favoring the darovasertib combination.

    

  • Safety: The oral targeted combination proved remarkably manageable and safer than toxic checkpoint doublets. Grade 3/4 TRAEs were comparable between arms (40.6% combo vs. 37.0% ICT). The most common Grade 3+ events for the combo were class-specific: diarrhea, syncope, and hypotension. Treatment-Related Serious AEs (TR-SAEs) were radically lower for the targeted combo (9.2%) versus the checkpoint control arm (25.0%). Discontinuations due to TRAEs were exceptionally low for darovasertib at 2.5% (10% for crizotinib) compared to 19.0% in the ICT immunotherapy backbone.

• Impact:

  • Resolving a Massive Genomic Blindspot: Immunotherapies like tebentafusp (Kimmtrak) changed the game in uveal melanoma but are strictly restricted to HLA-A*02:01 positive patients (~45% of the population). OptimUM-02 establishes an effective option for the remaining ~55% who are HLA-A*02:01 negative and otherwise faced poor prognoses on standard cutaneous melanoma regimens.

  • Defeating the Immunotherapy Paradigm: Proving a targeted oral doublet can achieve an HR of 0.42 and a 37.1% response rate against a backdrop where ~77% of patients received ipilimumab/nivolumab establishes molecular targeting as vastly superior to immune checkpoint blockade in GNAQ/11-driven ocular malignancies.

• Next steps: In late April 2026, the FDA accepted darovasertib + crizotinib into the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program. IDEAYA has already initiated the rolling submission process. They expect to complete the formal New Drug Application (NDA) filing in H2 2026, paving the way for an expedited approval pathway. Clinically, because early phase data showed darovasertib also works well regardless of HLA status, IDEAYA is exploring expansion strategies into HLA-A*02:01 positive mUM. More importantly, active registrational studies are underway testing darovasertib in the neoadjuvant and adjuvant settings for localized primary uveal melanoma to prevent metastatic recurrence entirely.

Link to top ⬆️

Honorable Mention Kelonia / Eli Lilly - KLN-1010 (in vivo BCMA CAR-T) / Phase 1/2 (MM)

The clinical data presented for KLN-1010 at ASCO 2026 backs up Eli Lilly’s massive $7 billion acquisition of Kelonia Therapeutics. By generating CAR-T cells directly inside the patient’s body, the candidate bypasses the severe toxicities, delays, and manufacturing hurdles that limit traditional cellular therapies.

• Indication: Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow microenvironment. Pathophysiologically, this expansion is driven by genetic abnormalities (such as t(11;14) translocations or del(17p)) and hyperactive signaling pathways (including NF-κB and JAK/STAT), which trigger the overproduction of a monoclonal immunoglobulin (M-protein) and disrupt normal hematopoiesis and bone remodeling. This results in the classic CRAB clinical features: Calcium elevation, Renal insufficiency, Anemia, and osteolytic Bone lesions. The contemporary frontline standard of care relies heavily on a quadruplet induction regimen combining an anti-CD38 monoclonal antibody (e.g., daratumumab or isatuximab), a proteasome inhibitor (e.g., bortezomib), an immunomodulatory drug (e.g., lenalidomide), and dexamethasone. For transplant-eligible patients, this intensive induction is followed by high-dose chemotherapy conditioning and an autologous stem cell transplant (ASCT), followed by maintenance therapy designed to sustain minimal residual disease (MRD) negativity. When the disease inevitably enters the relapsed/refractory (RRMM) setting, the therapeutic paradigm shifts toward highly active, novel immunotherapies, specifically BCMA-targeted CAR-T cell therapies (such as cilta-cel) and T-cell engaging bispecific antibodies (such as teclistamab or talquetamab).

• Mechanism: KLN-1010 is an off-the-shelf, intravenously administered in vivo anti-BCMA CAR-T cell therapy. It utilizes Kelonia’s proprietary in vivo Gene Placement System (iGPS), which leverages a highly optimized, replication-incompetent lentiviral vector. The vector particles feature precise envelope modifications and targeting molecules that specifically home in on and transduce endogenous T cells inside the body, steering clear of non-target cells. Once the vector docks, it delivers the genetic cargo to integrate and express the anti-BCMA CAR molecule directly on the patient’s circulating T cells, transforming them into tumor-killing effectors in situ.

• Trial design: Phase I inMMyCAR open-label, multi-center, dose-escalation study (NCT07075185) tested KLN-1010 in 18 heavily pretreated, highly refractory patients with Relapsed/Refractory Multiple Myeloma (MM). Unlike commercial ex vivo CAR-Ts that require harsh fludarabine/cyclophosphamide chemotherapy to clear space in the bone marrow, KLN-1010 was infused via a single IV line into non-chemically depleted patients.

• Data (press release):

  • Efficacy: The interim results drew immense praise at the ASCO meeting. 100% (18/18 patients) responded to the single infusion and achieved minimal residual disease (MRD)-negative bone marrow status at day 30 post-infusion. For the cohort with ≥4 months of extended follow-up (n=6), responses continued to deepen over time. 4 patients achieved a Stringent Complete Response (sCR) and 2 achieved a Very Good Partial Response (VGPR). The earliest dosed patients show ongoing, deep MRD-negative persistence beyond 9 to 10 months. Correlative tracking confirmed that in vivo CAR-T kinetics and persistence in the peripheral blood and bone marrow exceeded the traditional curves frequently seen in standard ex vivo manufacturing, even across diverse baseline T-cell phenotypes.

  • Safety: While 16 out of 18 patients experienced CRS, it was notably mild and transient, entirely restricted to Grade 1 or 2. No Grade ≥3 CRS occurred. There were 2 cases of early-onset neurotoxicity: 1 Grade 1 and 1 Grade 3. Both resolved completely with standard management. Crucially, there were zero cases of delayed-onset neurotoxicity (such as Parkinsonian symptoms) and no severe, prolonged cytopenias.

• Impact:

  • True Outpatient Democratization: Since it cuts out lymphodepletion and keeps severe CRS at zero, the Safety Review Committee officially backed outpatient dosing. This shifts CAR-T away from specialized academic ICUs and into community oncology centers.

  • Erasing the Vein-to-Vein Wait: Standard cell manufacturing takes 4 to 8 weeks, a window in which aggressive myeloma often progresses. KLN-1010 registered a median time of just 13 days from patient consent to infusion, essentially an off-the-shelf biologic timeline.

  • Validation of Lilly’s $7B Bet: Eli Lilly executed the acquisition of Kelonia for $3.25 billion upfront (escalating to $7 billion with milestones) just weeks before ASCO. Lilly executives publicly labeled the 100% response rate as “nutty,” solidifying their immediate leadership in the next wave of genetic medicine alongside competitor AstraZeneca (whose rival in vivo lentiviral asset, ESO-T01, did not present new data at this meeting).

• Next steps: Kelonia (now operating under Lilly) is concluding its dose-escalation cohorts to formally establish the Recommended Phase 2 Dose (RP2D) and open an expanded Phase 2 efficacy cohort under its newly granted FDA Fast Track designation. Backed by the clean safety profile and lack of cytopenias, clinical strategies are already being drawn up to move KLN-1010 into frontline or early-relapse multiple myeloma, where a patient’s healthier T-cell fitness could yield even more durable in vivo kinetics. Lilly plans to leverage the underlying iGPS lentiviral vector platform to swap out the BCMA binder for CD19/CD20 or solid tumor targets, scaling the asset across a wider oncologic pipeline.

Link to top ⬆️

To contact us, please send us an email at biotechreadout@gmail.com

Disclaimers

Investigational Status Disclaimer

The therapeutic candidates discussed in this newsletter are currently in clinical development and have not been approved for commercial sale by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other global regulatory authorities. Their safety and efficacy have not been established. References to pipeline products and ongoing clinical trials involve significant risks and uncertainties. Statements regarding the potential safety, potency, or efficacy of investigational drugs reflect current hypotheses and are not a guarantee of future performance or regulatory clearance. The outcome of clinical trials is inherently unpredictable, and clinical results from earlier stages may not be predictive of results in later, larger-scale trials.

No Medical Advice Disclaimer

This newsletter is for informational and educational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.

No Patient-Provider Relationship Disclaimer

The information provided in this newsletter is for educational and analytical purposes only. Receipt of this information, or any interaction with this content, does not create a physician-patient, pharmacist-patient, or any other professional-provider relationship between you and the authors or publishers. This newsletter should not be used as a substitute for a personal consultation with a qualified healthcare professional.

Forward-Looking Statements Disclaimer

This newsletter contains “forward-looking statements” regarding future events, including clinical trial timing, regulatory milestones, and projected market performance. These statements are based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied. We undertake no obligation to update these statements as a result of new information or future developments.

Third-Party Links & Content Disclaimer

This newsletter contains links to third-party websites, including clinical trial registries and corporate presentations. Biotech Readout does not endorse, guarantee, or assume responsibility for the accuracy or reliability of any information offered by third-party providers.

Errors and Omissions Disclaimer

While we strive for technical accuracy, the information in this newsletter is provided on an “as is” basis with no guarantees of completeness, accuracy, or timeliness. Biotech Readout assumes no liability for any errors or omissions in the content of this publication.

Non-Endorsement Disclaimer

Any reference to specific commercial products, processes, or services by trade name, trademark, or manufacturer does not constitute or imply an endorsement or recommendation by the author. All trademarks are the property of their respective owners.

No Investment Advice Disclaimer

This newsletter is for informational purposes only and does not constitute financial, investment, or legal advice. The author is not a registered investment advisor. You should consult with a professional financial advisor before making any investment decisions. The biotechnology sector is highly volatile; past performance is not indicative of future results.

Conflict of Interest Disclaimer

The author of this newsletter maintains a position of independence. At the time of publication, the author holds no direct financial interest, equity, or options in any of the companies mentioned in this report. No compensation has been received from any third party to feature or analyze specific therapeutic candidates or corporate entities.

Introduction

On June 1, 2026, the French pharmaceutical giant Servier announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments (Servier press release, Edgewise press release). At the heart of the deal is sevasemten, an orally administered fast skeletal myosin inhibitor, with a projected Phase 3 Becker Muscular Dystrophy (BMD) data readout anticipated in late 2026. Kevin Koch, Ph.D., President and CEO of Edgewise Therapeutics remarked that the deal is about, “placing sevasemten with an acquirer that has the global scale, patient commitment, and commercial reach to maximize its potential.” Rather than incurring the heavy commercialization expenses of launching an orphan drug independently, the company handed off the late-stage global execution to Servier’s established neurological infrastructure.

The $1.55 billion upfront payment almost quadruples Edgewise’s cash and equivalents in a single stroke (was $499 million in March 2026), capitalizing their transition into a cardiovascular focused company with the following pipeline:

• EDG-7500 (a novel cardiac sarcomere modulator for Hypertrophic Cardiomyopathy): This is positioned to become Edgewise’s lead asset upon completion of the muscular dystrophy business divestment. It is currently anticipated to report 12-week data from Part D of the CIRRUS-HCM trial in the second quarter of 2026. This data, covering both obstructive (oHCM) and non-obstructive (nHCM) patients, will inform the Phase 3 design, which is anticipated to start in the fourth quarter of 2026.

• EDG-15400 (a novel cardiac sarcomere modulator for HFpEF): Projected to enter Phase 2 later in 2026, targeting heart failure with preserved ejection fraction.

• EDG-003: A preclinical asset targeting an undisclosed cardiometabolic indication.

Here, we explore how Alan Russell started Edgewise Therapeutics, how sevasemten was developed, and the history of Becker Muscular Dystrophy (BMD).

Alan Russell Flexes His Entrepreneurial Muscle

Edgewise Therapeutics emerged directly from the core muscle-biology research and industry experience of Alan Russell, Ph.D., who co-founded the company in 2017 and serves as its Chief Scientific Officer (CSO). Before co-founding Edgewise, Dr. Russell spent nearly two decades defining the biophysics of muscle contraction and therapeutic intervention.

He was a foundational scientist at Cytokinetics, where he co-invented tirasemtiv and reldesemtiv, small molecules designed to amplify muscle contractility for conditions like ALS. He was subsequently recruited by GlaxoSmithKline (GSK) to serve as Vice President and Head of the Muscle Metabolism Discovery Performance Unit. At GSK, Russell managed a massive global infrastructure dedicated to uncovering therapeutic interventions for patients with severely compromised muscle function. However, big pharma pipelines often favor broad metabolic approaches or mainstream modalities (like gene therapy and anti-inflammatories) when addressing rare neuromuscular diseases.

By 2017, Russell decided to step away from his executive track at GSK. He saw room for improvement in how the industry was addressing dystrophies like Duchenne (DMD) and Becker (BMD). The prevailing drug development consensus focused heavily on restoring missing proteins or suppressing downstream inflammation. Russell wanted to target the upstream mechanical root cause: contraction-induced microdamage. Since dystrophic muscle fibers lack structural integrity, every ordinary contraction tears them apart. Russell’s hypothesis was that a highly selective, low-affinity fast skeletal myosin inhibitor could act as a mechanical “shock absorber,” potentially easing the stress on the fibers without paralyzing the patient. Realizing that this highly specialized, mechanics-first approach required an agile, single-purpose vehicle, Russell left corporate pharma to build a platform from scratch.

Russell’s move solidified when he partnered with key venture and operational architects to turn the biophysical thesis into a viable company. He teamed up with Peter Thompson, M.D. (a Partner at OrbiMed) and Badreddin Edris, Ph.D. (an investment professional at OrbiMed and later co-founder of SpringWorks). Edgewise Therapeutics was incorporated in May 2017. OrbiMed provided the initial seed capital and they chose Boulder, Colorado as the operating base, a location deliberately selected to leverage the deep pool of muscle-biology expertise concentrated at the University of Colorado Boulder. During this initial launch phase, they established the foundational chemical platform and the core skeletal muscle thesis.

Once the early scientific groundwork was laid and the company was ready to scale toward formal asset discovery and clinical development, the board appointed Kevin Koch, Ph.D. (co-founder of Array BioPharma, which was acquired by Pfizer for $11.4 billion in 2019) as CEO. Dr. Koch’s proven track record in Colorado’s biotech ecosystem, specifically his experience as the co-founder and former CSO of Boulder-based Array BioPharma, was strategically brought in to transition Edgewise from an early-stage startup into an operational, clinical-stage company.

From there, Edgewise built a robust institutional investor base through heavily oversubscribed venture rounds to fund its lead skeletal program, sevasemten (EDG-5506), a selective fast skeletal myosin inhibitor. In September 2019, Edgewise closed a $50 million Series B financing round, co-led by Novo Holdings A/S and U.S. Venture Partners (USVP). The primary objective of the Series B capital was to scale up manufacturing, complete IND-enabling toxicology studies, and finalize the transition of sevasemten from an optimized benchtop compound into a stable, orally bioavailable clinical candidate for Becker (BMD) and Duchenne (DMD) muscular dystrophies.

With $50 million in the bank, Alan Russell and his scientific team built out a highly specialized, proprietary screening platform. Traditional high-throughput screening (HTS) in biopharma typically measures simple biochemical bindings or basic cellular viability. Edgewise had to build something much more complex: a functional muscle-biomechanics platform. The team engineered micro-physiological systems (including in vitro engineered human muscle tissues) that could simulate the precise mechanical strains experienced by a dystrophic muscle during physical contraction. During this window, the company solidified its translational strategy by mapping out downstream mechanical injury biomarkers, specifically Fast Skeletal Muscle Troponin I (TNNI2). They demonstrated in preclinical models that protecting the sarcolemma (cell membrane) from tearing resulted in an immediate, sharp drop in this structural protein’s leakage, giving them a clear biomarker scorecard to use in future human trials.

Their functional muscle-biomechanics platform was crucial for reasons that go beyond identifying development candidates that hit skeletal myosin. Russell’s allosteric skeletal myosin modulators needed to be finely tuned because they needed to overcome the toxicity of non-selective skeletal myosin inhibitors. Blebbistatin, discovered in 2003, is an allosteric inhibitor of myosin II. In a laboratory petri dish, it is incredibly effective at stopping cellular and muscle contraction. However, blebbistatin is a notoriously poorly behaved chemical tool. For a drug hunter looking at it as a starting point, it was a minefield of liabilities:

• Paralysis: Administering the drug to a living organism resulted in profound, widespread muscle paralysis and cardiovascular collapse.

• Severe Cytotoxicity: It breaks down into toxic byproducts when exposed to blue light (phototoxicity), making it dangerous to cells.

• Abysmal Solubility: It precipitates out of solution easily, making it virtually impossible to formulate into a pill that a human body could absorb cleanly.

• Cross-Reactivity: It lacks the safety margins needed to keep from interfering with non-muscle cellular processes.

For these reasons, the biotech industry viewed skeletal myosin inhibition as a toxic mechanism that would actively rob muscular dystrophy patients of the precious little strength they had left. The industry consensus was that the entire chemical class of myosin inhibitors was inherently un-druggable for systemic human diseases. Russell bet his new company on the belief that modern computational chemistry and high-throughput biomechanical screening could completely rewrite this chemical scaffold from scratch. Russell and his team at Edgewise had to accomplish a staggering feat of molecular engineering. They used blebbistatin’s known binding interactions with the myosin head to design a drug, sevasemten (EDG-5506), that inverted the historic paradigm. Instead of shutting down contraction, sevasemten was optimized in preclinical models to spare slow-twitch postural muscles entirely and modulate the peak force of fast-twitch (Type II) fibers by an estimated 10% to 15%. This was observed to protect dystrophin-deficient cell membranes from stress-induced rupture in preclinical models, while leaving >85% of the muscle’s functional capacity completely intact in these models, thereby preserving basic strength while clipping the top-end destructive peak forces.

To demonstrate that their approach could have a workable therapeutic window, Edgewise evaluated sevasemten in rigorous in vivo challenge models, including the mdx mouse and the sapje zebrafish. Preclinical subjects were subjected to downstream downhill running exercises, a high-stress eccentric contraction protocol designed to rapidly degrade dystrophic muscle. Untreated or non-selectively inhibited models showed widespread sarcolemma (membrane) tearing, massive calcium influx, and profound physical exhaustion. Animals treated with sevasemten demonstrated a significant reduction in contraction-induced injury within these studies. Crucially, their overall grip strength, exercise capacity, and voluntary ambulation remained relatively unimpaired (see the graphs below).